tobramycin profile

Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

tobramycin is involved in 1 pathway(s), involving a total of 1 unique proteins and 4 unique compounds

ID Source	ID
PubMed CID	36294
CHEMBL ID	1747
CHEBI ID	28864
SCHEMBL ID	2838
MeSH ID	M0021611

Synonym
BIDD:GT0503
AB00052438-12
tobramitsetin
lilly 47663
tenemycin
nebramycin
nebramycin vi
tobramaxin
nsc-180514
tobramycetin
tenebrimycin
nebramycin 6
smr000058793
MLS000069544
o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4))-2-deoxy-d-streptamine
nebramycin factir 6
(1s,2s,3r,4s,6r)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-d-glucopyranoside
CHEBI:28864 ,
(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-d-glucopyranoside
tobracin (tn)
D00063
TOB ,
bethkis (tn)
tobi (tn)
tobramycin (jp17/usp)
tobrex (tn)
SPECTRUM_001072
SPECTRUM5_001038
BSPBIO_000587
cas-32986-56-4
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
tobramicin
(2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol
tobrex
nebcin (sulfate)
d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribohexopyranosyl-(1->4)]-2-deoxy-
BPBIO1_000647
PRESTWICK3_000544
TOY ,
AB00513858
C00397
3'-deoxykanamycin b
nebramycin factor 6
32986-56-4
tobramycin
DB00684
BSPBIO_002036
KBIOGR_001104
KBIOSS_001552
KBIO2_006688
KBIO3_001536
KBIO2_001552
KBIO2_004120
SPECTRUM2_000078
SPECTRUM3_000588
SPECTRUM4_000752
SPBIO_000295
SPECTRUM1500579
o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1-6))-2-deoxy-l-streptamine
nsc 180514
streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-tyrideoxy-alpha-d-ribohexopyranosyl-(1-6))-2-deoxy-, d-
d-streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1-4))-2-deoxy-
gotabiotic
nebicin
tobramicina [inn-spanish]
streptamine, o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-6))-2-deoxy-, d-
hsdb 3259
deoxykanamycin b
tobrased
tobramycinum [inn-latin]
4-(2,6-diamino-2,3,6-trideoxy-alpha-d-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-d-glycopyranosyl)-2-deoxystreptamine
1-epitobramycin
aktob
tobramycine [inn-french]
c18h37n5o9
o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4))-2-deoxy-d-streptamine
tobralex
tobacin
tobi
einecs 251-322-5
brn 1357507
HMS2092M17
HMS2090B16
T2503
o-[3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->6)]-o-[2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1->4)]-2-deoxy-d-streptamine
(2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
obramycin
CHEMBL1747
HMS2096N09
nsc757352
nsc-757352
pharmakon1600-01500579
tox21_110626
dtxsid8023680 ,
dtxcid903680
tobramycinum
tobramicina
tobramycine
CCG-39936
bethkis
kitabis pak
unii-vz8rrz51vk
tobi podhaler
tobramycin [usan:usp:inn:ban:jan]
vz8rrz51vk ,
bdbm50366778
sprc-ab01
S2514
AKOS016339662
tobradex component tobramycin
tobramycin [ep monograph]
tobramycin [hsdb]
tobramycin [who-dd]
tobramycin component of tobradex
tobradex st component tobramycin
tobramycin component of tobrasone
tobramycin [mart.]
d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-(2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1->4))-2-deoxy-
tobramycin [vandf]
tobramycin component of zylet
tobramycin [usp-rs]
tobrasone component tobramycin
tobramycin [usp monograph]
vantobra
tobramycin [mi]
o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1.alpha.6))-2-deoxy-l-streptamine
zylet component tobramycin
tobramycin component of tobradex st
tobramycin [orange book]
tobramycin [jan]
tobramycin [inn]
tobramycin [usan]
HY-B0441
SCHEMBL2838
KS-1405
tobramycin base
tobramycin, antibiotic for culture media use only
Q-201837
o-3-amino-3-deoxy-?-d-glucopyranosyl-(1-6)-o-[2,6-diamino-2,3,6-trideoxy-?-d-ribohexopyranosyl-(1-4)]-2-deoxy-d-streptamine
d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1->6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1->4)]-2-deoxy-
AB00052438_13
AB00052438_14
(2s,3r,4s,5s,6r)-4-amino-2-{[(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
SR-01000721898-2
sr-01000721898
torbamycin
sr-05000001726
SR-05000001726-2
(2s,3r,4s,5s,6r)-4-amino-2-(((1s,2s,3r,4s,6r)-4,6-diamino-3-(((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol
SR-05000001726-1
SBI-0051915.P003
HMS3713N09
(2s,3r,4s,5s,6r)-4-amino-2-((1s,2s,3r,4s,6r)-4,6-diamino-3-((2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2h-pyran-2-yloxy)-2-hydroxycyclohexyloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,5-diol
o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-6)-o-[2,6-diamino-2,3,6-trideoxy-alpha-d-ribohexopyranosyl-(1-4)]-2-deoxy-d-streptamine
HB4564
tobramycin,(s)
Q1758380
BRD-K05619559-001-12-7
nebramycin factor 6;deoxykanamycin b
gtpl10930
kitabis
tobradex (tobramycin + dexamethasone)
tobramycin deuterated
d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl-(1?6)-o-[2,6-diamino-2,3,6-trideoxy-.alpha.-d-ribo-hexopyranosyl-(1?4)]-2-deoxy-
EN300-7480857
tobramycinum (latin)
tobramycin (usan:usp:inn:ban:jan)
tobramycin inhalation solution
tobramycin (mart.)
s01aa12
tobramycin (usp monograph)
tobramycin (usp-rs)
tobramicina (inn-spanish)
o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,6-trideoxy-alpha-d-ribo-hexopyranosyl-(1alpha6))-2-deoxy-l-streptamine
j01gb01
tobramycin ophthalmic solution
tobramycininhalation solution pak
tobramycin (ep monograph)
tobramycine (inn-french)
tobramycinum (inn-latin)
tobramycin inhalation
at02 - tobramycin

Excerpt	Reference
"Tobramycin is a broad-spectrum aminoglycoside antibiotic agent. "	( Kulik, A; Maier, H; Martinovic, L; Mitousis, L; Musiol-Kroll, EM; Stiefel, A; Stockert, S; Wohlleben, W, 2021)
"Tobramycin is an antibiotic used extensively to treat P."	( Blanco-Cabra, N; Dupin, D; Gracia, R; Loinaz, I; Marradi, M; Movellan, J; Salvador, C; Torrents, E, 2022)
"Tobramycin is a powerful and effective aminoglycoside, approved for complicated infections and reinfections and indicated mainly against Gram-negative bacteria, such as"	( Chiesa, E; Conti, B; Dorati, R; Genta, I; Pisani, S; Rosalia, M; Tottoli, EM, 2022)
"Tobramycin (TOB) is an aminoglycoside antibiotic. "	( Cai, R; Han, X; Zhou, N, 2020)
"Tobramycin (TOB) is a standard anti-pseudomonal antibiotic; however, in biofilm infections, its efficacy severely decreases due to limited permeability across the biofilm matrix."	( Carvalho-Wodarz, CS; Horstmann, JC; Lehr, CM; Prestidge, CA; Thomas, N; Thorn, CR, 2021)
"Tobramycin (TOB) is a promising aminoglycoside antibiotic used to treat various bacterial infections, including S."	( Abba, Y; Karunanidhi, A; Lulu, GA; Mohamad Yusof, L; Mohd Fauzi, F; Othman, F, 2018)
"Tobramycin is an aminoglycoside antibiotic of which the 24 h exposure correlates with efficacy. "	( Brüggemann, RJM; Knibbe, CAJ; Mouton, JW; Smit, C; van Dongen, HPA; Wasmann, RE; Wiezer, MJ, 2019)
"Tobramycin is an aminoglycoside antibiotic, normally used to treat Pseudomonas aeruginosa pulmonary infection in CF patients."	( Altamura, N; Borgatti, M; Breveglieri, G; Castaldo, R; Finotti, A; Gambari, R; Panin, GC; Salvatori, F; Zuccato, C, 2013)
"Tobramycin inhalation is an accepted treatment of chronic pseudomonal infection in cystic fibrosis (CF) patients. "	( Gąszczyk, G; Mazurek, H; Sands, D; Sapiejka, E, 2014)
"Tobramycin is an important broad spectrum aminoglycoside antibiotic widely used against severe Gram-negative bacterial infections. "	( Hong, W; Li, H; Wen, S; Xiao, J, 2014)
"Tobramycin is a critical cystic fibrosis treatment however it causes ototoxicity. "	( Campbell, KC; Cooper, MD; Fox, DJ; Hargrove, TL; Meech, RP; Roberts, MH; Rybak, LP; Speil, CA; Verhulst, SJ; Yanik, SC, 2016)
"Tobramycin is an aminoglycoside currently used to combat lung infections in individuals with CF."	( Hebert, WP; Mastoridis, P; O'Toole, GA; Orazi, G; Price, KE; Ruoff, KL, 2015)
"Tobramycin was shown to be a highly active antibiotic in the treatment of salmonellosis of infants."	( Bobrovitskaia, AI; Bukhteeva, ER; Ivanova, SS; Vereshchagin, IA; Zhuravleva, OD, 1984)
"Tobramycin is an aminoglycoside used in the treatment of infection against gram-negative bacteria. "	( Banerjee, SK; Dasgupta, A; Hunter, RL; Jagannath, C, 2000)
"Tobramycin is an aminoglycoside aminocyclitol antibiotic with pharmacological similarities to gentamycin. "	( Bailey, RR; Peddie, B, 1977)
"Tobramycin proved to be an effective antimicrobial in these patients."	( Meyers, BR, 1977)
"Tobramycin is a new aminoglycoside antibiotic with a broad antibacterial spectrum in vitro, and pharmacokinetic properties similar to those for gentamicin. "	( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1976)
"Tobramycin is a new antibiotic resembling gentamicin. "	( Ducan, IB; Penner, JL, 1975)
"Tobramycin is a new aminoglycoside antibiotic with pharmacological similarities to gentamicin. "	( Bailey, RR; Peddie, B, 1976)
"Tobramycin is a new aminoglycoside antibiotic for prescription ophthalmologic use in the United States."	( Ridgway, HB; Schorr, WF, 1977)
"Tobramycin is a newly marketed aminoglycoside which closely resembles gentamicin in antimicrobial activity, pharmacology, clinical efficacy, and toxicity. "	( McCracken, GH; Nelson, JD, 1976)
"Tobramycin is a new aminoglycoside antibiotic prepared at the Institute of New Antibiotics, the USSR Academy of Medical Sciences."	( Filippos'iants, ST; Shevniuk, LA; Vinogradova, IV, 1989)

Excerpt	Reference
"Tobramycin/Dexamethasone has a quicker anti-inflammatory effect but needs IOP monitoring."	( Passani, A; Passani, F; Pianini, V; Rossi, GC, 2010)
"Tobramycin/Dexamethasone has a quicker anti-inflammatory effect but needs IOP monitoring."	( Passani, A; Passani, F; Pianini, V; Rossi, GC, 2010)
"Tobramycin has been shown to be effective in the management of these patients."	( Bothra, M; Kabra, SK; Lodha, R, 2012)
"Tobramycin has been given orally to eight human volunteers for four successive days, to investigate its effect on the Gram-negative enterobacilli as well as on the endogenous anaerobic microflora. "	( Mulder, JG; van der Waaij, D; Welling, GW; Wiersma, WE, 1984)
"Oral tobramycin for 7 days has been shown to be of benefit as an adjunct to conventional medication in acute ulcerative colitis. "	( Axon, AT; Burke, DA; Lobo, AJ; Sobala, GM, 1993)
"Tobramycin has the lower MICs than the other aminoglycosides to Pseudomonas aeruginosa."	( Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P, 1998)
"Tobramycin has been shown to be safe and effective when given intravenously in combination antibiotic therapy for infected patients with acute leukemia or other profound pancytopenic states. "	( Fabre, S; Hilmer, R; Jennis, F; Vincent, PC, 1976)

Excerpt	Reference
"Both tobramycin and colistin cause acute renal tubular injury with a significant rise in urinary NAG excretion. "	( Bosomworth, M; Clifton, I; Conway, SP; Etherington, C; Peckham, DG, 2007)
"Tobramycin seemed to enhance the resolution of inflammation by a more rapid decline in C-reactive protein levels."	( Alestig, K; Eilard, T; Ek, E; Hebelka, M; Johansson, E; Olinder-Nielsen, AM; Sandberg, T, 1997)
"Tobramycin has the lower MICs than the other aminoglycosides to Pseudomonas aeruginosa."	( Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P, 1998)

Excerpt	Reference
"A tobramycin-treated 24 h biofilm resulted in live and dead cells detaching from the biofilm, while treatment of a 72 h biofilm preferentially killed subpopulations on the periphery of the mushroom stalk."	( Engel, J; Haagensen, J; Huang, L; Spormann, AM; Verotta, D; Yang, K, 2017)
"Tobramycin treatment leads to increased lung function and fewer clinical exacerbations in CF patients, and modestly reduces the density of P."	( Barnaby, R; Gerber, SA; Hogan, DA; Jackson, AA; Koeppen, K; Stanton, BA, 2019)
"Tobramycin (0.3%) treatment was applied four times daily for 1 month postoperatively."	( Hou, CH; Hsiao, CH; Huang, YC; Kang, EY, 2019)
"Tobramycin is the treatment of choice, but persistent usage enables the infectious organisms to activate defence mechanisms, making eradication rarely successful."	( George, AM; Iredell, J; Middleton, PG; Treerat, P; Widmer, F, 2008)
"The tobramycin treatment also inhibited MUC5AC mRNA expression at 12h after lipopolysaccharide stimulation (P<0.05) and suppressed NFκB activation 60min after lipopolysaccharide stimulation (P<0.001)."	( Araki, N; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, K; Yamamoto, Y; Yanagihara, K, 2011)
"Tobramycin, used in the treatment of infections caused by Gram-negative bacteria, requires therapeutic drug monitoring (TDM) due to its narrow therapeutic index. "	( Coulthard, K; Lind, A; Madsen, V; Rasmussen, M, 2004)
"Tobramycin-treated mice differed from untreated animals in that many more of them discharged infected pellets, and their pellets contained 5- greater than 300 times more campylobacters."	( Berry, LJ; Field, LH; Underwood, JL, 1984)
"Tobramycin-treated eyes received erythromycin ointment after surgery; ofloxacin-treated eyes received petrolatum ointment."	( Discepola, MJ; Goldstein, DA; Jackson, WB; Kirsch, LS, 1995)
"Tobramycin treatment (daily dose 10 mg/kg) was started 4 days after surgery, either in a single daily dose or in 3 divided doses at 8 h intervals, for 2, 3, 5, 7 or 10 days."	( Fillastre, JP; Grise, G; Herscovici, L; Lemeland, JF; Thauvin, C, 1988)
"Treatment with tobramycin at 4 μg/ml combined with clarithromycin at 200 μg/ml eradicated all five biofilms, while tobramycin-azithromycin at the same concentrations eradicated only three biofilms."	( Dehaye, JP; El Manssouri, N; Nagant, C; Traore, H; Tré-Hardy, M; Vanderbist, F; Vaneechoutte, M, 2010)
"Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures)."	( Norden, CW; Shinners, E, 1985)

Role	Description
antibacterial agent	A substance (or active part thereof) that kills or slows the growth of bacteria.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
toxin	Poisonous substance produced by a biological organism such as a microbe, animal or plant.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
amino cyclitol glycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Tobramycin Action Pathway	1	4

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Protein Rev	HIV-1 M:B_HXB2R	Kd	4.1100	0.1800	2.1450	4.1100	AID82302
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1643)

Assay ID	Title	Year	Journal	Article
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID325978	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 100 ug/ml by rotating disk reactor method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
AID283540	Antibacterial activity against Pseudomonas aeruginosa FE57Z with inactivated rplY and mexZ genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID573199	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T380C mutant gene selected at 0.5 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID283548	Antibacterial activity against Pseudomonas aeruginosa FE63 containing inactivated rplY and PA5471 genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID564468	Antimicrobial activity against Pseudomonas aeruginosa isolate 1093 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID446139	Antibacterial activity against R-methylase expressing Citrobacter amalonaticus 06AB0010 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID559054	Antibacterial activity against Streptococcus agalactiae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID283547	Antibacterial activity against Pseudomonas aeruginosa FE60 containing inactivated mexXY gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID563523	Antibacterial activity against Pseudomonas aeruginosa NY220 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID522933	Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1716767	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 32 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID564686	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID561323	Antimicrobial activity against Klebsiella pneumoniae isolate 132 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID532083	Antimicrobial against Pseudomonas aeruginosa 1494 harboring phnA allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1318937	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 85322	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573536	Antibacterial activity against Serratia marcescens Sm2723 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID519183	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 4 ug/ml of cefepime exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID534194	Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID1580091	Antibacterial activity against colistin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID559484	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559050	Antibacterial activity against Staphylococcus hominis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID68696	In vitro inhibitory activity against Escherichia coli ATCC 25922; Value ranges from 0.25-1 ug/mL	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID326536	Antimicrobial activity against Mycobacterium abscessus CH10 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID396030	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID164370	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21509 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID525556	Cmax in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID573533	Antibacterial activity against Enterobacter cloacae El3518 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1629135	Selectivity ratio, ratio of IC50 for cytosolic eukaryotic translation in rabbit reticulocyte S30 extract to IC50 for 16S rRNA A-site in Escherichia coli S30 extract	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID285611	Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID126452	Dissociation constant for binding to mitochondrial 12S rRNA construct M5 was determined	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Decoding region bubble size and aminoglycoside antibiotic binding.
AID460799	Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID560274	Toxicity in Pseudomonas aeruginosa ATCC 27853 infected Swiss mouse	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID559043	Antibacterial activity against vancomycin- resistant Enterococcus faecium by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564451	Antimicrobial activity against Pseudomonas aeruginosa isolate 1036 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID780476	Antimicrobial activity against Pseudomonas aeruginosa PaM02 assessed as growth inhibition at 0.008 umol/ml by microtitre plate reader analysis	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Spectroscopic identification and anti-biofilm properties of polar metabolites from the medicinal plant Helichrysum italicum against Pseudomonas aeruginosa.
AID622389	Antibacterial activity against colistin-sensitive Pseudomonas aeruginosa after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID285587	Antimicrobial activity against Pseudomonas aeruginosa 65.36-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID525570	AUC (0 to infinity) in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID523068	Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1056842	Antibacterial activity against TEM-1/SHV-12/CTX-15 expressing Enterobacter intermedius isolate 243 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID573535	Antibacterial activity against Enterobacter cloacae El1573 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID774219	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID1716635	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 1024 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID330985	Antimicrobial activity against Staphylococcus epidermis	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID530322	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID559061	Antibacterial activity against Streptococcus anginosus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559065	Antibacterial activity against Streptococcus mitis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID554434	Ratio of MIC for Pseudomonas aeruginosa 2715 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1447591	Disruption of proton motive force in Pseudomonas aeruginosa PAO1 cytoplasmic membrane assessed as repression of bacterial swimming motility at 0.0156 to 0.125 MIC after 20 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID509866	Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID283220	Antimicrobial activity against Pseudomonas aeruginosa PA0905	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID559260	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID496006	Antimicrobial activity against imipenem resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID1881518	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID559077	Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559084	Antibacterial activity against Proteus mirabilis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID65060	Concentration required for half maximum rate of enhanced [3H]DHS (Dihydrostreptomycin) uptake in Escherichia coli K12 (ATCC 25868)was estimated from dose-response curves	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID529159	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID559070	Antibacterial activity against Acinetobacter calcoaceticus by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID572137	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID523494	Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID544955	Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1846502	Antibacterial activity against Pseudomonas aeruginosa NC02 cystic fibrosis assessed as tobramycin MIC in presence of berberine
AID774215	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID1318925	Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 101243	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID560598	Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1716634	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 128 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID519179	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 4ug/ml of gentamycin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1653587	Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 20 mg/kg, ip administrated for 60 days and measured after 1 year by Spearman-Karber technique analysis relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID278810	Antibacterial activity against Escherichia coli BL21(DE3) expressing Pseudomonas aeruginosa APH(3')-2b	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID563519	Antibacterial activity against Pseudomonas aeruginosa NY214 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID508731	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID523071	Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID565279	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID394683	Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID560262	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID498107	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID559058	Antibacterial activity against levofloxacin-susceptible Streptococcus pneumoniae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID518817	Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1422369	Antibacterial activity against Pseudomonas aeruginosa PA22 harboring surexp MexXY by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID425070	Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID559584	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1056852	Antibacterial activity against CTX-15 expressing Stenotrophomonas maltophilia isolate 125 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID622395	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microbroth dilution method in presence of Mg2+	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID1873910	Antibacterial activity against Enterococcus faecium incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1846516	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa NC06 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID585435	Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID540236	Phospholipidosis-positive literature compound observed in human
AID519180	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 1 ug/ml of oflaxacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID521593	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 7.0 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID374112	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID559059	Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498126	Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1422364	Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID559075	Antibacterial activity against Enterobacter cloacae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573532	Antibacterial activity against Klebsiella pneumoniae Kp2730 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534167	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1459347	Antibacterial activity against Staphylococcus aureus 209P incubated at room temperature for 30 mins followed by incubation at 37 degC for 12 hrs by two-fold dilution method	2016	Journal of natural products, 10-28, Volume: 79, Issue:10	Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities.
AID565066	Antibacterial activity against CTX-M-15 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID519181	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of Norfloxacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID571919	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559512	Antibacterial activity against Lancefield Streptococcus sp. 'group G' assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285577	Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1873906	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID768035	Antibacterial activity against Bacillus subtilis 168 harboring AAC(6')/APH(2'')-pRB374 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID326548	Antimicrobial activity against Mycobacterium abscessus R53 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID497947	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573546	Antibacterial activity against Klebsiella oxytoca Ko0426 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1846515	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa AR48 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID496005	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID497943	Antibacterial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID554391	Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1422374	Antibacterial activity against Escherichia coli PAZ505H8101 harboring AAC6'-1B by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573523	Antibacterial activity against Enterobacter cloacae isolate El216 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1139968	Binding affinity to menin (unknown origin) by isothermal titration calorimetry analysis	2014	Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
AID278808	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID564691	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID498121	Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID565065	Antibacterial activity against CTX-M-14 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID573538	Antibacterial activity against Citrobacter amalonaticus Ca38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID546619	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID573548	Antibacterial activity against Escherichia coli Ec158 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID166713	Tested for binding affinity against RNA construct B	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID560278	Bactericidal activity against Pseudomonas aeruginosa NH57388A infected in Swiss neutropenic mouse assessed as reduction in lung bacterial load at 60 mg/kg BID administered 24 hrs post infection through aerosol	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID532079	Antimicrobial against Pseudomonas aeruginosa 32455 harboring phzS allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID573520	Antibacterial activity against Klebsiella pneumoniae isolate Kp266 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1824801	Antibacterial activity against Pseudomonas aeruginosa 1129 assessed as bacterial growth inhibition by broth microdilution method	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	New
AID1716769	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 1024 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1716759	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID496008	Antimicrobial activity against piperacillin-tazobactam resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID498116	Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID523499	Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573525	Antibacterial activity against Klebsiella oxytoca isolate Ko238 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID446134	Antibacterial activity against MexEF expressing Pseudomonas aeruginosa PA03 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID644960	Displacement of ethidium bromide from human pre-hsa-mir-155 miRNA after 30 mins	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID324854	Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID521836	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID559081	Antibacterial activity against Moraxella catarrhalis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID561324	Antimicrobial activity against Klebsiella pneumoniae isolate 132 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID531864	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by CTC staining	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID544954	Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID544958	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID162761	In vitro inhibitory activity against Pseudomonas aeruginosa ATCC 27853	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID498089	Antibacterial activity against Pseudomonas aeruginosa PA881 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1881521	Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID1322251	Antibacterial activity against AAC6'-2A expressing Pseudomonas aeruginosa F03 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID1374166	Antibacterial activity against Escherichia coli ATCC 25922 incubated at 37 degC for 20 hrs by standard broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID571889	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID405819	Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID283221	Antimicrobial activity against Escherichia coli XL1-Blue pPA95S29	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID768027	Antibacterial activity against Bacillus anthracis 34F2 Sterne by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID534178	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1422376	Antibacterial activity against Klebsiella pneumoniae 700603 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID1318903	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID203329	Antibacterial activity expressed as MIC value was determined on Serratia marcescens A-20019 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID521600	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 cells at 50 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID572129	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID560590	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID498304	Antibacterial activity against Pseudomonas aeruginosa PA5063 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID498113	Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID520698	Antimicrobial activity against Escherichia coli isolate DH10B by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID573503	Antibacterial activity against Escherichia coli isolate Ec9381 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID164254	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20897 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID573212	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID518816	Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID559044	Antibacterial activity against Listeria monocytogenes by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID162730	Antibacterial activity expressed as MIC value was determined on Proteus mirabilis A-9900 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID498108	Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1318933	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 79199	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID546620	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1318923	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 264-104354	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1780308	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as resistance development by measuring fold increase in MIC
AID279941	Antibiotic susceptibility by resistance against non-MDR Pseudomonas aeruginosa from samples collected from patients	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID1422371	Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID498117	Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID326534	Antimicrobial activity against Mycobacterium chelonae after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID533855	Antibacterial activity against nonpigmented rapidly growing Mycobacterium fortuitum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID1447475	Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID522932	Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID559046	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID283538	Antibacterial activity against Pseudomonas aeruginosa FE53G with inactivated mexZ and nuoG genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID584556	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID2940	Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID523405	Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID544957	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573193	Antimicrobial activity against mutS::lox,mexD::lox-deficient Pseudomonas aeruginosa PAOMSMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1716661	Antibacterial activity against Pseudomonas aeruginosa 200 harboring efflux mutant assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID533861	Antibacterial activity against nonpigmented rapidly growing Mycobacterium septicum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID544965	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID533565	Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID326539	Antimicrobial activity against Mycobacterium abscessus NTU445 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID573517	Antibacterial activity against Serratia marcescens isolate Sm203 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID498085	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation by microtiter plate reader assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID559528	Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1364568	Bactericidal activity against multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID1318909	Antibacterial activity against gentamicin-resistant Escherichia coli isolate CAN-ICU 61714 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID559051	Antibacterial activity against Staphylococcus lugdunensis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID424862	Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID559069	Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498119	Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID498131	Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID428872	Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID519407	Antibacterial activity against 16S rRNA methylase rmtB and CTX-M-65 ESBL producing rifampin resistant Escherichia coli isolate ECRB1 by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.
AID559483	Antibacterial activity against Serratia marcescens by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1846511	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C31 assessed as reduction in MIC in presence of berberine by broth microdilution method
AID1666867	Inhibition of swarming motility of Escherichia coli clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID542044	Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1678759	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID544956	Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID509870	Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID561315	Antimicrobial activity against Enterobacter cloacae isolate 101 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID573401	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID546621	Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1318924	Antibacterial activity against pandrug-resistant Pseudomonas aeruginosa isolate 91433	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID2937	Dissociation constant with dimeric 16S rRNA RNA construct B	2001	Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22	Novel synthesis and RNA-binding properties of aminoglycoside dimers conjugated via a naphthalene diimide-based intercalator.
AID531754	Antibacterial activity against Pseudomonas aeruginosa 2439 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1873907	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1056836	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 235 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID571909	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID561321	Antimicrobial activity against Escherichia coli isolate 48 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID531865	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by BacLight Live/Dead staining	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID529643	Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID375076	Binding affinity to A-site RNA	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID523492	Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID768031	Antibacterial activity against Staphylococcus aureus expressing NorA by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID1139967	Binding affinity to menin (unknown origin) assessed as thermal stability at 400 uM by differential scanning fluorimetry (Rvb = 40.46 degC)	2014	Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
AID559518	Antibacterial activity against Streptococcus constellatus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1319017	Ratio of MIC for Pseudomonas aeruginosa PAO1 after 25 serial passages to MIC for Pseudomonas aeruginosa PAO1 prior to 25 serial passages	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID324311	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID498302	Antibacterial activity against Pseudomonas aeruginosa PA1054 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID530330	Antimicrobial activity against Escherichia coli XL1-Blue by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID544949	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1873909	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID559056	Antibacterial activity against Lancefield Streptococcus sp. group F by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID326541	Antimicrobial activity against Mycobacterium abscessus R51 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID498127	Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID559502	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID572127	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559513	Antibacterial activity against levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498297	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 2 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID166717	Tested for binding affinity against RNA construct D	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID324862	Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1265777	Antibacterial activity against Escherichia coli assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID564015	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID534176	Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1056834	Antibacterial activity against GIM-1 expressing Pseudomonas aeruginosa isolate 197 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID236835	Maximum Frel value for binding to 3'-Fl-AM1A-Rhd in Bacillus subtilis tyr	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA.
AID1846505	Antibacterial activity against Pseudomonas aeruginosa NC06 cystic fibrosis assessed as reduction in bacterial growth
AID561313	Antimicrobial activity against Enterobacter cloacae isolate 37 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID559524	Antibacterial activity against Acinetobacter baumannii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1873913	Antibacterial activity against Escherichia coli incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1318964	Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 75 mg/kg administered as single dose measured after 96 hrs	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID554385	Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID326547	Antimicrobial activity against Mycobacterium abscessus R65 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID394700	Antibacterial activity against MexXY-OprM pump-independent aminoglycoside-resistant Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID573194	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring duplication mutation at nucleotide 333 in nfxB gene selected at 0.5 ug/ml of azithromycin by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1447465	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID542063	Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID326545	Antimicrobial activity against Mycobacterium abscessus R54 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID559598	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID622391	Antibacterial activity against Colistin resistant Burkholderia cepacia after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID573210	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID529645	Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID559072	Antibacterial activity against Citrobacter freundii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1318932	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 108590	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID523507	Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID67421	In vitro inhibitory activity against Enterococcus faecalis ATCC 29212; Value ranges from 8-32 ug/mL	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID1450010	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages at sub-MIC to MIC after 1 passage by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID1231668	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth incubated for 72 hrs by CLSI based method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Colloidal and antibacterial properties of novel triple-headed, double-tailed amphiphiles: exploring structure-activity relationships and synergistic mixtures.
AID1447582	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as ratio of MIC after 25 serial passages to MIC before 25 serial passages by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID573209	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G539A mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID573516	Antibacterial activity against Serratia marcescens isolate Sm201 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID324866	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID257552	Antibacterial activity against Escherichia coli	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.
AID285586	Antimicrobial activity against Pseudomonas aeruginosa 65.36-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1716657	Antibacterial activity against Stenotrophomonas maltophilia CAN-ICU 62584 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID529516	Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID572133	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1780306	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as reduction in bacterial growth by broth microdilution assay
AID531868	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells assessed as concentration and time required inactivate 2 log bacterial cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID65067	Percent killing of the total Escherichia coli K12 (ATCC 25868)cells at the C50 concentration was determined.	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID531756	Antibacterial activity against Pseudomonas aeruginosa 2126 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID523516	Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1139964	Inhibition of N-terminal FITC-labeled MBM1 interaction to menin (unknown origin) after 1 hr by fluorescence polarization assay	2014	Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
AID577222	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring phoU::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID1629130	Antimicrobial activity against aminoglycoside-resistant Burkholderia cepacia ATCC 25416 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID559541	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559047	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID497949	Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as inhibition of biofilm formation by microtiter plate reader assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID584563	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573542	Antibacterial activity against Escherichia coli Ec9381 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1716891	Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID559055	Antibacterial activity against Lancefield Streptococcus sp. 'group C' by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID555557	Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID1716768	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 16 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID425071	Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID519188	Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa clinical isolate	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID405818	Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID510963	Antimicrobial activity against ESBL producing Escherichia coli assessed as nonsusceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.
AID1716709	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID508487	Antimicrobial activity against Pseudomonas aeruginosa isolate BNL-1681 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID498099	Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1716651	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID496007	Antimicrobial activity against Ceftazidime resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID520639	Antimicrobial activity against Escherichia coli MRY05-3283 expressing qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID571691	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1374177	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID559543	Antibacterial activity against levofloxacin susceptible Serratia marcescens assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1716711	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID525557	AUC (0 to infinity) in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID1322248	Antibacterial activity against NorA expressing Staphylococcus aureus 1 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID283543	Antibacterial activity against Pseudomonas aeruginosa FE57UZ with inactivated rplY, galU and mexZ genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID544960	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID584575	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID285582	Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID446132	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID534173	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1271376	Antimicrobial activity against Gram-positive Bacillus anthracis str. Sterne after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID285608	Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID768037	Antibacterial activity against Streptococcus pyogenes Serotype M12 MGAS9429 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID544959	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID559048	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1906414	Antibacterial activity against Methicillin resistant Staphylococcus aureus ATCC BAA -1556 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, May-05, Volume: 235	Amphiphilic cyclic peptide [W
AID625836	Antibacterial activity against Escherichia coli by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID508480	Antimicrobial activity against Pseudomonas aeruginosa isolate AK5493 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID571899	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID283531	Antibacterial activity against Pseudomonas aeruginosa FE49 with inactivated galU gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID774221	Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID396031	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID372844	Antibacterial activity against Acinetobacter baumannii isolate C expressing 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID1318929	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86079	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID525572	Tmax in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID573521	Antibacterial activity against Serratia marcescens isolate Sm211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID165224	In vitro inhibitory activity against Pseudomonas aeruginosa ATCC 35151	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID573402	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID561318	Antimicrobial activity against Enterobacter cloacae isolate 153 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID584555	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497948	Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID498137	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 4 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID283542	Antibacterial activity against Pseudomonas aeruginosa FE57GU with inactivated rplY, nuoG and galU genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID532087	Antimicrobial against Pseudomonas aeruginosa 8666 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID571690	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID340859	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID573513	Antibacterial activity against Escherichia coli isolate Ec158 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534170	Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID396026	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID544951	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID559600	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID446137	Antibacterial activity against TriABC expressing MexAB, MexCD, MexEF, MexXY deleted Pseudomonas aeruginosa PA405 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID544962	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID283533	Antibacterial activity against Pseudomonas aeruginosa FE57 with inactivated rplY gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1364627	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID425073	Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID559063	Antibacterial activity against Streptococcus constellatus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285601	Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID565071	Antibacterial activity against CTX-M-15 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID584573	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1721429	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method	2020	Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17	Synthesis of novel lignan-like compounds and their antimicrobial activity.
AID554397	Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID69749	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20683 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1850994	Binding affinity to human double stranded DNA by SPR analysis	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Identification of sugar-containing natural products that interact with i-motif DNA.
AID554396	Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559514	Antibacterial activity against non-levofloxacin susceptible Streptococcus pneumoniae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID164372	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-9834A organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1716654	Antibacterial activity against gentamicin, tobramycin, ciprofloxacin-resistant Escherichia coli ATCC 97615 harboring aac(3')IIa gene assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID560263	Antimicrobial activity against Pseudomonas aeruginosa isolate NH57388A by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
AID1873908	Antibacterial activity against Cronobacter sakazakii ATCC 29544 incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1780305	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Gly120Ala mutant assessed as reduction in bacterial growth by broth microdilution assay
AID544952	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID561329	Antimicrobial activity against azide-resistant Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1459349	Antifungal activity against Candida albicans FIM709 incubated at room temperature for 30 mins followed by incubation at 32 degC for 12 hrs by two-fold dilution method	2016	Journal of natural products, 10-28, Volume: 79, Issue:10	Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities.
AID1716715	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID495511	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1716659	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID564465	Antimicrobial activity against Pseudomonas aeruginosa isolate 971 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID533853	Antibacterial activity against nonpigmented rapidly growing Mycobacterium chelonae after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID573331	Antibacterial activity against Klebsiella pneumoniae isolate Kp1945 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID434366	Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID572123	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1780304	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as reduction in bacterial growth by broth microdilution assay
AID559596	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID498112	Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID163076	Antibacterial activity expressed as MIC value was determined on Proteus stuartii A-21210 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID285598	Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID446133	Antibacterial activity against MexCD expressing Pseudomonas aeruginosa PA01 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID564464	Antimicrobial activity against Pseudomonas aeruginosa isolate 968 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID330982	Antimicrobial activity against Escherichia coli BAS849	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID1716649	Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID496004	Antimicrobial activity against drug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID322313	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID1716872	Antibacterial activity against Pseudomonas aeruginosa 114228 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID559060	Antibacterial activity against Streptococcus pyogenes by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID534299	Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573515	Antibacterial activity against Serratia marcescens isolate Sm220 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1322253	Antibacterial activity against triABC deficient Pseudomonas aeruginosa PA406 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID554398	Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID495517	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1678765	Antibacterial activity against Escherichia coli ATCC 25922 using cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID405425	fAUC (0 to 24 hrs) in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID564461	Antimicrobial activity against Pseudomonas aeruginosa isolate 856 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID508479	Antimicrobial activity against Pseudomonas aeruginosa isolate PA66 producing metallo-beta-lactamase VIM4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID405825	Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1629131	Antimicrobial activity against aminoglycoside-resistant Escherichia coli ATCC BAA-2452 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID1318906	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID285607	Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID278861	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID529649	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1716650	Antibacterial activity against Enterococcus faecium ATCC 27270 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID532080	Antimicrobial against Pseudomonas aeruginosa 3208 harboring phzM allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID394701	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, ANT(2'')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID405455	Antibacterial activity against Escherichia coli 1540 isolate by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID525555	Half life in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID373987	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID565069	Antibacterial activity against SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID559066	Antibacterial activity against Streptococcus oralis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID69756	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-22356 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID573549	Antibacterial activity against Klebsiella pneumoniae Kp149 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID498295	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 8 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1322247	Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID496009	Antimicrobial activity against tobramycin resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID1318901	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86052	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID559086	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID531755	Antibacterial activity against Pseudomonas aeruginosa 2126 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID544966	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID525553	AUClast in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID544961	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573499	Antibacterial activity against Citrobacter amalonaticus isolate Ca38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID65071	Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID495510	Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID768032	Antibacterial activity against Mycobacterium smegmatis str. MC2 155 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID1846503	Antibacterial activity against Pseudomonas aeruginosa NC04 cystic fibrosis assessed as reduction in bacterial growth
AID529647	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID326546	Antimicrobial activity against Mycobacterium abscessus R61 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1271381	Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 1 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID245161	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID498122	Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1716729	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID326538	Antimicrobial activity against Mycobacterium abscessus R39 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID559587	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as microbial doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID405450	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as lung bacterial count at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1716655	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa CAN-ICU 62308 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID572121	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1846495	Bactericidal activity against Pseudomonas aeruginosa K1525 mexY mutant assessed as reduction in log increase in tolerant cells at 1000 times MIC measured after 24 hrs
AID559064	Antibacterial activity against Streptococcus intermedius by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID394685	Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID561317	Antimicrobial activity against Enterobacter cloacae isolate 153 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1716871	Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID521590	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 5.7 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID622394	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microbroth dilution method in presence of Mg2+	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID405453	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID374113	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID561325	Antimicrobial activity against Klebsiella pneumoniae isolate 135 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID495513	Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1447484	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 91433 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID405823	Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID554393	Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559520	Antibacterial activity against Streptococcus mitis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1846520	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C54 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method
AID495518	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID424857	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID571687	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID497944	Antibacterial activity against Burkholderia cepacia clinical isolates by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573495	Antibacterial activity against Citrobacter amalonaticus isolate Ca3927 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID164252	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20717 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1322257	Antibacterial activity against AAC6'-IB expressing Escherichia coli PAZ505H8101 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID278806	Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID544823	Antimicrobial activity against Pseudomonas aeruginosa Xen 5 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 200 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1475190	Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
AID460803	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BAA-1605 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID532085	Antimicrobial against Pseudomonas aeruginosa 8564 harboring pyrX allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1271385	Antimicrobial activity against Mycobacterium smegmatis MC2-155 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID525551	AUC (0 to infinity) in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID207038	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-20240 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID405817	Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID535691	Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID509865	Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID330983	Antimicrobial activity against Pseudomonas aeruginosa 27853	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID564459	Antimicrobial activity against Pseudomonas aeruginosa isolate 988 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID563518	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID564452	Antimicrobial activity against Pseudomonas aeruginosa isolate 944 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID573207	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G461A mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559076	Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID425074	Antimicrobial activity against Escherichia coli DH10B in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID521597	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 5.7 by bioluminescence assay	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID522928	Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1056841	Antibacterial activity against TEM-1/SHV-12 expressing Aeromonas hydrophila isolate 268 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID559068	Antibacterial activity against Streptococcus sanguinis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559536	Antibacterial activity against Moraxella catarrhalis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498125	Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1716658	Antibacterial activity against Acinetobacter baumannii CAN-ICU 63169 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID561319	Antimicrobial activity against Escherichia coli isolate 17 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID544967	Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID405824	Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID523493	Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1873905	Antibacterial activity against Staphylococcus aureus incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID285606	Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573509	Antibacterial activity against Citrobacter amalonaticus isolate Ca1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523497	Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID495516	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID283535	Antibacterial activity against Pseudomonas aeruginosa FE10U with inactivated nuoG and galU genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID529160	Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID1459350	Antifungal activity against Aspergillus niger R330 incubated at room temperature for 30 mins followed by incubation at 32 degC for 12 hrs by two-fold dilution method	2016	Journal of natural products, 10-28, Volume: 79, Issue:10	Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities.
AID1318935	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 83182	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID531870	Ratio of antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as concentration and time required inactivate 2 log bacterial cells to antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells asses	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID1716653	Antibacterial activity against Escherichia coli CAN-ICU 63074 (AMK 32) assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID278804	Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1447476	Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID573195	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring deletion mutation at nucleotide 231-244 in nfxB gene selected at 1 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559079	Antibacterial activity against Klebsiella pneumoniae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1447483	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P264-104354 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285691	Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID577221	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gatA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID1780309	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 RS21000 and RS21005 mutant assessed as resistance development by measuring fold increase in MIC
AID577224	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring mmsA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID573722	Antibacterial activity against Klebsiella oxytoca Ko238 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID584568	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1716737	Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID768029	Antibacterial activity against Escherichia coli MC1061 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID573724	Antibacterial activity against Serratia marcescens Sm265 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1881516	Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID326543	Antimicrobial activity against Mycobacterium abscessus R47 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID571907	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1139966	Binding affinity to menin (unknown origin) assessed as thermal stability at 200 uM by differential scanning fluorimetry (Rvb = 40.46 degC)	2014	Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
AID1364634	Antibacterial activity against Acinetobacter baumannii ATCC 19606 infected in C57BL/6 mouse assessed as survival rate at 6 mg/kg, ip administered as single dose measured for 5 days (Rvb = <20%)	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID245157	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1906418	Antibacterial activity against Pseudomonas aeruginosa ATCC 27883 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, May-05, Volume: 235	Amphiphilic cyclic peptide [W
AID559052	Antibacterial activity against Staphylococcus saprophyticus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498133	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID559062	Antibacterial activity against Streptococcus bovis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559546	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia assessed as assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1422368	Antibacterial activity against Pseudomonas aeruginosa FO3 harboring AAC6'-2A by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID533857	Antibacterial activity against nonpigmented rapidly growing Mycobacterium mageritense after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID498111	Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID508728	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID434368	Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by broth microdilution method	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID534306	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID559067	Antibacterial activity against Streptococcus salivarius by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID322316	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID498132	Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID529161	FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
AID1846488	Bactericidal activity against wild type Pseudomonas aeruginosa K767 persisters assessed as reduction in CFU at 20 times MIC incubated for 24 hrs by planktonic persistance assay
AID523072	Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1716763	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1318916	Antibacterial activity against Acinetobacter baumannii isolate CAN-ICU 63169 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID69748	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20665 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID565282	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID1846496	Antibacterial activity against Pseudomonas aeruginosa C61 assessed as log reduction of bacterial population measured after 24 hrs
AID530329	Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 Ala108Thr mutant gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID559071	Antibacterial activity against Acinetobacter lwoffii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID561322	Antimicrobial activity against Escherichia coli isolate 48 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID584561	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID446135	Antibacterial activity against MexAB expressing Pseudomonas aeruginosa PA21 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID531747	Antibacterial activity against Pseudomonas aeruginosa EryR by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1716652	Antibacterial activity against gentamicin-resistant Escherichia coli CAN-ICU 61714 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID405427	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID523504	Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559073	Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498361	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrB containing isogenic acrB knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID573192	Antimicrobial activity against mexD::lox-deficient Pseudomonas aeruginosa PAOMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID405444	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS infected in C57BL/6J mouse assessed as mortality at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1881517	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID425072	Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID495514	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID559508	Antibacterial activity against Staphylococcus warneri assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564454	Antimicrobial activity against Pseudomonas aeruginosa isolate 1060 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID285592	Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID584574	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573537	Antibacterial activity against Klebsiella pneumoniae Kp7564 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID497946	Antibacterial activity against Alcaligenes xylosoxidans by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1447485	Antibacterial activity against multidrug/extremely drug-resistant/colistin-resistant Pseudomonas aeruginosa isolate 101243 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID521592	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 7.0 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID572131	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573508	Antibacterial activity against Klebsiella oxytoca isolate Ko1156 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1447461	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1629124	Antimicrobial activity against Haemophilus influenzae ATCC 49247 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID509867	Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID163075	Antibacterial activity expressed as MIC value was determined on Proteus stuartii A-20894 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1716864	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID577226	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISlacZ/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID1422367	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID554392	Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID285605	Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1056843	Antibacterial activity against CTX-15 expressing Enterobacter cloacae isolate 51 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID573531	Antibacterial activity against Klebsiella pneumoniae Kp1239 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID283541	Antibacterial activity against Pseudomonas aeruginosa FE53GU with inactivated mexZ, nuoG and galU genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID560276	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 infected in Swiss neutropenic mouse assessed as mouse survival rate at 120 mg/kg BID administered 24 hrs post infection through aerosol	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
AID559094	Effect on survival of Escherichia coli K-12 BW25113 biofilm harboring pCA24N ptac::yafQ plasmid assessed as increase in cell survival after 24 hrs pretreated with 5 uM of IPTG for 4 hrs relative to wild-type Escherichia coli K-12 BW25114	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID1721428	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2020	Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17	Synthesis of novel lignan-like compounds and their antimicrobial activity.
AID498096	Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID525554	Tmax in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID283529	Antibacterial activity against Pseudomonas aeruginosa PAO1 by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1233142	Antibacterial activity against methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID1318910	Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1678763	Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID559085	Antibacterial activity against Proteus vulgaris by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID497945	Antibacterial activity against Stenotrophomonas maltophilia by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID768030	Antibacterial activity against Staphylococcus aureus ATCC 29213 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID245186	Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853; Range is 0.25-1	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID245117	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID498298	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 4 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID285603	Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573500	Antibacterial activity against Klebsiella pneumoniae isolate Kp38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1716766	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 64 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID245155	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID559057	Antibacterial activity against Lancefield Streptococcus sp. 'group G' by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID394714	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID498109	Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1265776	Antibacterial activity against Staphylococcus aureus assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID523491	Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1846524	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa NC06 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method
AID559645	Antimicrobial activity against Extended-spectrum beta-lactamase producing Escherichia coli clinical isolate assessed as resistant isolate	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region.
AID405432	fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID573190	Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID326549	Antimicrobial activity against Mycobacterium abscessus R49 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID523506	Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1318930	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86141	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID559497	Antibacterial activity against vancomycin- resistant Enterococcus faecalis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559042	Antibacterial activity against vancomycin- resistant Enterococcus faecalis by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID622393	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by microbroth dilution method in absence of Mg2+	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID394684	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1716646	Antibacterial activity against methicillin-resistance Staphylococcus aureus ATCC 33592 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID508725	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID544963	Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID535694	Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID2938	Dissociation constant towards 16S rRNA construct A	2000	Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14	Enhanced binding of aminoglycoside dimers to a "dimerized" A-site 16S rRNA construct.
AID561328	Antimicrobial activity against Klebsiella pneumoniae isolate 202 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1318931	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 92014	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID164251	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20653 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID498110	Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1716735	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID622388	Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID1629127	Antimicrobial activity against Klebsiella pneumoniae ATCC 10031 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID245160	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID544636	Antimicrobial activity against Staphylococcus aureus Xen 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1318936	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 84745	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID428873	Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1846508	Antibacterial activity against Pseudomonas aeruginosa NC10 cystic fibrosis assessed as tobramycin MIC in presence of berberine
AID372846	Antibacterial activity against Acinetobacter baumannii isolate E expressing 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID424860	Antimicrobial activity against Escherichia coli XL1-Blue by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID533854	Antibacterial activity against nonpigmented rapidly growing Mycobacterium peregrinum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID559080	Antibacterial activity against Legionella pneumophila by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID523513	Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1716723	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID405419	fCmax in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID405820	Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID144015	In vitro anti-mycobacterial activity expressed as minimum inhibitory concentration against Mycobacterium fortuitum ATCC 6841	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.
AID1233138	Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7386 after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID573211	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 0.5 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID533860	Antibacterial activity against nonpigmented rapidly growing Mycobacterium porcinum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID573497	Antibacterial activity against Serratia marcescens isolate Sm2723 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID559078	Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559585	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID554395	Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID544953	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID565067	Antibacterial activity against CTX-M-15 and SHV-27 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID326533	Antimicrobial activity against Mycobacterium abscessus after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID283545	Antibacterial activity against Pseudomonas aeruginosa FE57GUZ with inactivated rplY, nuoG, galU and mexZ genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID508490	Antimicrobial activity against Pseudomonas aeruginosa isolate K45-32 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID1233136	Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus B19506 after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID521834	Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID625923	Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents.
AID1442617	Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection assessed as reduction in log10CFU per gram of lung at 40 mg/kg, in bid administered 2 to 12 hrs of post-infection measured after 24 hrs relative to untrea	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID1678760	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID285600	Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1716862	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth by measuring doxycycline MIC at 0.25 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 16 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID396028	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID573186	Antimicrobial activity against Pseudomonas aeruginosa PAO1 biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID405090	Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID405443	Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as mortality at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID559074	Antibacterial activity against Enterobacter aerogenes by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1422378	Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID555554	Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID584577	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1265778	Antibacterial activity against Bacillus subtilis assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID394682	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID559095	Bactericidal activity against Escherichia coli K-12 BW25113 biofilm harboring pCA24N ptac::yafQ plasmid assessed as log reduction of viable cells after 24 hrs pretreated with 5 uM of IPTG for 4 hrs	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID498104	Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID68018	Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-9656 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID774218	Antibacterial activity against Pseudomonas aeruginosa F03 expressing AAC6'-2A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID559589	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID559599	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1322254	Antibacterial activity against Acinetobacter lwoffii ATCC 17925 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID405437	fCmax/MIC ratio in Pseudomonas aeruginosa PAOdeltamutS infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID1906417	Antibacterial activity against imipenem resistant Klebsiella pneumoniae ATCC BAA 1705 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, May-05, Volume: 235	Amphiphilic cyclic peptide [W
AID535850	Antimicrobial against Pseudomonas aeruginosa 33410 harboring phoU allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1846504	Antibacterial activity against Pseudomonas aeruginosa NC04 cystic fibrosis assessed as tobramycin MIC in presence of berberine
AID559545	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID622384	Antibacterial activity against Staphylococcus aureus after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID533568	Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1447467	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID324864	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID394706	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(3')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID460800	Antibacterial activity against Acinetobacter baumannii UH8407 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID554399	Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1629126	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID523508	Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID584566	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1846518	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C30 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method
AID565073	Antibacterial activity against CTX-M-14 ESBL producing Morganella morganii assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID497950	Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as inhibition of biofilm formation by microtiter plate reader assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573196	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring nfxB T248C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID534192	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID554387	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559527	Antibacterial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID560599	Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf wild type gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1447472	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1846521	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C59 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method
AID1318938	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573506	Antibacterial activity against Klebsiella pneumoniae isolate Kp3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID521595	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 7.0 by bioluminescence assay	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID524003	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID522931	Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID584571	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID245112	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID556760	Antimicrobial activity against extended spectrum beta-lactamase CTX-M-2-producing Pseudomonas aeruginosa isolate P6208	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
AID532078	Antimicrobial against Pseudomonas aeruginosa 30848 harboring phoU allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1447482	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P262-101856 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1233137	Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7425 after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID559097	Antimicrobial activity against yafQ gene-deficient Escherichia coli K-12 BW25113 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID424858	Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID285612	Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1410916	Stabilization of pre-miR-21 RNA (unknown origin) assessed as increase in melting temperature at 10 uM by UV-spectrophotometric analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan.
AID584554	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID559092	Bactericidal activity against yafQ gene-deficient Escherichia coli K-12 BW25113 biofilm assessed as log reduction of viable cells after 24 hrs relative to wild-type Escherichia coli K-12 BW25113	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID244967	Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID394704	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1, ANT(2'')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID559544	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573198	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAA biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559049	Antibacterial activity against Staphylococcus haemolyticus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285689	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID1318963	Antibacterial activity against extremely drug-resistant Pseudomonas aeruginosa isolate 104354 infected in Galleria mellonella assessed as larvae survival at 50 mg/kg administered as single dose measured after 24 hrs (Rvb = 27 %)	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID774220	Antibacterial activity against Acinetobacter lwoffii AI.88-483 expressing APH3'-6A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID768025	Inhibition of protein synthesis in Escherichia coli S30 extracts after 90 mins by coupled transcription/translation assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID559082	Antibacterial activity against Morganella morganii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID529456	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID584570	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID498093	Antibacterial activity against Pseudomonas aeruginosa PA861 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1428626	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID523892	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID340858	Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID1716662	Antibacterial activity against Pseudomonas aeruginosa 750 harboring efflux mutant assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID324860	Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID559521	Antibacterial activity against Streptococcus oralis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1780303	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 assessed as reduction in bacterial growth by broth microdilution assay
AID322318	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID544824	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID584559	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1318921	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 260-97103	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID622398	Bactericidal activity against Staphylococcus aureus DSM 799 assessed as log decrease in bacterial count at MIC after 2 hrs by time-kill assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID428871	Antibacterial activity against Escherichia coli CSH-2 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID523495	Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID283549	Antibacterial activity against Pseudomonas aeruginosa FE64 containing inactivated rplY and mexXY genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID285583	Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID164255	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21294 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID532088	Antimicrobial against Pseudomonas aeruginosa 3465 harboring tsaA allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID245158	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID519314	Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID520697	Antimicrobial activity against Escherichia coli DH10B harboring p05283 carrying qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID573539	Antibacterial activity against Klebsiella pneumoniae Kp38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID570782	Antimicrobial activity against multidrug-resistant Acinetobacter baumannii assessed as resistant isolates by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID1318918	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID207039	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-21978 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID394699	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID555556	Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID565072	Antibacterial activity against SHV-12 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID534297	Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID571901	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID563522	Antibacterial activity against Pseudomonas aeruginosa NY219 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID374111	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID163066	ntibacterial activity expressed as MIC value was determined on Proteus rettgeri A-21207 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID207043	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-9537 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID207041	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22210 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID531863	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction in bacterial count at 10 mg/L after 50 mins by plate count method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID1716770	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth by measuring doxycycline MIC at 8 ug/ml incubated for 18 hrs in presence of doxycycline by broth microdilution assay (Rvb = 64 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1678762	Antibacterial activity against Acinetobacter baumannii ATCC 19606 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID534166	Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1318908	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID245154	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID525562	Cmax in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID564690	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID498100	Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573725	Antibacterial activity against Citrobacter youngae CyB38 transconjugant harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID554384	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559506	Antibacterial activity against Staphylococcus lugdunensis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID521599	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 assessed as log reduction in viable counts at 150 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID573723	Antibacterial activity against Klebsiella pneumoniae Kp204 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1716660	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID534303	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID199517	Compound was tested for the inhibition of Rev-RBE RNA complex formation	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID498084	Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as inhibition of biofilm formation by microtiter plate reader assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID530328	Antimicrobial activity against Escherichia coli XL1-Blue harboring pGEM-T carrying aacA4 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID285576	Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498095	Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID531749	Antibacterial activity against Pseudomonas aeruginosa FK06 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1846510	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C30 assessed as reduction in MIC in presence of berberine by broth microdilution method
AID126451	Dissociation constant for binding to mitochondrial 12S rRNA construct M4 was determined	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Decoding region bubble size and aminoglycoside antibiotic binding.
AID559045	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573494	Antibacterial activity against Enterobacter cloacae isolate El3518 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID498129	Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID554400	Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID564462	Antimicrobial activity against Pseudomonas aeruginosa isolate 913 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID257554	Antibacterial activity against Staphylococcus aureus	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.
AID573721	Antibacterial activity against Escherichia coli Ec221 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID525561	Half life in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID523511	Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1374182	Antibacterial activity against Klebsiella pneumoniae CMCC 46117 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID372847	Antibacterial activity against Escherichia coli DH10B expressing Acinetobacter baumannii isolate B 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID498091	Antibacterial activity against Pseudomonas aeruginosa PA5026 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID285597	Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573400	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1716867	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID279939	Antibiotic susceptibility by resistance against Pseudomonas aeruginosa from samples collected from patients	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID68016	Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-21006 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID564685	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID573530	Antibacterial activity against Citrobacter youngae isolate CyB38 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523067	Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID565230	Antimicrobial activity against Mycobacterium chelonae 9917 by resazurine microtiter assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID498118	Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID559807	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene complemented with wild type DNA oxidative repair system mutY gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1716870	Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID768026	Antibacterial activity against biofilm negative Staphylococcus epidermidis ATCC 12228 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID542065	Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID326535	Antimicrobial activity against Mycobacterium fortuitum after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID542106	Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID285574	Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573191	Antimicrobial activity against mutS::lox,nfxB gene-deficient Pseudomonas aeruginosa PAOMSNB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID573333	Antibacterial activity against Enterobacter cloacae isolate El3280 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID519406	Antibacterial activity against Escherichia coli DH10B harboring pBCSK expressing rmtB gene by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.
AID446140	Antibacterial activity against R-methylase expressing Escherichia coli 06AB003 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID559515	Antibacterial activity against Streptococcus pyogenes assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID498103	Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID69757	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-9632 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1780307	Antibacterial activity against wild type Pseudomonas aeruginosa LESB58 LpxA Ser150Ala mutant assessed as resistance development by measuring fold increase in MIC
AID554402	Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID531867	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as respiratory activity by CTC-DAPI staining	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID521842	Antibacterial activity against Escherichia coli J53 by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID584576	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573197	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAB biofilm harboring nfxB G125T mutant gene selected at 0.5 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559532	Antibacterial activity against non-ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573213	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T544C mutant gene selected at 4 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID498092	Antibacterial activity against Pseudomonas aeruginosa PA876 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1716706	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1442616	Antibacterial activity against Pseudomonas aeruginosa PA1145 in BALB/c mouse model of lung infection administered intranasally as bid for 2 to 12 hrs of post-infection measured after 24 hrs	2017	Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.
AID498134	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID531752	Antibacterial activity against Pseudomonas aeruginosa 3308 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID573332	Antibacterial activity against Klebsiella pneumoniae isolate Kp2730 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID533569	Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID166711	Tested for binding affinity against RNA construct A	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID559053	Antibacterial activity against Staphylococcus warneri by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1691822	Antibacterial activity against Pseudomonas aeruginosa PAO1 biofilm cells assessed as reduction in bacterial growth after 2 days by resazurin dye based assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID1056835	Antibacterial activity against SIM-1 expressing Acinetobacter baumannii isolate 170 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID322317	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID324868	Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1881515	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID529457	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID532082	Antimicrobial against Pseudomonas aeruginosa 3894 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1318902	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID498097	Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1319004	Induction of cytoplasmic membrane depolarization in Pseudomonas aeruginosa PAO1 by DiSC3(5) dye based fluorescence assay	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573188	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID534168	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1364567	Growth inhibition of Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID278859	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID584558	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID424863	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID1447477	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID324874	Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID126450	Dissociation constant for binding to mitochondrial 12S rRNA construct M3 was determined	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Decoding region bubble size and aminoglycoside antibiotic binding.
AID1374179	Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID525569	Oral bioavailability in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID571917	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID508485	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-43038 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID520638	Antimicrobial activity against Escherichia coli MRY04-1060 expressing qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID394702	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID564019	Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID561320	Antimicrobial activity against Escherichia coli isolate 17 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID285609	Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1850992	Binding affinity to human telomeric i-motif DNA by SPR analysis	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Identification of sugar-containing natural products that interact with i-motif DNA.
AID1385464	Antimicrobial activity against Streptococcus agalactiae after 24 hrs by two-fold dilution method	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Helvolic Acid Derivatives with Antibacterial Activities against Streptococcus agalactiae from the Marine-Derived Fungus Aspergillus fumigatus HNMF0047.
AID554440	Ratio of MIC for Pseudomonas aeruginosa 2933 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID326552	Antimicrobial activity against Mycobacterium fortuitum V61 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1447468	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285578	Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1716719	Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID554401	Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID498300	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 0.25 ug/ml up to 48 hrs in absence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID554390	Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID498094	Antibacterial activity against Pseudomonas aeruginosa PA5020 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID521596	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 7.0 by bioluminescence assay	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID498130	Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1322259	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID534304	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID525574	Cmax in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID1322250	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID508730	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1678761	Antibacterial activity against Acinetobacter baumannii ATCC 19606 using cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID396032	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID285575	Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531751	Antibacterial activity against Pseudomonas aeruginosa 3308 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID584579	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1233135	Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus 7419 after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID544821	Antimicrobial activity against Pseudomonas aeruginosa Xen 5 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID573526	Antibacterial activity against Klebsiella pneumoniae isolate Kp204 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523512	Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID508722	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID559592	Antimicrobial activity against Pseudomonas aeruginosa PAO1 selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID531753	Antibacterial activity against Pseudomonas aeruginosa 2439 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID326551	Antimicrobial activity against Mycobacterium fortuitum V13 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1271382	Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 2 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID521591	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 at pH 5.7 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID95884	Antibacterial activity expressed as MIC value was determined on Klebsiella pneumonia A-20468 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1447462	Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33592 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID424861	Antimicrobial activity against Escherichia coli XL1-Blue harboring pGTAAC-32 with cloned aac(6)'-32 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID1666868	Inhibition of swarming motility of Burkholderia cepacia clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID1422373	Antibacterial activity against Escherichia coli ATCC 25922 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID544820	Antimicrobial activity against Staphylococcus epidermidis Xen 43 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1716645	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID285580	Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1846514	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C84 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID285690	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID1580090	Antibacterial activity against novobiocin-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID446141	Antibacterial activity against R-methylase expressing Enterobacter aerogenes 06AB008 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID571697	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1629125	Antimicrobial activity against Haemophilus influenzae ATCC 10211 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID207055	In vitro inhibitory activity against Staphylococcus aureus ATCC 29213	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID532081	Antimicrobial against Pseudomonas aeruginosa 3434 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID554394	Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID525559	AUClast in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1319015	Inhibition of circular DNA translation in Escherichia coli S30 extract after 60 mins by luciferase reporter gene assay	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID534296	Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID508484	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-20287 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID1271383	Antimicrobial activity against Gram-negative Haemophilus influenzae ATCC 51907 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID529653	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID519177	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 8 ug/ml of amikacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1447474	Antibacterial activity against gentamicin/tobramycin-resistant Pseudomonas aeruginosa isolate CANWARD-2011 96846 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID532090	Antimicrobial against Pseudomonas aeruginosa 46396 harboring katA allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID564460	Antimicrobial activity against Pseudomonas aeruginosa isolate 1006 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID278801	Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID525563	AUC (0 to infinity) in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID573540	Antibacterial activity against Morganella morganii Mm38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID245162	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID278809	Antibacterial activity against Escherichia coli BL21(DE3)	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.
AID577225	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring yaaA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID285644	Antimicrobial activity against Pseudomonas aeruginosa 15H5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID322314	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID571923	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID508481	Antimicrobial activity against Pseudomonas aeruginosa isolate B4-25753 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID534298	Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID163042	Antibacterial activity expressed as MIC value was determined on Proteus rettgeri A-9637 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1318907	Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID530321	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID1846509	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C25 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID1716721	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID544950	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID542064	Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID69753	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20895 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID560600	Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf (TTG-ATG) mutant gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID561314	Antimicrobial activity against Enterobacter cloacae isolate 37 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1318911	Antibacterial activity against gentamicin/tobramycin/ciprofloxacin-resistant Escherichia coli isolate CANWARD-2011 97615 harboring AAC3-2A after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID531869	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as concentration and time required inactivate 2 log bacterial cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID498124	Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573204	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T41C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1881522	Antibacterial activity against Enterococcus faecium ATCC 27270 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID396033	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1824803	Antibacterial activity against Pseudomonas aeruginosa FB assessed as bacterial growth inhibition by broth microdilution method	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	New
AID69754	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-21218 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID257551	Antibacterial activity against Klebsiella pneumoniae	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.
AID564697	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID207056	In vitro inhibitory activity against Staphylococcus aureus MRSA 33591	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID559601	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1716636	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 1024 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID554437	Ratio of MIC for Pseudomonas aeruginosa 2729 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID554432	Ratio of MIC for Pseudomonas aeruginosa 615R to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID571921	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID546618	Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID1271380	Antimicrobial activity against Gram-positive Staphylococcus aureus ATCC 29213 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID768028	Antibacterial activity against Haemophilus influenzae ATCC 51907 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID278803	Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2]	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID573547	Antibacterial activity against Klebsiella oxytoca Ko1156 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID498301	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 0.25 ug/ml up to 48 hrs in presence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1271377	Antimicrobial activity against Gram-positive Bacillus cereus ATCC 17788 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID584578	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1716648	Antibacterial activity against methicillin-resistance Staphylococcus epidermidis CAN-ICU 61589 (CAZ>32) assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID285599	Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1580092	Antibacterial activity against novobiocin and test compound-resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages in presence of novobiocin by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID577004	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as viable bacterial count by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID1322249	Antibacterial activity against healthcare-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID245282	In vitro minimum inhibitory concentration against Staphylococcus aureus ATCC 29213; Range is 0.12-1	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID285688	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID498086	Antibacterial activity against Pseudomonas aeruginosa PA899 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID394708	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID774213	Antibacterial activity against Escherichia coli L58058.1 expressing ANT2''-1A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID508483	Antimicrobial activity against Pseudomonas aeruginosa isolate K34-7 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID565074	Antibacterial activity against CTX-M-14 ESBL producing Proteus mirabilis assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID565231	Antimicrobial activity against Mycobacterium chelonae 9917 harboring pZS01 carrying mspA gene by resazurine microtiter assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID326540	Antimicrobial activity against Mycobacterium abscessus NTU459 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID523488	Antimicrobial activity against Pseudomonas aeruginosa R70 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID508478	Antimicrobial activity against Pseudomonas aeruginosa isolate U9-19005 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID561316	Antimicrobial activity against Enterobacter cloacae isolate 101 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID498090	Antibacterial activity against Pseudomonas aeruginosa PA1036 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID82302	Tested for the ability to bind the HIV-1 RRE-RNA construct by fluorescence anisotropy	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Binding of dimeric aminoglycosides to the HIV-1 rev responsive element (RRE) RNA construct.
AID559539	Antibacterial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564016	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID571893	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID544829	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID559523	Antibacterial activity against Streptococcus sanguinis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID166716	Tested for binding affinity against RNA construct C; n.b. means no observable binding	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID768036	Antibacterial activity against Bacillus subtilis 168 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID625925	Antibacterial activity against Pseudomonas aeruginosa by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents.
AID497951	Antibacterial activity against Pseudomonas aeruginosa PA5063 assessed as inhibition of biofilm formation by microtiter plate reader assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID207042	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22231 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID1873911	Antibacterial activity against Streptococcus dysgalactiae incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID534305	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID326544	Antimicrobial activity against Mycobacterium abscessus R50 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID572135	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1809539	Anti-bioflim activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bioflim formation incubated for 24 hrs by crystal violet staining based assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as
AID521840	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID622385	Antibacterial activity against oxacillin-sensitive Staphylococcus aureus after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID531750	Antibacterial activity against Pseudomonas aeruginosa FK06 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID534300	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID531745	Antibacterial activity against Pseudomonas aeruginosa PAO1 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID565281	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID523398	Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1716637	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID573720	Antibacterial activity against Citrobacter koseri Ck211 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID565280	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID1185007	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 after 18 to 20 hrs by microbroth dilution technique	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Bioreductively Activated Reactive Oxygen Species (ROS) Generators as MRSA Inhibitors.
AID573187	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID564455	Antimicrobial activity against Pseudomonas aeruginosa isolate 1095 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID324872	Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID1846507	Antibacterial activity against Pseudomonas aeruginosa NC10 cystic fibrosis assessed as reduction in bacterial growth
AID69751	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20732 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID572139	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID285584	Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1716643	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID424879	Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID564456	Antimicrobial activity against Pseudomonas aeruginosa isolate 22 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1846490	Bactericidal activity against Pseudomonas aeruginosa K767 wild type assessed as decrease in cell fluorescence in presence of berberine by ethidium bromide efflux assay (Rvb = 10%)
AID559505	Antibacterial activity against Staphylococcus hominis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1322261	Cytotoxicity against mouse J774 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID571692	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID486971	Antibacterial activity against Klebsiella pneumoniae ATCC 27736 after 24 hrs by micro broth dilution method	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID325976	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 10 ug/ml by rotating disk reactor method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
AID324870	Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID245113	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1678767	Antibacterial activity against Enterococcus faecalis ATCC 51299 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1318913	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID523066	Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID534771	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID554433	Ratio of MIC for Pseudomonas aeruginosa 3020R to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1716764	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID535849	Antimicrobial against Pseudomonas aeruginosa PAO1 by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID245115	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID1540370	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of planktonic cells growth at >0.15 uM incubated for 24 to 25 hrs	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Glycocluster Tetrahydroxamic Acids Exhibiting Unprecedented Inhibition of
AID1846506	Antibacterial activity against Pseudomonas aeruginosa NC06 cystic fibrosis assessed as tobramycin MIC in presence of berberine
AID519189	Antimicrobial activity against mexXY-OprM-overproducing Pseudomonas aeruginosa isolate PA/XY assessed as zone of inhibition by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1666869	Inhibition of swarming motility of Salmonella enterica clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID523502	Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID559583	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID460802	Antibacterial activity against Acinetobacter baumannii AB0043 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID774217	Antibacterial activity against Pseudomonas aeruginosa PA22 (PT629) expressing MexXY after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID446131	Antibacterial activity against ANT2'-2a expressing Escherichia coli L58058.1 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID1716644	Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID498115	Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1447464	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1271378	Antimicrobial activity against Gram-positive Bacillus subtilis 168 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID285591	Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1422370	Antibacterial activity against Pseudomonas aeruginosa PA406 harboring triABC deletion mutant by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID573206	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T562C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID297186	Antibacterial activity against multidrug resistant Staphylococcus aureus 49589	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.
AID573522	Antibacterial activity against Citrobacter koseri isolate Ck211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID498114	Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID521583	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 infected in mouse J774A.1 macrophage assessed as log reduction in viable counts at 150 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID573501	Antibacterial activity against Morganella morganii isolate Mm38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID508489	Antimicrobial activity against Pseudomonas aeruginosa isolate K44-24 producing metallo-beta-lactamase IMP14 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID1716641	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1265779	Antibacterial activity against Salmonella assessed as growth inhibition incubated for 24 hrs at 37 degC by agar well diffusion method	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.
AID164250	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20601 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID523396	Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID565283	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID519186	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 4 ug/ml of cefepime exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1716713	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID278860	Antiproliferative effect against HeLa cells after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID238131	Binding dissociation constant towards 3'-Fl-AM1A-Rhd in Bacillus subtilis tyrS	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA.
AID245116	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID278857	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID563521	Antibacterial activity against Pseudomonas aeruginosa NY217 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID525558	Oral bioavailability in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID559530	Antibacterial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID584569	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID324310	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID285593	Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498123	Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID774214	Antibacterial activity against Escherichia coli PAZ505H8101 expressing AAC6'-1B after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID564018	Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1716868	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID573524	Antibacterial activity against Escherichia coli isolate Ec221 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573189	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID768034	Antibacterial activity against Listeria monocytogenes ATCC 19115 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID1271379	Antimicrobial activity against Gram-positive Listeria monocytogenes ATCC 19115 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID573330	Antibacterial activity against Klebsiella pneumoniae isolate Kp1239 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1447473	Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate CAN-ICU 62308 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID554438	Ratio of MIC for Pseudomonas aeruginosa 2804 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID283536	Antibacterial activity against Pseudomonas aeruginosa FE53U with inactivated mexZ and galU genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID573399	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID322315	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID559806	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene complemented with wild type DNA oxidative repair system mutT gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID531862	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilms	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID508488	Antimicrobial activity against Pseudomonas aeruginosa isolate OS-210 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID564466	Antimicrobial activity against Pseudomonas aeruginosa isolate 821 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID577223	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID1716638	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1318914	Antibacterial activity against gentamicin/tobramycin-resistant Pseudomonas aeruginosa isolate CANWARD-2011 96846 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573529	Antibacterial activity against Acinetobacter baumannii isolate AbN450 harboring IblaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523503	Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573203	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID531866	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as biofilm assessed as membrane integrity by BacLight Live/Dead staining	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID1493078	Antibacterial activity against vancomycin-resistant Enterococcus faecalis 12 by dilution susceptibility test	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2.
AID1846523	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa AR48 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1653583	Anti-leprotic activity against Mycobacterium leprae infected in BALB/c weanling mouse assessed as bacteria killing at 20 mg/kg, ip administrated for 60 days and measured after 1 year by most probable number technique analysis relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID1322258	Antibacterial activity against ANT2''-IA expressing Escherichia coli L8058.1 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID520696	Antimicrobial activity against Escherichia coli DH10B harboring p041060 carrying qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID1447487	Synergistic antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs in presence of minocycline by checkerboard assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID509869	Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID529303	Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID564453	Antimicrobial activity against Pseudomonas aeruginosa isolate 1050 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1846489	Bactericidal activity against Pseudomonas aeruginosa K1525 mexY mutant persisters assessed as reduction in CFU at 20 times MIC incubated for 24 hrs by planktonic persistance assay
AID1385465	Antimicrobial activity against Staphylococcus aureus after 24 hrs by two-fold dilution method	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	Helvolic Acid Derivatives with Antibacterial Activities against Streptococcus agalactiae from the Marine-Derived Fungus Aspergillus fumigatus HNMF0047.
AID1846513	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C59 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID584572	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1139965	Binding affinity to menin (unknown origin) assessed as thermal stability at 50 uM by differential scanning fluorimetry (Rvb = 40.46 degC)	2014	Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.
AID554441	Ratio of MIC for Pseudomonas aeruginosa 2998 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID446128	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID521582	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 infected in mouse J774A.1 cells at 50 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID559590	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID531746	Antibacterial activity against Pseudomonas aeruginosa FE60 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1629129	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID533859	Antibacterial activity against nonpigmented rapidly growing Mycobacterium smegmatis after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID525573	Half life in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID1850993	Binding affinity to human c-Myc promoter i-motif DNA by SPR analysis	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Identification of sugar-containing natural products that interact with i-motif DNA.
AID394707	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, AAC(3')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID559500	Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571905	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID405422	Half life of free unbound fraction in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID498299	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 8 times MIC up to 48 hrs in presence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID523397	Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID584557	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID534172	Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID405436	fCmax/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID555555	Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID1629132	Antimicrobial activity against aminoglycoside-resistant Klebsiella pneumoniae ATCC BAA-2470 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID565068	Antibacterial activity against CTX-M-15 and SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID1846501	Antibacterial activity against Pseudomonas aeruginosa NC02 cystic fibrosis assessed as reduction in bacterial growth
AID279940	Antibiotic susceptibility by resistance against MDR Pseudomonas aeruginosa from samples collected from patients	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
AID573201	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T533C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID534169	Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1677266	Antibacterial activity against Pseudomonas aeruginosa PAO200 harboring mexAB-oprM efflux deficient mutant	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1056839	Antibacterial activity against TEM-1/CTX-M-15 expressing Aeromonas caviae isolate 260 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID559531	Antibacterial activity against ciprofloxacin-susceptible Haemophilus influenzae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559594	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID532084	Antimicrobial against Pseudomonas aeruginosa 40198 harboring nirJ allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1364571	Growth inhibition of multidrug-resistant Acinetobacter baumannii ATCC BAA 18002 after 48 hrs by resazurin dye based broth microdilution method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID340860	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID564463	Antimicrobial activity against Pseudomonas aeruginosa isolate 927 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1482267	Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID446127	Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PT629 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID283544	Antibacterial activity against Pseudomonas aeruginosa FE57GZ with inactivated rplY, nuoG and mexZ genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID519405	Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli isolate ECRB1 by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.
AID572145	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID326550	Antimicrobial activity against Mycobacterium abscessus V120 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1318904	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis isolate CANWARD-2008 81388 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1233139	Antibacterial activity against patient-derived methicillin-resistant Staphylococcus aureus K1 after 18 to 20 hrs by microbroth dilution method	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.
AID245118	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID207040	Antibacterial activity expressed as MIC value was determined on Staphylococcus aureus A-22058 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID285589	Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1846498	Antibacterial activity against Pseudomonas aeruginosa K1525 mexY mutant assessed as reduction in bacterial growth rate in presence of berberine
AID531758	Antibacterial activity against Pseudomonas aeruginosa 1956 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID1447478	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID523510	Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID324858	Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID533567	Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573511	Antibacterial activity against Morganella morganii isolate Mm1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID521575	Reduction in light emission by Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 cells after 5 mins	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID571689	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573496	Antibacterial activity against Enterobacter cloacae isolate El1573 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID571913	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID446124	Antibacterial activity against APH30-VIa expressing Acinetobacter lwoffii AI.88-483 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID533852	Antibacterial activity against nonpigmented rapidly growing Mycobacterium abscessus after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID559510	Antibacterial activity against Lancefield Streptococcus sp. 'group C' assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID571911	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID525552	Oral bioavailability in 15 hrs fasted BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID372845	Antibacterial activity against Acinetobacter baumannii isolate D expressing 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1678769	Antibacterial activity against Staphylococcus aureus ATCC 43300 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID584565	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1459348	Antibacterial activity against Escherichia coli ATCC 0111 incubated at room temperature for 30 mins followed by incubation at 37 degC for 12 hrs by two-fold dilution method	2016	Journal of natural products, 10-28, Volume: 79, Issue:10	Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities.
AID283546	Antibacterial activity against Pseudomonas aeruginosa KJ7106 with inactivated PA5471 gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1629123	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID1322260	Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID1716733	Antibacterial activity against Pseudomonas aeruginosa 260-97103 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID510964	Antimicrobial activity against CTX-M15/CTX-M14 ESBL producing Escherichia coli ST131 clonal complex isolate assessed as nonsusceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.
AID285594	Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID563597	Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolates by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
AID559096	Antimicrobial activity against Escherichia coli K-12 BW25113 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID625924	Antibacterial activity against Klebsiella pneumoniae ATCC 27736 by micro-broth dilution method	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents.
AID559803	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID544964	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID498088	Antibacterial activity against Pseudomonas aeruginosa PA880 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID571887	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584562	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID542049	Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1447466	Antibacterial activity against Enterococcus faecium ATCC 27270 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID559529	Antibacterial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID559542	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1447587	Induction of cytoplasmic membrane depolarization in Pseudomonas aeruginosa PAO1 up to 1200 secs by diSC3-5 staining based fluorescence assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID285573	Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID509868	Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID283539	Antibacterial activity against Pseudomonas aeruginosa FE57G with inactivated rplY and nuoG genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID519408	Antibacterial activity against 16S rRNA methylase RmtB and CTX-M-65 ESBL producing Escherichia coli DH10B by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.
AID508482	Antimicrobial activity against Pseudomonas aeruginosa isolate K34-73 producing metallo-beta-lactamase VIM4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID529651	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1447479	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 100036 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1716705	Antibacterial activity against Pseudomonas aeruginosa 100036 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID525565	AUClast in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID573403	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID523501	Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1677265	Antibacterial activity against Pseudomonas aeruginosa PAO750 harboring mexAB-oprM/mexCD-oprJ/mexEF-oprN/mexJK/mexXY/opmH efflux deficient mutant	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID573205	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID283532	Antibacterial activity against Pseudomonas aeruginosa FE53 with inactivated mexZ gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1271384	Antimicrobial activity against Gram-negative Pseudomonas aeruginosa PAO1 after 16 to 24 hrs by micro-dilution method	2015	ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1447488	Synergistic antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs in presence of rifampicin by checkerboard assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID559509	Antibacterial activity against Streptococcus agalactiae assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1906415	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in microbial growth incubated for 24 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, May-05, Volume: 235	Amphiphilic cyclic peptide [W
AID326553	Antimicrobial activity against Mycobacterium fortuitum V146 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID564017	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID559501	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID394703	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing ANT(2'')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID559099	Bactericidal activity against Escherichia coli K-12 BW25113 stationary-phase planktonic cell assessed as log reduction of viable cells after 24 hrs	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID1449931	Inhibition of RND efflux pump in Pseudomonas aeruginosa PAO1 assessed as potentiation of minocycline-induced antibacterial activity at 8 ug/ml after 18 to 24 hrs by checker board assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID257550	Antibacterial activity against Streptococcus faecalis	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.
AID565063	Antibacterial activity against CTX-M-15 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID1678768	Antibacterial activity against Staphylococcus aureus ATCC 43300 using Cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID585434	Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID1809549	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bacterial growth for complete inhibition of bacterial growth incubated for 24 hrs	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as
AID1678766	Antibacterial activity against Escherichia coli ATCC 25922 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1447463	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis isolate CANWARD-2008 81388 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID622387	Antibacterial activity against Escherichia coli after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID564458	Antimicrobial activity against Pseudomonas aeruginosa isolate 896 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1493076	Antibacterial activity against vancomycin-resistant Enterococcus faecium 7 by dilution susceptibility test	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Antibacterial 3,6-Disubstituted 4-Hydroxy-5,6-dihydro-2H-pyran-2-ones from Serratia plymuthica MF371-2.
AID498106	Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1422372	Antibacterial activity against Acinetobacter lwoffii AI.88-483 harboring APH3'-6A by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID1449930	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 to 24 hrs by microbroth dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.
AID561327	Antimicrobial activity against Klebsiella pneumoniae isolate 202 expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1881520	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 61589 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID774216	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID559597	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of tobramycin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID573519	Antibacterial activity against Escherichia coli isolate Ec211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID559517	Antibacterial activity against Streptococcus bovis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573505	Antibacterial activity against Enterobacter cloacae isolate El3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID405822	Antimicrobial activity against Escherichia coli DH5alpha	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1318917	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID285602	Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523496	Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID523490	Antimicrobial activity against Pseudomonas aeruginosa AHP Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1322255	Antibacterial activity against APH3'-VIA expressing Acinetobacter lwoffii AI.88-483 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID166719	Tested for binding affinity against RNA construct E	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.
AID571915	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID521580	Antibacterial activity against Salmonella enterica serovars Typhimurium ATCC 14028 assessed as log reduction in viable counts at 150 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID1056844	Antibacterial activity against TEM-1/CTX-M-15 expressing Enterobacter cloacae isolate 62 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID559519	Antibacterial activity against Streptococcus intermedius assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID396029	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID405091	Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID523500	Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID69755	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-22045 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID573208	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB C116T mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID571895	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID584567	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID768033	Antibacterial activity against Bacillus cereus ATCC 11778 by double-dilution technique	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.
AID1716633	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 2048 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID573510	Antibacterial activity against Citrobacter freundii isolate Cf1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID559522	Antibacterial activity against Streptococcus salivarius assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1716865	Antibacterial activity against Pseudomonas aeruginosa 101885 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1374181	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID523514	Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID405431	fAUC (0 to 24 hrs)/MIC ratio in Pseudomonas aeruginosa PAO1 infected C57BL/6J mouse at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID498360	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52145R assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID1580081	Induction of outer membrane permeabilization in Pseudomonas aeruginosa PAO1 assessed as increase in accumulation of NPN by measuring fluorescence intensity at 14 ug/ml measured immediately by NPN dye uptake assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1666883	Inhibition of swarming motility of Pseudomonas aeruginosa HONKR at 10 ug incubated for 18 to 24 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID495509	Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID446123	Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID573541	Antibacterial activity against Klebsiella pneumoniae Kp38045 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID326542	Antimicrobial activity against Mycobacterium abscessus NTU446 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID283537	Antibacterial activity against Pseudomonas aeruginosa FE57U with inactivated rplY and galU genes by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1666866	Inhibition of swarming motility of Pseudomonas aeruginosa clinical isolates incubated for 16 to 20 hrs	2020	Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5	Optimized plant compound with potent anti-biofilm activity across gram-negative species.
AID622392	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by microbroth dilution method in absence of Mg2+	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID424859	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID498102	Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID523517	Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1422366	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID559533	Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1580096	Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 by checkerboard assay	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID508726	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1691821	Antibacterial activity against Pseudomonas aeruginosa PAO1 planktonic cells assessed as reduction in bacterial growth after 18 hrs by resazurin dye based assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1.
AID542585	Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID446130	Antibacterial activity against AAC6'-2b expressing Escherichia coli PAZ505H8101 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID1716869	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID495515	Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1873914	Antibacterial activity against Pseudomonas aeruginosa LTP-3 incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1824802	Antibacterial activity against Pseudomonas aeruginosa 1167 assessed as bacterial growth inhibition by broth microdilution method	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	New
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID498136	Antibacterial activity against Pseudomonas aeruginosa PAM1032 overexpressing multidrug efflux pump MexAB-OprM assessed as reduction in log CFU/ml at 2 times MIC up to 48 hrs in absence of cystic fibrosis patient sputum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1447471	Antibacterial activity against gentamicin/tobramycin/ciprofloxacin-resistant Escherichia coli isolate CANWARD-2011 97615 harboring AAC3-2A after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID531757	Antibacterial activity against Pseudomonas aeruginosa 1956 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID534171	Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1716656	Antibacterial activity against gentamicin, tobramycin-resistant Pseudomonas aeruginosa CANWARD 96846 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1716640	Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID572141	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534177	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID325977	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count at 50 ug/ml by rotating disk reactor method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
AID535697	Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID1422365	Antibacterial activity against Staphylococcus aureus SA-1 expressing NorA pump by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID508741	Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID554442	Ratio of MIC for Pseudomonas aeruginosa 3066 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1422375	Antibacterial activity against Escherichia coli L8058.1 harboring ANT2'-1A by microdilution assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID559534	Antibacterial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID508486	Antimicrobial activity against Pseudomonas aeruginosa isolate BU-36178 producing metallo-beta-lactamase VIM2 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
AID560591	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID495512	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID523515	Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID486970	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by micro broth dilution method	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID1447469	Antibacterial activity against gentamicin-resistant Escherichia coli isolate CAN-ICU 61714 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID69750	Antibacterial activity expressed as MIC value was determined on Escherichia coli A-20697 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID559593	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1811206	Antibiofilm activity against Pseudomonas aeruginosa assessed as reduction in CFU at 0.5 ug/ml	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Divergent synthesis and biological evaluation of 2-(trifluoromethyl)pyridines as virulence-attenuating inverse agonists targeting PqsR.
AID460801	Antibacterial activity against Acinetobacter baumannii 3304 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID559526	Antibacterial activity against Acinetobacter lwoffii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID324856	Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID565070	Antibacterial activity against CTX-M-14 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID238114	Dissociation constant of the compound	2004	Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17	Validation of automated docking programs for docking and database screening against RNA drug targets.
AID498098	Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573507	Antibacterial activity against Klebsiella oxytoca isolate Ko0426 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID285579	Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID508727	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID1318922	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 262-101856	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1447470	Antibacterial activity against amikacin-resistant Escherichia coli isolate CAN-ICU 63074 after 24 hrs by macrobroth dilution method	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID573504	Antibacterial activity against Morganella morganii isolate Mm1229 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID498101	Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID573527	Antibacterial activity against Serratia marcescens isolate Sm265 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID394705	Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, ANT(2'')-1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID573498	Antibacterial activity against Klebsiella pneumoniae isolate Kp7564 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID486969	Antibacterial activity against Escherichia coli after 24 hrs by micro broth dilution method	2010	European journal of medicinal chemistry, Jun, Volume: 45, Issue:6	'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID326537	Antimicrobial activity against Mycobacterium abscessus R31 isolate after 3 to 5 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID425069	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
AID1716717	Antibacterial activity against Pseudomonas aeruginosa 101243 assessed as fractional inhibitory concentration index in presence of doxycycline incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID508721	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID165226	In vitro inhibitory activity against Pseudomonas aeruginosa PAO-1	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID559498	Antibacterial activity against vancomycin- resistant Enterococcus faecium assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1846497	Antibacterial activity against wild type Pseudomonas aeruginosa K767 assessed as reduction in bacterial growth rate in presence of berberine
AID1447481	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate P259-96918 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID523069	Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID525564	Oral bioavailability in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID523498	Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID164371	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-22233 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID573514	Antibacterial activity against Klebsiella pneumoniae isolate Kp149 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523505	Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1716626	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 0.25 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 32 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID446126	Antibacterial activity against AAC6'-2a expressing Pseudomonas aeruginosa F03 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID446125	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID1677267	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1846499	Antibacterial activity against Pseudomonas aeruginosa NC01 cystic fibrosis assessed as reduction in bacterial growth
AID257553	Antibacterial activity against Pseudomonas aeruginosa	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.
AID1846519	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C31 assessed as reduction in tolerant cell in presence of berberine by broth microdilution method
AID1716632	Antibacterial activity against Pseudomonas aeruginosa 264-101354 assessed as reduction in bacterial growth by measuring chloramphenicol MIC at 8 ug/ml incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay (Rvb = 4096 ug/ml)	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID285585	Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1824799	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as bacterial growth inhibition by broth microdilution method	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	New
AID573534	Antibacterial activity against Citrobacter amalonaticus Ca3927 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID65062	Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID446136	Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID559415	Antimicrobial activity against Acinetobacter baumannii 3208 expressing multiple-antibiotic resistance gene AbaR5 by Viek 2 system	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii.
AID573202	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring deletion od C534 in nfxB mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1678764	Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using DMSO as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID573545	Antibacterial activity against Klebsiella pneumoniae Kp3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID283534	Antibacterial activity against Pseudomonas aeruginosa FE57 containing inactivated rplY gene with pARAL25 by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID544828	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1716866	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID559507	Antibacterial activity against Staphylococcus saprophyticus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID285596	Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID525567	Half life in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID531748	Antibacterial activity against Pseudomonas aeruginosa EryR harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID523518	Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID571897	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID428869	Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID164256	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-21508 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID559535	Antibacterial activity against Legionella pneumophila assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID534302	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID559098	Bactericidal activity against yafQ gene-deficient Escherichia coli K-12 BW25113 stationary-phase planktonic cell assessed as log reduction of viable cells after 24 hrs	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.
AID533858	Antibacterial activity against nonpigmented rapidly growing Mycobacterium alvei after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID323690	Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID525571	AUClast in normally fed BALB/c mouse at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID559540	Antibacterial activity against Proteus vulgaris assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573518	Antibacterial activity against Klebsiella pneumoniae isolate Kp211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID564696	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as resistance isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID522929	Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1881519	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 assessed as reduction in bacterial growth after 18 hrs by microbroth dilution method	2021	RSC medicinal chemistry, Sep-23, Volume: 12, Issue:9	A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against
AID1374178	Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID2939	Dissociation constant towards 16S rRNA construct B	2000	Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14	Enhanced binding of aminoglycoside dimers to a "dimerized" A-site 16S rRNA construct.
AID542584	Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID559586	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID573544	Antibacterial activity against Enterobacter cloacae El3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID521594	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 at pH 5.7 by bioluminescence assay	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID559511	Antibacterial activity against Lancefield Streptococcus sp. group F assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID373986	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID68015	Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-20364 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID559537	Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1809548	Anti-bioflim activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of bioflim formation measured at MBIC50 concentration incubated for 24 hrs by crystal violet staining based assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as
AID1716765	Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID285610	Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID446138	Antibacterial activity against MexAB, MexCD, MexEF, MexXY, TriABC deleted Pseudomonas aeruginosa PA406 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID278802	Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID523509	Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1629134	Inhibition of cytosolic eukaryotic translation in rabbit reticulocyte S30 extract measured after 60 mins by coupled transcription/translation-based luciferase reporter gene assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID245239	In vitro minimum inhibitory concentration against Escherichia coli ATCC 25922; Range is 0.25-1	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID519182	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrW mutant and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID571891	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID554386	Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573512	Antibacterial activity against Klebsiella pneumoniae isolate Kp4614	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1629122	Antimicrobial activity against Pseudomonas aeruginosa ATCC 47085 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID428870	Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1846522	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C84 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method
AID396027	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID565229	Antimicrobial activity against Mycobacterium chelonae ATCC 35752 harboring pZS01 carrying mspA gene by resazurine microtiter assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID1322256	Antibacterial activity against Escherichia coli ATCC 25922 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID559595	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutT mutant gene selected in presence of Ceftazidime by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID498305	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID572143	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534175	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID245043	In vitro minimum inhibitory concentration against Staphylococcus aureus MRSA 3359	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID523070	Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1846517	Antibacterial activity against cystic fibrosis isolate Pseudomonas aeruginosa C25 assessed as log reduction in tolerant cell in presence of berberine by broth microdilution method
AID559499	Antibacterial activity against Listeria monocytogenes assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID405449	Antibacterial activity against Pseudomonas aeruginosa PAO1 infected in C57BL/6J mouse assessed as lung bacterial count at 10 mg/kg, ip administered every 6 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID519178	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY agrZ mutant and MexZ mutant gene selected after 1 ug/ml of tobramycin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1629133	Binding affinity to 16S rRNA A-site in Escherichia coli S30 extract assessed as inhibition of translation measured after 30 mins by coupled transcription/translation-based luciferase reporter gene assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID1422377	Cytotoxicity against mouse J774 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.
AID245278	In vitro minimum inhibitory concentration against Enterococcus faecalis 29212; range is 8-32 ug/ml	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID498087	Antibacterial activity against Pseudomonas aeruginosa PA1022 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID278858	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID559504	Antibacterial activity against Staphylococcus haemolyticus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056845	Antibacterial activity against TEM-1/SHV-12 expressing Enterobacter cloacae isolate 306 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID532086	Antimicrobial against Pseudomonas aeruginosa 9256 harboring ybhO allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID519185	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 0.25 ug/ml of ciprofloxacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID508729	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID524005	Antimicrobial activity against Acinetobacter sp. harboring aacA4 gene assessed as percent resistant isolates	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID521601	Antibacterial activity against Salmonella enterica serovars virchow isolate 101591 infected in mouse J774A.1 macrophage assessed as log reduction in viable counts at 150 ug/ml after 1hr	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.
AID1056838	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 4024 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID571699	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559591	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutL mutant gene complemented with wild type DNA oxidative repair system mutY gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1824800	Antibacterial activity against Pseudomonas aeruginosa 1121 assessed as bacterial growth inhibition by broth microdilution method	2022	Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1	New
AID554388	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1318926	Antibacterial activity against Pseudomonas aeruginosa PAO1	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1716762	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID565228	Antimicrobial activity against Mycobacterium chelonae ATCC 35752 by resazurine microtiter assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID544825	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID559602	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutM mutant gene selected in presence of ciprofloxacin by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID523487	Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID508724	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID533856	Antibacterial activity against nonpigmented rapidly growing Mycobacterium mucogenicum after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID534301	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1318928	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86067	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID498120	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1318915	Antibacterial activity against Stenotrophomonas maltophilia isolate CAN-ICU 62584 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584564	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID498362	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrR containing isogenic acrR knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID559525	Antibacterial activity against Acinetobacter calcoaceticus assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564467	Antimicrobial activity against Pseudomonas aeruginosa isolate 1080 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID1318927	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86053	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID330987	Antimicrobial activity against Enterococcus faecalis 29212	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID1318934	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 80621	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID1322252	Antibacterial activity against MexXY expressing Pseudomonas aeruginosa PA22 by microdilution method	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID1056840	Antibacterial activity against CTX-15 expressing Aeromonas caviae isolate 258 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID573528	Antibacterial activity against Acinetobacter isolate A74510 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID278805	Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID324852	Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID540237	Phospholipidosis-positive literature compound observed in rat
AID126449	Dissociation constant for binding to mitochondrial 12S rRNA construct M2 was determined	2002	Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16	Decoding region bubble size and aminoglycoside antibiotic binding.
AID554389	Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573543	Antibacterial activity against Morganella morganii Mm1229 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID510962	Antimicrobial activity against Escherichia coli assessed as nonsusceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.
AID1364570	Bactericidal activity against Acinetobacter baumannii ATCC 19606 after 48 hrs by resazurin dye based microdilution method	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.
AID522930	Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID498303	Antibacterial activity against Pseudomonas aeruginosa PA1042 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID285604	Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID525566	Tmax in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID1678780	Antibacterial activity against Enterococcus faecalis ATCC 51299 using Cyrene as solvent by broth microdilution method	2020	RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1	Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID245114	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; R=Resistant	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID572119	Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID434367	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by broth microdilution method	2009	European journal of medicinal chemistry, Aug, Volume: 44, Issue:8	Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.
AID498306	Antibacterial activity against Pseudomonas aeruginosa PA5043 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID1056850	Antibacterial activity against TEM-1/SHV-12 expressing Klebsiella pneumoniae isolate 303 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID572125	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID622390	Antibacterial activity against colistin-resistant Inquilinus limosus after 24 hrs by microbroth dilution method	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.
AID1629128	Antimicrobial activity against Escherichia coli ATCC 25922 measured after 24 hrs by double-dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Effects of 5-O-Ribosylation of Aminoglycosides on Antimicrobial Activity and Selective Perturbation of Bacterial Translation.
AID565064	Antibacterial activity against SHV-12 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.
AID508723	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID542047	Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID573502	Antibacterial activity against Klebsiella pneumoniae isolate Kp38045 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID245119	Minimum inhibitory concentration against Pseudomonas aeruginosa PAO-1; Range is 0.25-1	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID285588	Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533566	Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID571903	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1318905	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis isolate CAN-ICU 61589 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID564457	Antimicrobial activity against Pseudomonas aeruginosa isolate 878 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
AID283222	Antimicrobial activity against Escherichia coli XL1-Blue [pBluescript 2 SK(+)	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID330986	Antimicrobial activity against Enterococcus faecium 49624	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1716761	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of doxycycline by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID532089	Antimicrobial against Pseudomonas aeruginosa 312 harboring PBPP allele by broth dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID325975	Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as log reduction of bacterial count by rotating disk reactor method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.
AID1374180	Antibacterial activity against Klebsiella pneumoniae ATCC 4352 incubated at 37 degC for 20 hrs by agar dilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Design, synthesis and antibacterial evaluation of honokiol derivatives.
AID531861	Antimicrobial activity against Pseudomonas aeruginosa PAO1 grown as planktonic cells assessed as concentration and time required inactivate 1 log bacterial cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.
AID498128	Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID544635	Antimicrobial activity against Pseudomonas aeruginosa Xen 5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID525568	Cmax in normally fed BALB/c mouse at 10 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID563520	Antibacterial activity against Pseudomonas aeruginosa NY215 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
AID1716647	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis CANWARD 81388 assessed as reduction in bacterial growth incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1873912	Antibacterial activity against Staphylococcus chromogenes incubated for 16 to 20 hrs by broth microdilution method	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1716760	Antibacterial activity against Pseudomonas aeruginosa 262-101856 assessed as fractional inhibitory concentration incubated for 18 hrs in presence of chloramphenicol by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID1318919	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID529304	Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID1580087	Antibacterial activity against wild type Acinetobacter baumannii ATCC 17978 assessed as resistant development at sub-MIC measured after 7 days of passaging by microbroth dilution method relative to control	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID164253	Antibacterial activity expressed as MIC value was determined on Pseudomonas aeruginosa A-20741 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID523489	Antimicrobial activity against Pseudomonas aeruginosa R20 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID330984	Antimicrobial activity against Staphylococcus aureus 29213	2007	Nature, May-03, Volume: 447, Issue:7140	PTC124 targets genetic disorders caused by nonsense mutations.
AID283530	Antibacterial activity against Pseudomonas aeruginosa FE10 with inactivated nuoG gene by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1716731	Antibacterial activity against Pseudomonas aeruginosa 259-96918 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID519184	Antimicrobial activity against MexXY-OprM-overproducing Pseudomonas aeruginosa PAO1 harboring MexY and MexZ mutant gene selected after 8 ug/ml of amikacin exposure	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
AID1056837	Antibacterial activity against TEM-1/SHV-12 expressing Escherichia coli isolate 237 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID533862	Antibacterial activity against nonpigmented rapidly growing Mycobacterium wolinskyi after 3 days by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
AID1846500	Antibacterial activity against Pseudomonas aeruginosa NC01 cystic fibrosis assessed as tobramycin MIC in presence of berberine
AID521838	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID559516	Antibacterial activity against Streptococcus anginosus assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1716739	Antibacterial activity against Pseudomonas aeruginosa 91433 assessed as fractional inhibitory concentration index in presence of chloramphenicol incubated for 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Jul-15, Volume: 174	Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.
AID405816	Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR31	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID405821	Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID584560	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID245156	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID498105	Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
AID446129	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.
AID1846512	Antibacterial activity against clinical isolate Pseudomonas aeruginosa C54 assessed as fold reduction in MIC in presence of berberine by broth microdilution method
AID245159	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID372842	Antibacterial activity against Acinetobacter baumannii isolate A expressing 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID278856	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID68017	Antibacterial activity expressed as MIC value was determined on Enterobacter cloacae A-21136 organism	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.
AID534174	Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID561326	Antimicrobial activity against Klebsiella pneumoniae isolate 135 transconjugant expressing aac(6')-Ib-cr gene	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
AID1318912	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by microtitre broth dilution method	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID554436	Ratio of MIC for Pseudomonas aeruginosa 2721 to MIC for Pseudomonas aeruginosa PAO1	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID525560	Tmax in normally fed BALB/c mouse at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Fasting increases tobramycin oral absorption in mice.
AID1447480	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 101885 after 18 hrs by microtiter dilution assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
AID372843	Antibacterial activity against Acinetobacter baumannii isolate B expressing 16S rRNA methylase armA gene	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.
AID559588	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene assessed as doubling time	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.
AID1318920	Antibacterial activity against multidrug/extremely drug-resistant/colistin-susceptible Pseudomonas aeruginosa isolate 259-96918	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573200	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB C116T mutant gene selected at 1 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID559503	Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1706 (37.28)	18.7374
1990's	734 (16.04)	18.2507
2000's	824 (18.01)	29.6817
2010's	967 (21.13)	24.3611
2020's	345 (7.54)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	629 (12.83%)	5.53%
Reviews	199 (4.06%)	6.00%
Case Studies	468 (9.55%)	4.05%
Observational	21 (0.43%)	0.25%
Other	3,585 (73.13%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (117)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis[NCT01560962]		100 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to research staffs unable to continue.)
Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention[NCT05376670]		44 participants (Actual)	Observational	2022-04-20	Completed
Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session[NCT03904836]	Phase 1	11 participants (Actual)	Interventional	2019-01-31	Completed
Phase 1 Feasibility Trial of Inhaled Tobramycin in Preterm Infants With Bronchopulmonary Dysplasia[NCT04560179]	Phase 1	54 participants (Anticipated)	Interventional	2022-03-22	Recruiting
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®[NCT01288170]		12 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Topical Antibiotics in Chronic Rhinosinusitis[NCT03673956]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2018-09-26	Completed
A Multicenter, Human Factors Validation Study in Cystic Fibrosis Patients Aged 6 Years and Older to Evaluate the User Interface of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules[NCT03502070]	Phase 4	47 participants (Actual)	Interventional	2018-06-26	Completed
Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial[NCT03715322]	Phase 3	350 participants (Anticipated)	Interventional	2018-10-26	Recruiting
A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vi[NCT01111383]	Phase 3	209 participants (Actual)	Interventional	2009-09-30	Completed
Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis (CRITIC) A Randomized Pharmacokinetic Comparison of Tobramycin in Cystic Fibrosis[NCT01207245]	Phase 4	18 participants (Actual)	Interventional	2011-05-31	Completed
Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment[NCT02440828]	Phase 4	80 participants (Anticipated)	Interventional	2015-03-31	Completed
Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection[NCT02102152]		40 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
Use of Antibiotic Contained Calcium Sulfate Carrier in Acute Periprosthetic Infections(APPI) of Total Knee Replacements[NCT02107924]		0 participants (Actual)	Observational	2014-04-30	Withdrawn(stopped due to No Funding)
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.[NCT01337219]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2011-04-30	Recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics[NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis[NCT02035488]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2013-10-31	Completed
Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study[NCT02269969]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2015-03-31	Completed
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified[NCT02526004]		223 participants (Actual)	Interventional	2013-10-01	Completed
An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for [NCT03739528]	Phase 3	808 participants (Actual)	Interventional	2018-09-03	Completed
A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects[NCT00388505]	Phase 3	517 participants (Actual)	Interventional	2006-02-28	Completed
What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa[NCT01044719]	Phase 4	240 participants (Anticipated)	Interventional	2010-01-31	Not yet recruiting
The Effectiveness of Antibiotic Cement Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Feasibility Study[NCT01079559]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis[NCT00097773]	Phase 2	304 participants (Actual)	Interventional	2004-09-30	Completed
Acute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture Wounds[NCT04872400]	Phase 4	120 participants (Anticipated)	Interventional	2021-06-14	Active, not recruiting
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Successfully Completed Participation in Study CTBM100C2303E1[NCT01069705]	Phase 3	49 participants (Actual)	Interventional	2010-02-12	Completed
A Phase 1 Study in Healthy Volunteers Investigating the Delivery of Tobramycin Using the TobrAir® 6.0 Device Compared With the Delivery of Marketed Tobramycin Nebuliser Solution (TOBI®) by PARI LC® PLUS and PARI TurboBoy® SX and With Delivery of Tobramyci[NCT02207426]	Phase 1	12 participants (Actual)	Interventional	2014-07-31	Completed
Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study[NCT02497365]		32 participants (Actual)	Interventional	2015-09-30	Completed
Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic Fibrosis[NCT03485456]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2019-05-29	Recruiting
Pilot for Vancomycin and Tobramycin Powder Use in Acute Open Fractures in the Emergency Department[NCT05849090]	Early Phase 1	50 participants (Anticipated)	Interventional	2023-03-27	Enrolling by invitation
Efficiency and Safety of Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis: a Non-randomized Controlled Study[NCT05353101]	Phase 1	48 participants (Actual)	Interventional	2020-07-01	Completed
The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study[NCT02137161]	Phase 4	62 participants (Actual)	Interventional	2013-11-30	Completed
Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery[NCT01103401]		145 participants (Actual)	Interventional	2009-10-31	Completed
A Phase 2 Multicenter Feasibility Trial to Evaluate Safety and Efficacy in Patients Treated for Hip or Knee Prosthetic Joint Infection (PJI) With Alternating Irrigation of Vancomycin Hydrochloride (HCl) and Tobramycin Sulfate in Two-Stage Exchange Arthrop[NCT03721328]	Phase 2	15 participants (Actual)	Interventional	2018-10-26	Completed
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants[NCT01349738]		200 participants (Anticipated)	Observational	2011-05-31	Enrolling by invitation
A Study of the Clinical Benefit of Tobramycin Inhalation Solution[NCT06106789]		1,600 participants (Anticipated)	Observational	2021-01-01	Active, not recruiting
VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia[NCT02528123]		187 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
Efficacy of Antibiotic (Tobramycin) Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients: A Multicenter Double-blind Randomized Controlled Trial[NCT02888730]	Phase 3	86 participants (Actual)	Interventional	2017-02-16	Terminated(stopped due to No suffisant recruitment)
A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis[NCT01028027]	Phase 3	357 participants (Actual)	Interventional	2009-10-31	Completed
Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis (CF)[NCT02489955]		0 participants	Interventional	2015-02-28	Recruiting
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis[NCT00705159]	Phase 4	137 participants (Actual)	Interventional	2008-06-30	Completed
Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients[NCT03308253]	Phase 4	60 participants (Anticipated)	Interventional	2018-07-16	Recruiting
Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial[NCT06093191]	Phase 4	364 participants (Anticipated)	Interventional	2023-09-25	Recruiting
Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Inh[NCT02113397]		1 participants (Actual)	Observational	2014-04-30	Terminated(stopped due to Insufficient enrollment)
A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis[NCT00105469]	Phase 3	743 participants (Actual)	Interventional	2004-07-31	Completed
A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects[NCT00420628]	Phase 4	108 participants (Actual)	Interventional	2006-11-30	Completed
Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction[NCT02540785]		41 participants (Actual)	Interventional	2014-04-30	Completed
A Pilot Study of Digital Breast Tomosynthesis Guided Near-infrared Tomographic Optical Breast Imaging (DBT-TOBI) in Monitoring Response of Breast Cancer to Neoadjuvant Therapy[NCT03822312]		30 participants (Actual)	Interventional	2019-02-01	Active, not recruiting
Effects of Holy-Comod and Tears Naturale Forte on Ocular Surface and Tear Inflammatory Mediators in Patients After Phaco+IOL[NCT02817191]		80 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study[NCT02478710]	Phase 4	16 participants (Actual)	Interventional	2015-06-30	Terminated
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT - A Multicenter Randomized Control Trial[NCT04678154]	Phase 3	1,200 participants (Anticipated)	Interventional	2021-05-07	Recruiting
Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects[NCT00420836]	Phase 1	20 participants	Interventional	2006-04-30	Completed
A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic[NCT00885365]	Phase 3	324 participants (Actual)	Interventional	2009-04-30	Completed
A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects[NCT00634192]	Phase 3	50 participants (Anticipated)	Interventional	2008-02-29	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).[NCT00918957]	Phase 3	62 participants (Actual)	Interventional	2009-06-30	Completed
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy[NCT02918409]	Phase 4	51 participants (Actual)	Interventional	2016-08-26	Completed
Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.[NCT01400750]	Phase 4	61 participants (Actual)	Interventional	2001-08-31	Completed
Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways[NCT00774072]	Phase 2	9 participants (Actual)	Interventional	2008-10-31	Completed
An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution (AZLI) Versus Tobramycin Inhalation Solution (TIS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects With Cystic Fibrosis Followe[NCT00757237]	Phase 3	274 participants (Actual)	Interventional	2008-08-31	Completed
Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis[NCT02717871]	Phase 3	35 participants (Actual)	Interventional	2016-03-31	Completed
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection[NCT06016088]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
[NCT00834171]		50 participants (Actual)	Observational	2009-01-31	Completed
Effect of Various Treatment Modalities on Dendritic Vial Ulcer[NCT05313828]		40 participants (Anticipated)	Observational	2022-03-18	Recruiting
Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis[NCT02551796]		75 participants (Actual)	Interventional	2015-09-30	Completed
Comparison of Antibiotics for Pseudomonas in Early CF[NCT00823238]	Phase 1	21 participants (Actual)	Interventional	2004-07-31	Completed
The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis[NCT00391976]	Phase 3	123 participants (Actual)	Interventional	2003-11-30	Completed
Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension[NCT03975374]	Early Phase 1	5,000 participants (Anticipated)	Interventional	2019-06-15	Not yet recruiting
[NCT01938417]		12 participants (Actual)	Observational	2006-10-31	Completed
Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects[NCT01953367]	Phase 1	72 participants (Actual)	Interventional	2013-09-30	Completed
Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis[NCT01460836]		0 participants	Observational	2010-04-30	Completed
A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis[NCT00006280]	Phase 2	98 participants	Interventional	2000-02-29	Completed
Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity[NCT01608555]	Phase 4	10 participants (Anticipated)	Interventional	2012-01-31	Completed
Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty[NCT05429671]	Phase 3	80 participants (Anticipated)	Interventional	2022-06-20	Enrolling by invitation
Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.[NCT02657473]	Phase 2/Phase 3	58 participants (Actual)	Interventional	2016-08-13	Completed
Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial[NCT00992355]		97 participants (Actual)	Interventional	2009-01-31	Completed
A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension[NCT00198523]	Phase 3	132 participants	Interventional	2005-07-31	Completed
Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers[NCT00695435]	Phase 1	21 participants (Actual)	Interventional	2008-06-30	Completed
Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa[NCT01315678]	Phase 3	302 participants (Actual)	Interventional	2012-02-29	Completed
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care[NCT01431326]		3,520 participants (Actual)	Observational	2011-11-30	Completed
A Randomized, Double-masked, Parallel Comparison of Ocular Tolerance and IOP Effects of Zylet vs TobraDex Administered Four Times Daily for Four Weeks in Healthy Volunteers[NCT00532961]	Phase 4	310 participants (Actual)	Interventional	2005-02-28	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects[NCT00125346]	Phase 3	98 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to per Data Monitoring Committee recommendation)
A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis[NCT00447577]	Phase 4	276 participants (Actual)	Interventional	2007-01-31	Completed
Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial[NCT05169229]	Phase 2/Phase 3	850 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia[NCT00050401]	Phase 3	500 participants	Interventional	2002-07-31	Completed
Prospective Study Investigating Antibiotic Elution From Free Intra-articular Vancomycin and Tobramycin After Cementless Total Knee Arthroplasty[NCT04297631]	Phase 4	20 participants (Actual)	Interventional	2020-02-14	Completed
Standard vs. Biofilm Susceptibility Testing in CF[NCT00153634]		75 participants (Actual)	Interventional	2004-03-31	Completed
A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of T[NCT00399945]	Phase 1	12 participants	Interventional	2006-05-31	Completed
[NCT00576251]	Phase 3	221 participants (Actual)	Interventional	2007-10-31	Completed
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules[NCT02178540]	Phase 4	45 participants (Actual)	Interventional	2014-08-31	Completed
Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber[NCT00257790]	Phase 4	210 participants	Interventional	2001-09-30	Completed
Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial[NCT01740947]	Phase 4	485 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Superiority was no longer attainable)
A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs[NCT02449031]		409 participants (Actual)	Observational [Patient Registry]	2015-05-05	Completed
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.[NCT00982930]	Phase 3	55 participants (Actual)	Interventional	2009-08-12	Completed
TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin[NCT02677701]	Phase 4	119 participants (Actual)	Interventional	2016-10-21	Completed
A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis[NCT01677403]	Phase 4	120 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Bromfenac Ophthalmic Solution 0.1% for Postoperative Ocular Pain and Inflammation Related To Pterygium Surgery[NCT04022811]	Phase 4	60 participants (Actual)	Interventional	2016-10-31	Completed
A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension[NCT00362895]	Phase 3	995 participants (Actual)	Interventional	2006-04-30	Completed
Prospective Randomized Study Investigating the Characterization of Antibiotics From Antibiotic Impregnated Cement After Total Knee Arthroplasty[NCT03928522]	Phase 4	60 participants (Actual)	Interventional	2019-01-28	Completed
[NCT01155999]	Phase 3	286 participants (Actual)	Interventional	2008-12-31	Completed
Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures[NCT03705962]	Phase 3	11 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Unable to continue study due to funding and personnel restraints)
Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia[NCT01559753]	Phase 4	225 participants (Actual)	Interventional	1998-01-31	Completed
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial[NCT02054156]	Phase 3	221 participants (Actual)	Interventional	2014-06-30	Completed
A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU)[NCT02389036]	Phase 3	20,010 participants (Actual)	Interventional	2017-05-01	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa I[NCT01641822]	Phase 3	107 participants (Actual)	Interventional	2012-12-31	Completed
Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation[NCT05076955]	Early Phase 1	100 participants (Anticipated)	Interventional	2021-03-31	Recruiting
A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin[NCT02873806]	Phase 4	53 participants (Actual)	Interventional	2013-03-31	Completed
Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction[NCT02958514]		20 participants (Actual)	Interventional	2016-11-30	Completed
[NCT00004829]	Phase 3	200 participants	Interventional	1995-06-30	Completed
Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?[NCT04964947]	Phase 3	600 participants (Anticipated)	Interventional	2022-01-10	Recruiting
An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis[NCT01844778]	Phase 4	60 participants (Actual)	Interventional	2013-08-31	Completed
A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments[NCT01230593]		150 participants (Actual)	Interventional	2010-11-30	Completed
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas [NCT02015663]	Phase 4	32 participants (Actual)	Interventional	2014-01-31	Terminated
Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients[NCT01270347]	Phase 3	267 participants (Actual)	Interventional	2011-01-31	Completed
A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis[NCT03464435]	Phase 4	20 participants (Actual)	Interventional	2016-11-01	Completed
Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis[NCT01456780]	Phase 4	60 participants (Actual)	Interventional	2011-08-31	Completed
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities[NCT05361941]		132 participants (Anticipated)	Interventional	2022-09-06	Recruiting
Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients[NCT03341741]	Phase 3	26 participants (Actual)	Interventional	2014-03-11	Completed
Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192]	Phase 2	43 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to NIAID terminated the study due to low subject enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Patient Physical Exam as Measured by the Lund-Kennedy Endoscopic Exam Scores.

Scores are measured on a 0-2 scale for nasal polyps, edema, and secretions in both right and left nasal cavities. Total scores range from 0 to 12 with higher scores indicating greater evidence of sinonasal disease on physical exam. (NCT03673956)
Timeframe: Baseline, Post-intervention (within 21 days of intervention completion)

Intervention	units on a scale (Mean)
Mupirocin Antibiotic Nasal Saline Rinse	-5.3
Tobramycin Topical Antibiotic Nasal Saline Rinse	-3
Levofloxacin Topical Antibiotic Nasal Saline Rinse	-2.4
Vancomycin Topical Antibiotic Nasal Saline Rinse	0

Change in Patient Symptoms as Measured by the Sino-Nasal Outcomes Test (SNOT-22) Survey

Scores are measured from 0-5 in a 22-item validated survey. Total scores range from 0-110 with higher scores indicating greater burden of sinonasal symptoms. (NCT03673956)
Timeframe: Baseline, Post-intervention (within 21 days of intervention completion)

Intervention	units on a scale (Mean)
Mupirocin Antibiotic Nasal Saline Rinse	-18
Tobramycin Topical Antibiotic Nasal Saline Rinse	14
Levofloxacin Topical Antibiotic Nasal Saline Rinse	-25.5
Vancomycin Topical Antibiotic Nasal Saline Rinse	-11

Subjects Who Developed Antibiotic Resistance Organisms

Number of subjects who developed new antibiotic resistance organisms measured by nasal swab of the affected sinonasal cavity and sent for stain, culture, and sensitivity. (NCT03673956)
Timeframe: Post-intervention (within 21 days of intervention completion)

Intervention	Participants (Count of Participants)
Mupirocin Antibiotic Nasal Saline Rinse	0
Tobramycin Topical Antibiotic Nasal Saline Rinse	0
Levofloxacin Topical Antibiotic Nasal Saline Rinse	1
Vancomycin Topical Antibiotic Nasal Saline Rinse	0

Number of Participants With Critical Use Errors and Close Calls Associated With the Simulated Inhalation of One Dose Using TOBI Podhaler

Critical use errors and close calls for the following: placing of capsule into the top of the mouthpiece, failure to replace mouthpiece, failure to adequately pierce capsule, failure to release before inhaling, multiple piercing of capsule, exhalation into mouthpiece, inadequate seal around mouthpiece, inadequate inhalation technique, failure to use reserve device when capsule not adequately pierced, failure to administer 4 capsules per dose, swallowing of capsule (NCT03502070)
Timeframe: 1 Day

Intervention	Participants (Count of Participants)
Open-Label Placebo	4

Adverse Events

Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group. (NCT03739528)
Timeframe: During all the treatment until day 15

Intervention	Participants (Count of Participants)
	Patients with TEAEs	Patients with serious TEAEs	Patients with TEAEs suspected to be study related	Patients with TEAEs leading to discontinuation	Patients with fatal TEAEs	Patients with severe TEAEs
Levofloxacin + Dexamethasone Followed by Dexamethasone	56	4	26	4	1	3
Tobramycin + Dexamethasone	51	2	26	3	0	0

Burning, Stinging, Blurred Vision

Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	score on a scale (Mean)
	Burning: visit 3 - day 4	Burning: visit 4 - day 8	Burning: visit 5 - day 15	Stinging: visit 3 - day 4	Stinging: visit 4 - day 8	Stinging: visit 5 - day 15	Blurred vision: visit 3 - day 4	Blurred vision: visit 4 - day 8	Blurred vision: visit 5 - day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.08	0.06	0.07	0.05	0.07	0.06	0.06	0.06	0.03
Tobramycin + Dexamethasone	0.09	0.11	0.07	0.04	0.07	0.04	0.05	0.04	0.01

Global Evaluation of Local Tolerability

Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability. (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	score on a scale (Mean)
	Visit 3 - Day 4	Visit 4 - Day 8	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.03	0.01	0.02
Tobramycin + Dexamethasone	0.01	0.03	0.02

Intraocular Pressure (IOP)

IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg. (NCT03739528)
Timeframe: At day 0 (screening) and at day 4, 8, 15

Intervention	mmHg (Mean)
	Visit 1 - Screening	Visit 3 - Day 4	Visit 4 - Day 8	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	15.16	14.26	14.29	14.45
Tobramycin + Dexamethasone	15.12	14.49	14.45	14.37

Number of Participants With Endophthalmitis

The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs. (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	Participants (Count of Participants)
	Visit 3 - Day 4: no diagnosis of endophthalmitis	Visit 4 - Day 8: no diagnosis of endophthalmitis	Visit 5 - Day 15: no diagnosis of endophthalmitis
Levofloxacin + Dexamethasone Followed by Dexamethasone	393	391	389
Tobramycin + Dexamethasone	393	393	391

Total Ocular Symptoms Score (TOSS)

The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe. (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	score on a scale (Mean)
	Visit 3 - Day 4	Visit 4 - Day 8	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.29	0.28	0.17
Tobramycin + Dexamethasone	0.37	0.26	0.17

Visual Acuity

"Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction.~Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision.~Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes." (NCT03739528)
Timeframe: At day 0 (screening) and at day 15

Intervention	decimal score (Mean)
	Visit 1 - Screening	Visit 5 - Day 15
Levofloxacin + Dexamethasone Followed by Dexamethasone	0.41	0.88
Tobramycin + Dexamethasone	0.41	0.89

Conjunctival Hyperemia

Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable). (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	Participants (Count of Participants)
	Visit 3 - Day 472467252		Visit 3 - Day 472467251	Visit 4 - Day 872467251	Visit 4 - Day 872467252	Visit 5 - Day 1572467252	Visit 5 - Day 1572467251
	Score>0	Score=0
Levofloxacin + Dexamethasone Followed by Dexamethasone	337
Tobramycin + Dexamethasone	323
Levofloxacin + Dexamethasone Followed by Dexamethasone	58
Tobramycin + Dexamethasone	70
Levofloxacin + Dexamethasone Followed by Dexamethasone	348
Tobramycin + Dexamethasone	358
Levofloxacin + Dexamethasone Followed by Dexamethasone	47
Tobramycin + Dexamethasone	35
Levofloxacin + Dexamethasone Followed by Dexamethasone	371
Tobramycin + Dexamethasone	375
Levofloxacin + Dexamethasone Followed by Dexamethasone	24
Tobramycin + Dexamethasone	18

Number of Participants Without Signs of Anterior Ocular Chamber Inflammation

Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). (NCT03739528)
Timeframe: Day 0 (screening), 4, 8

Intervention	Participants (Count of Participants)
	Visit 1 - Screening72467251		Visit 1 - Screening72467252	Visit 3 - Day 472467252	Visit 3 - Day 472467251	Visit 4 - Day 872467252	Visit 4 - Day 872467251
	Number of participants without signs	Number of participants with signs
Levofloxacin + Dexamethasone Followed by Dexamethasone	395
Tobramycin + Dexamethasone	393
Levofloxacin + Dexamethasone Followed by Dexamethasone	0
Tobramycin + Dexamethasone	0
Levofloxacin + Dexamethasone Followed by Dexamethasone	289
Tobramycin + Dexamethasone	302
Levofloxacin + Dexamethasone Followed by Dexamethasone	106
Tobramycin + Dexamethasone	91
Levofloxacin + Dexamethasone Followed by Dexamethasone	338
Tobramycin + Dexamethasone	341
Levofloxacin + Dexamethasone Followed by Dexamethasone	57
Tobramycin + Dexamethasone	52

Ocular Pain/Discomfort: 4-point Scale

Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). (NCT03739528)
Timeframe: Day 4, 8, 15

Intervention	Participants (Count of Participants)
	Visit 3 - Day 4: Presence/absence of ocular pain72467252		Visit 3 - Day 4: Presence/absence of ocular pain72467251	Visit 4 - Day 8: Presence/absence of ocular pain72467251	Visit 4 - Day 8: Presence/absence of ocular pain72467252	Visit 5 - Day 15: Presence/absence of ocular pain72467252	Visit 5 - Day 15: Presence/absence of ocular pain72467251
	Score=0	Score>0
Levofloxacin + Dexamethasone Followed by Dexamethasone	360
Tobramycin + Dexamethasone	361
Levofloxacin + Dexamethasone Followed by Dexamethasone	35
Tobramycin + Dexamethasone	32
Levofloxacin + Dexamethasone Followed by Dexamethasone	366
Tobramycin + Dexamethasone	366
Levofloxacin + Dexamethasone Followed by Dexamethasone	29
Tobramycin + Dexamethasone	27
Levofloxacin + Dexamethasone Followed by Dexamethasone	377
Tobramycin + Dexamethasone	373
Levofloxacin + Dexamethasone Followed by Dexamethasone	18
Tobramycin + Dexamethasone	20

Antipseudomonal Antibiotic Usage During the Study

The average number of days patients required antipseudomonal antibiotics during the course of the study. (NCT00388505)
Timeframe: 25 Weeks

Intervention	days (Mean)
Tobramycin Inhalation Powder (TIP)	34.5
Tobramycin Solution for Inhalation (TOBI)	40.1

Hospitalization Due to Respiratory Events During the Study

The average number of days patients were hospitalized due to respiratory events during the course of the study. (NCT00388505)
Timeframe: 25 Weeks

Intervention	days (Mean)
Tobramycin Inhalation Powder (TIP)	15.6
Tobramycin Solution for Inhalation (TOBI)	15.3

Change From Baseline in Pseudomonas Aeruginosa Sputum Density

Three Pseudomonas aeruginosa biotypes were assessed in patient's sputum; mucoid, dry and small colony variant. Overall density is defined as the sum of all bio-types in Pseudomonas aeruginosa density. (NCT00388505)
Timeframe: Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25).

Intervention	log10 Colony forming units/g (Mean)
	Baseline [N=279, 192]	Change from Baseline at Week 5 [N=202, 145]	Change from Baseline at Week 13 [N=170, 125]	Change from Baseline at Week 21 [N= 157, 126]	Change from Baseline: Final Visit [N=263, 179]
Tobramycin Inhalation Powder (TIP)	7.23	-1.76	-1.54	-1.61	-0.53
Tobramycin Solution for Inhalation (TOBI)	7.35	-1.32	-1.11	-0.77	-0.33

Change From Baseline in Tobramycin Minimum Inhibitory Concentration

The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. The MIC of tobramycin against total Pseudomonas aeruginosa colonization was assessed over the course of the study. (NCT00388505)
Timeframe: Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25)

Intervention	μg/mL (Mean)
	Baseline [N=308, 208]	Change from Baseline at Week 5 [N=239, 173]	Change from Baseline at Week 8 [N=215, 157]	Change from Baseline at Week 21 [N=199, 154]	Change from Baseline: Final Visit [N=298, 202]
Tobramycin Inhalation Powder (TIP)	35.39	38.47	35.59	29.83	30.89
Tobramycin Solution for Inhalation (TOBI)	42.45	5.80	20.68	14.13	3.27

Number of Participants With Treatment-emergent Adverse Events

An adverse event (AE) is any untoward medical occurrence, including any unfavorable and unintended sign, symptom or disease temporally associated with the use of the study medication that does not necessarily have a causal relationship with study medication. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability, is a congenital anomaly or defect, or is a significant medical event that may jeopardize the patient or require intervention to prevent one of the outcomes listed above. (NCT00388505)
Timeframe: 25 weeks

Intervention	participants (Number)
	Any adverse event	Serious adverse event	Death	Discontinued due to AE(s)	Discontinued due to SAE(s)
Tobramycin Inhalation Powder (TIP)	278	85	3	46	14
Tobramycin Solution for Inhalation (TOBI)	176	61	0	17	6

Patient Satisfaction Assessed Using the Treatment Satisfaction Questionnaire for Medication

Patient's self-reported treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, a validated instrument) which was modified by adding four study-specific questions; the standard fourteen questions of the TSQM were not altered. Responses to nearly all items are rated on a five-point or seven-point rating scale and the items are factored into 4 domains. The TSQM domain scores range from 0 to 100 with higher scores representing higher satisfaction for that domain. (NCT00388505)
Timeframe: Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21).

Intervention	Scores on a scale (Mean)
	Cycle 1: Effectiveness [N=264, 189]	Cycle 1: Side Effects [N=263, 190]	Cycle 1: Convenience [N=264, 190]	Cycle 1: Global Satisfaction [N=264, 190]	Cycle 2: Effectiveness [N=241, 170]	Cycle 2: Side Effects [N=239, 170]	Cycle 2:Convenience [N=241, 170]	Cycle 2: Global Satisfaction [N=241, 170]	Cycle 3: Effectiveness [N=221, 162]	Cycle 3: Side Effects [N=215, 158]	Cycle 3: Convenience [N=221, 162]	Cycle 3: Global Satisfaction [N=221, 162]
Tobramycin Inhalation Powder (TIP)	74.1	92.1	82.3	75.4	74.5	93.6	81.1	76.6	74.9	91.5	81.6	75.2
Tobramycin Solution for Inhalation (TOBI)	64.6	92.4	58.1	20.19	64.6	93.8	57.0	70.2	65.5	94.1	56.6	72.2

Percentage of Participants With a Decrease From Baseline in Auditory Acuity

Audiology testing was performed only at selected centers. Auditory acuity was measured from 250 to 8000 Hertz using a standard dual-channel audiometer. (NCT00388505)
Timeframe: Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21)

Intervention	percentage of participants (Number)
	Cycle 1, Day 28 [N=60, 39]	Cycle 2, Day 28 [N=55, 34]	Cycle 3, Day 28 [N=54, 34]
Tobramycin Inhalation Powder (TIP)	13.3	12.7	18.5
Tobramycin Solution for Inhalation (TOBI)	10.3	0.0	11.8

Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%FEV1)

"Forced expiratory volume in one second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 is then converted to a percentage of normal (percent predicted) based on height, weight, and race. FEV1 was measured at Baseline (prior to beginning study treatment) and predose on Day 28 of Cycles 1, 2 and 3 and at the follow-up visit.~Relative change = 100 * ((Day 28 of Cycle 3 value - Baseline value)/ Baseline value)." (NCT00388505)
Timeframe: Baseline and Day 28 of Cycles 1, 2 and 3 (Weeks 5, 13 and 21) and Final Visit (Week 25)

Intervention	percent of predicted (Mean)
	Baseline [N=308, 209]	Change from Baseline at Week 5 [N=268, 194]	Change from Baseline at Week 13 [N=252, 178]	Change from Baseline at Week 21 [N=227, 171]	Change from Baseline: Final Visit [N=307, 209]
Tobramycin Inhalation Powder (TIP)	52.9	2.8	2.3	3.1	-0.4
Tobramycin Solution for Inhalation (TOBI)	52.8	3.6	4.3	2.3	-1.6

Serum Tobramycin Concentrations

Serum tobramycin concentrations were measured in a subset of participants at Week 1 (start of cycle 1), Week 5 (End of Cycle 1), Week 17 (start of cycle 3) and Week 21 (end of cycle 3). Serum samples were collected at pre-dose and post-dose at specified intervals; one specimen between 0 to 2 hours; two additional specimens between 2 and 5 hours (sample times must have been a minimum of 2 hours apart). (NCT00388505)
Timeframe: Weeks 1, 5, 17 and 21

Intervention	μg/mL (Mean)
	Week 1: Predose [N=28, 14]	Week 1: 0 to 2 hours [N=28, 14]	Week 1: 2 to 5 hours (1st sample) [N=26, 14]	Week 1: 2 to 5 hours (2nd sample) [N=25, 12]	Week 5: Predose [N=23, 13]	Week 5: 0 to 2 hours [N=23, 12]	Week 5: 2 to 5 hours (1st sample) [N=23, 11]	Week 5: 2 to 5 hours (2nd sample) [N=23, 8]	Week 17: Predose [N=24, 13]	Week 17: 0 to 2 hours [N=24, 13]	Week 17: 2 to 5 hours (1st sample) [N=24, 12]	Week 17: 2 to 5 hours (2nd sample) [N=23, 12]	Week 21: Predose [N=24, 13]	Week 21: 0 to 2 hours [N=24, 12]	Week 21: 2 to 5 hours (1st sample) [N=22, 12]	Week 21: 2 to 5 hours (2nd sample) [N=24, 11]
Tobramycin Inhalation Powder (TIP)	0.00	0.82	0.74	0.68	0.47	1.39	1.41	1.09	0.07	0.75	0.80	0.74	0.36	1.22	1.19	1.03
Tobramycin Solution for Inhalation (TOBI)	0.02	0.61	0.69	0.54	0.21	1.18	1.08	0.83	0.08	0.87	0.91	0.67	0.24	1.10	1.02	0.84

Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization

"The primary comparison is between the pooled culture-based group and the pooled cycled group. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month study

Intervention	number of participants (Number)
Cycled TIS	24
Culture-Based TIS	26
Oral Ciprofloxacin	29
Oral Placebo	21

Number of Participants With a Pulmonary Exacerbation Requiring Oral, Inhaled, or Oral Antibiotics

"The primary comparison is between the pooled culture-based group and the pooled cycled group. No interactions with ciprofloxacin were identified. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month time period

Intervention	participants (Number)
Cycled TIS	70
Culture-Based TIS	81
Oral Ciprofloxacin	83
Oral Placebo	68

Proportion of Participants With a Pa Positive Culture

"Proportion of participants with a Pa positive culture compared between (1) the pooled cycled therapy group (n=152) and pooled culture-based therapy group (n=152), and (2) between the pooled oral placebo (n=152)and pooled cipro groups (n=152).~Participants are included once in the cycled and culture-based columns, and once in the oral cipro and placebo columns" (NCT00097773)
Timeframe: Week 10 (after initial treatment course for Pa) through Month 18

,,,

Intervention	Participants (Number)
	No Pa positive cultures	1 Pa positive culture	2 Pa positive cultures	3 or more Pa positive cultures	Missing
Culture-Based TIS	85	38	18	9	2
Cycled TIS	109	17	9	13	4
Oral Cipro	97	22	13	14	6
Oral Placebo	97	33	14	8	0

Number of Days of Hospitalization Due to Respiratory Serious Adverse Events (SAEs)

The average number of days patients were hospitalized due to respiratory events during the study. (NCT01069705)
Timeframe: From time of consent to 4 weeks after study completion (up to 199 days)

Intervention	days (Mean)
Tobramycin Inhalation Powder (TIPnew)	16.5

Number of Participants Who Used New Antipseudomonal Antibiotic During Treatment Period

The rate of anti-pseudomonal antibiotics use were determined from the collection of concomitant medication during the study Treatment period. (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29)

Intervention	Participants (Count of Participants)
Tobramycin Inhalation Powder (TIPnew)	7

Number of Participants With Adverse Events (AEs)

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. (NCT01069705)
Timeframe: From time of first administration of study drug until study completion (up to 169 days)

Intervention	Participants (Count of Participants)
Tobramycin Inhalation Powder (TIPnew)	23

Number of Participants With Serious Adverse Events (SAEs)

A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. (NCT01069705)
Timeframe: From time of consent to 4 weeks after study completion (up to 199 days)

Intervention	Participants (Count of Participants)
Tobramycin Inhalation Powder (TIPnew)	2

Percentage of Participants With Hospitalization Due to Respiratory Serious Adverse Events (SAEs)

Intervention	percentage of participants (Number)
Tobramycin Inhalation Powder (TIPnew)	4.1

Change From Baseline in Pseudomonas Aeruginosa Sputum Density to Each Post-baseline Visit

Pseudomonas Aeruginosa Density refers to overall density, defined as the sum of Biotypes (mucoid, dry and small colony variant). Absolute change was determined using the formula; Change = Post-baseline value- baseline value. Absolute Change in Pseudomonas Aeruginosa Sputum density is measured in log 10 Colony Forming Units per gram (Log 10 CFU/g). (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	Log 10 CFU/g (Mean)
	Baseline	Change from Baseline to Cycle 5 (Day 1)	Change from Baseline to Cycle 5 (Day 29)	Change from Baseline to Cycle 6 (Day 1)	Change from Baseline to Cycle 6 (Day 29)	Change from Baseline to Cycle 7 (Day 1)	Change from Baseline to Cycle 7 (Day 29)	Change from Baseline to Follow-up (Week 57/Day 57)
Tobramycin Inhalation Powder (TIPnew)	7.4	-1.1	-3.7	-1.6	-3.6	-1.5	-2.6	-1.8

Change From Baseline in Tobramycin Minimum Inhibitory Concentration (MIC) Values for Pseudomonas Aeruginosa to Each Post-baseline Visit

Minimum Inhibitory Concentration (MIC) is defined as the lowest concentration of an antimicrobial agent required to inhibit the visible growth of a microorganism after overnight incubation. (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	microgram/millilitre (Mean)
	Baseline	Change from Baseline in Cycle 5 (Day 1)	Change from Baseline in Cycle 5 (Day 29)	Change from Baseline in Cycle 6 (Day 1)	Change from Baseline in Cycle 6 (Day 29)	Change from Baseline in Cycle 7 (Day 1)	Change from Baseline in Cycle 7 (Day 29)	Change from Baseline to Follow-up (Week 57/Day 57)
Tobramycin Inhalation Powder (TIPnew)	2.2	31.4	21.6	39.3	25.5	3.7	31.7	1.7

Percentage of Participants With a Decrease of ≥20% in Forced Expiratory Value in One Second (FEV1) Percent (%) Predicted From Pre-dose to 30-minute Post-dose

Airway Reactivity >= 20% relative decrease in FEV1% predicted from pre-dose to 30 minutes post-dose. Relative Change = 100 * (30 minutes Post-dose - Pre-dose)/Pre-dose assessed by the number and percentage of participants with a decrease of ≥ 20% in FEV1 % predicted from pre-dose to 30 minutes post-dose. (NCT01069705)
Timeframe: Pre-dose and post-dose of Day 1 and Day 29 of every Cycle (5, 6, 7)

Intervention	percentage of participants (Number)
	Acute Change from Pre-dose to 30 mins Post-dose Cycle 5 (Day 1)	Acute Change from Pre-dose to 30 mins Post-dose Cycle 5 (Day 29)	Acute Change from Pre-dose to 30 mins Post-dose Cycle 6 (Day 1)	Acute Change from Pre-dose to 30 mins Post-dose Cycle 6 (Day 29)	Acute Change from Pre-dose to 30 mins Post-dose Cycle 7 (Day 1)	Acute Change from Pre-dose to 30 mins Post-dose Cycle 7 (Day 29)
Tobramycin Inhalation Powder (TIPnew)	2.3	0.0	2.5	4.3	6.7	0.0

Percentage of Participants With Frequency Decrease From Baseline in the Post-baseline Audiology Tests

Auditory acuity of participants was measured using a standard dual-channel audiometer at frequencies from 250 to 8000 Hertz, and an audiogram (pure-tone air conduction) and tympanogram were performed by an audiologist. The categories reported includes >= 10dB decrease in 3 consecutive frequencies in either ear, >= 15dB decrease in 2 consecutive frequencies in either ear, and >= 20dB decrease in at least one frequency in either ear (NCT01069705)
Timeframe: Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	percentage of participants (Number)
	Cycle 5: Day 1; >= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 5: Day 1; >= 15 dB Decrease in 2 Consecutive Frequencies in Either Ear	Cycle 5: Day 1; >= 20 dB Decrease in at least one Frequency in Either Ear	Cycle 5: Day 29; >= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 5: Day 29; >= 15 dB Decrease in 2 Consecutive Frequencies in Either Ear	Cycle 5: Day 29; >= 20 dB Decrease in at least one Frequency in Either Ear	Cycle 6: Day 29; >= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 6: Day 29; >= 15 dB Decrease in 2 Consecutive Frequencies in Either Ear	Cycle 6: Day 29; >= 20 dB Decrease in at least one Frequency in Either Ear	Cycle 7: Day 29; ˃= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 7: Day 29; >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Cycle 7: Day 29; >= 20 dB Decrease in at Least One Frequency in Either Ear	Follow Up: Week 57/Day 57; ˃= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Follow Up: Week 57/Day 57; >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Follow Up: Week 57/Day 57; >= 20 dB Decrease in at Least One Frequency in Either Ear
Tobramycin Inhalation Powder (TIPnew)	0.0	0.0	0.0	0.0	5.3	0.0	0.0	5.3	0.0	10.5	5.3	5.3	20.0	0.0	0.0

Relative Change From Baseline of Forced Expiratory Flow Rate Over 25 and 75 Percent (FEF25-75%) Predicted to Each Post-baseline Visit

Forced Expiratory Flow Rate Over 25 and 75 Percent (FEF25-75%) is the forced expiratory flow from 25% to 75% of the Forced Vital Capacity (FVC). Relative change in FEF25-75% from baseline to pre-dose day X = (pre-dose day X FEF25-75 - baseline FEF25-75) / baseline FEF25-75) • 100. (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	percent change in (FEF25-75)% predicted (Mean)
	Baseline	Relative Change from Baseline to Cycle 5 (Day 1)	Relative Change from Baseline to Cycle 5 (Day 29)	Relative Change from Baseline to Cycle 6 (Day 1)	Relative Change from Baseline to Cycle 6 (Day 29)	Relative Change from Baseline to Cycle 7 (Day 1)	Relative Change from Baseline to Cycle 7 (Day 29)	Relative Change from Baseline to Follow-up (Week 57/Day 57)
Tobramycin Inhalation Powder (TIPnew)	36.8	37.7	43.2	35.1	34.3	44.4	36.1	35.6

Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to Each Post-baseline Visit

Forced expiratory volume in one second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 % predicted was a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day X FEV1 % predicted - baseline FEV1 % predicted) / baseline FEV1 % predicted) x 100. (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	percent change in FEV1 % predicted (Mean)
	Baseline	Relative Change from Baseline to Cycle 5 (Day 1)	Relative Change from Baseline to Cycle 5 (Day 29)	Relative Change from Baseline to Cycle 6 (Day 1)	Relative Change from Baseline to Cycle 6 (Day 29)	Relative Change from Baseline to Cycle 7 (Day 1)	Relative Change from Baseline to Cycle 7 (Day 29)	Relative Change from Baseline to Follow -Up (Week 57/Day 57)
Tobramycin Inhalation Powder (TIPnew)	59.5	11.4	12.6	8.6	11.9	9.0	10.1	8.1

Relative Change From Baseline of Forced Vital Capacity (FVC) Percent Predicted to Each Post-baseline Visit

Percent Predicted Forced Vital Capacity (FVC%) is the maximal exhaled breath volume following a maximal inhaled breath. Overall change in percent predicted FVC = (observed value)/(predicted value) * 100%. A higher value indicates a greater response. (NCT01069705)
Timeframe: Baseline, Cycles 5, 6, 7 (Days 1, 29) and Follow-up (Week 57/Day 57)

Intervention	percent change in FVC % predicted (Mean)
	Baseline	Relative Change from Baseline to Cycle 5 (Day 1)	Relative Change from Baseline to Cycle 5 (Day 29)	Relative Change from Baseline to Cycle 6 (Day 1)	Relative Change from Baseline to Cycle 6 (Day 29)	Relative Change from Baseline to Cycle 7 (Day 1)	Relative Change from Baseline to Cycle 7 (Day 29)	Relative Change from Baseline to Follow-up (Week 57/Day 57)
Tobramycin Inhalation Powder (TIPnew)	75.0	5.1	5.2	2.6	6.2	2.3	2.9	4.0

Safety Evaluations: Number and Frequency of Adverse Events Among Participants

The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions. (NCT03721328)
Timeframe: 12 months

Intervention	Participants (Count of Participants)
	Any Adverse Event	AE Relationship to NPWT Device UNRELATED	AE Relationship to Study Medication UNRELATED	AE Relationship to Study Treatment Procedure UNRELATED	Severity - Mild	Severity - Moderate	Severity - Severe	Serious Adverse Event	SAE Relationship to NPWT Device UNRELATED	SAE Relationship to Study Medication UNRELATED	SAE Relationship to Study Treatment Procedure UNRELATED	Suspected Adverse Reaction	Adverse Reactions
Experimental	14	14	14	14	14	7	6	7	7	7	7	0	0

Signs and Symptoms Composite Score - Change From Baseline to Day 15 - ITT Population

The CFB to Day 15 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population (NCT01028027)
Timeframe: Baseline, Day 15

Intervention	Score on a scale (Mean)
Loteprednol and Tobramycin	-11.64
Tobramycin and Dexamethasone	-11.98

Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population

The change from baseline (CFB) to Day 15 (Visit 4) in the ocular signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. Per protocol population (PP). (NCT01028027)
Timeframe: Baseline, Day 15

Intervention	Scores on a scale (Mean)
Loteprednol and Tobramycin	-11.63
Tobramycin and Dexamethasone	-12.41

Signs and Symptoms Composite Score - Change From Baseline to Day 8 - ITT Population

The CFB to Day 8 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population (NCT01028027)
Timeframe: Baseline, Day 8

Intervention	Score on a scale (Mean)
Loteprednol and Tobramycin	-8.91
Tobramycin and Dexamethasone	-9.96

Signs and Symptoms Composite Score - Change From Baseline to Day 8 - PP Population

The CFB to Day 8 (Visit 3) in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. (NCT01028027)
Timeframe: Baseline, Day 8

Intervention	Score on a scale (Mean)
Loteprednol and Tobramycin	-9.20
Tobramycin and Dexamethasone	-10.21

Signs and Symptoms Composite Score Change From Baseline to Day 3 - ITT Population

The CFB to Day 3 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population. (NCT01028027)
Timeframe: Baseline, Day 3

Intervention	Score on a scale (Mean)
Loteprednol and Tobramycin	-5.54
Tobramycin and Dexamethasone	-5.92

Signs and Symptoms Composite Score Change From Baseline to Day 3 - PP Population

The CFB to Day 3 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. PP population. (NCT01028027)
Timeframe: Baseline, Day 3

Intervention	Score on a scale (Mean)
Loteprednol and Tobramycin	-5.66
Tobramycin and Dexamethasone	-5.98

Change From Baseline in the Total Blepharoconjunctivitis Grade.

Change from baseline to visit 4 in the total blepharoconjunctivitis grade. Graded on a scale of 0-4, 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32. (NCT00705159)
Timeframe: Baseline to 15 days

Intervention	Score on a scale (Mean)
Loteprednol Etabonate and Tobramycin	-11.41
Loteprednol Etabonate	-11.23
Tobramycin	-10.68
Vehicle	-10.30

Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 2

Change from baseline in total blepharoconjunctivitis grade to visit 2(day 3) measured on a scale of 0-4. 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32. (NCT00705159)
Timeframe: Baseline to Day 3

Intervention	Score on a scale (Mean)
Loteprednol Etabonate and Tobramycin	-7.32
Loteprednol Etabonate	-7.74
Tobramycin	-5.94
Vehicle	-6.58

Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 3

Change from baseline in total blepharoconjunctivitis grade to visit 3(day 7) measured on a scale of 0-4. 0 (none), 1 (minimal/trace), 2 (mild), 3 (moderate), and 4 (severe). Grade range from 0-32. (NCT00705159)
Timeframe: Baseline to Day 7

Intervention	Score on a scale (Mean)
Loteprednol Etabonate and Tobramycin	-11.03
Loteprednol Etabonate	-10.94
Tobramycin	-9.90
Vehicle	-10.03

Number of Participants Who Achieved Bacterial Eradication at Visit 3

Bacterial eradication is defined as eradication of the causative pathogens as indicated by the absence of growth (0 colony forming units/mL) of the original infecting organism(s). (NCT00105469)
Timeframe: Visit 3 (Day 6)

Intervention	Participants (Number)
AzaSite	140
Tobramycin	148

Number of Participants Who Achieved Clinical Resolution at Visit 3

Clinical resolution is defined as absence of all three clinical signs (ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection). (NCT00105469)
Timeframe: Visit 3 (Day 6)

Intervention	Participants (Number)
AzaSite	127
Tobramycin	123

Assessment of Ocular Signs in the Study Eye - Visit 1

Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe. (NCT00420628)
Timeframe: Visit 1 (day 1)

Intervention	Units on a scale 0-4 (Mean)
	Lid Edema	Lid Erythema	Palpebral Conjunctival Injection	Meibomian Plugging
Loteprednol/Tobramycin	1.97	1.98	1.85	1.44
Vehicle	2.06	1.82	1.79	1.59

Assessment of Ocular Signs in the Study Eye - Visit 2

Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe. (NCT00420628)
Timeframe: Visit 2 (day 8)

Intervention	Units on a scale 0-4 (Mean)
	Lid Edema	Lid Erythema	Palpebral Conjunctival Injection	Meibomian Plugging
Loteprednol/Tobramycin	1.47	1.41	1.41	1.06
Vehicle	1.38	1.47	1.16	1.00

Assessment of Ocular Signs in the Study Eye - Visit 3

Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe. (NCT00420628)
Timeframe: Visit 3 (day 15)

Intervention	Units on a scale 0-4 (Mean)
	Lid Edema	Lid Erythema	Palpebral Conjunctival Injection	Meibomian Plugging
Loteprednol/Tobramycin	1.03	1.00	1.11	0.86
Vehicle	1.41	1.50	1.09	1.16

Investigators Global Assessment of the Clinical Condition

The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened. (NCT00420628)
Timeframe: Visit 3, day 8

Intervention	Participants (Number)
	Improved	Unchanged	Worse
Loteprednol/Tobramycin	36	25	2
Vehicle	17	13	2

Treatment Emergent Adverse Events

Study eye - Safety Population, At all visits 1,2,3 (NCT00420628)
Timeframe: day 1, day 8, day 15

Intervention	participants (Number)
	Conjunctivitis	Meibomianitis	Eyelid edema
Loteprednol/Tobramycin	2	1	0
Vehicle	0	1	1

Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal

Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded. (NCT00885365)
Timeframe: Day 0 (baseline), Week 4

Intervention	percentage predicted FEV1 (Mean)
Bramitob	6.99
TOBI	7.51

Change From Baseline at End of Weeks 2, 4, and 8 of Forced Vital Capacity (FVC) Expressed as Percentage of Predicted Normal

FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FVC values for children were different than the reference normal values used with adult participants. (NCT00885365)
Timeframe: Day 0 (baseline), Week 2, Week 4, Week 8

Intervention	percentage predicted FVC (Mean)
	Week 2 [n=156, 163]	Week 4 [n=153, 161]	Week 8 [n=153,159]
Bramitob	4.36	4.83	2.70
TOBI	5.36	5.58	5.04

Change From Baseline to End of Weeks 2, 4 and 8 in Body Mass Index (BMI)

(NCT00885365)
Timeframe: Day 0 (baseline), Weeks 2, 4 and 8

Intervention	kilograms/meters^2 (Mean)
	Week 2 [n=158, 163]	Week 4 [n=156, 161]	Week 8 [n=155,159]
Bramitob	0.10	0.12	0.16
TOBI	0.10	0.13	0.14

Change From Baseline to End of Weeks 2, 4 and 8 in Body Weight

Body weight was measured at all study visits as part of the physical examination. (NCT00885365)
Timeframe: Day 0 (baseline), Weeks 2, 4 and 8

Intervention	kilograms (Mean)
	Week 2 [n=158, 163]	Week 4 [n=156, 161]	Week 8 [n=155,159]
Bramitob	0.24	0.39	0.60
TOBI	0.22	0.42	0.53

Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Expiratory Volume in 1 Second (FEV1)

Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward). (NCT00885365)
Timeframe: Day 0 (baseline), Week 2, Week 4, Week 8

Intervention	liters (Mean)
	Week 2 [n=158, 163]	Week 4 [n=155, 161]	Week 8 [n=155,159]
Bramitob	0.18	0.20	0.16
TOBI	0.19	0.22	0.16

Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Vital Capacity (FVC)

FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry. (NCT00885365)
Timeframe: Day 0 (baseline), Week 2, Week 4, Week 8

Intervention	liters (Mean)
	Week 2 [n=156, 163]	Week 4 [n=153, 161]	Week 8 [n=153,159]
Bramitob	0.14	0.16	0.10
TOBI	0.16	0.18	0.16

Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%), Expressed as Percentage of Predicted Normal

Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated). Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEF 25-75% values for children were different than the reference normal values used with adult participants. (NCT00885365)
Timeframe: Day 0 (baseline), Week 2, Week 4, Week 8

Intervention	percentage predicted FEF 25-75% (Mean)
	Week 2 [n=156, 162]	Week 4 [n=154, 159]	Week 8 [n=154,158]
Bramitob	10.30	10.44	9.05
TOBI	8.57	9.32	6.41

Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%)

Difference in the forced expiratory flow rate in mid-exhalation measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated). (NCT00885365)
Timeframe: Day 0 (baseline), Week 2, Week 4, Week 8

Intervention	liters/second (Mean)
	Week 2 [n=156, 162]	Week 4 [n=154, 159]	Week 8 [n=154,158]
Bramitob	0.32	0.34	0.28
TOBI	0.28	0.29	0.21

Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal

Intervention	percentage predicted FEV1 (Mean)
	Week 2 [n=158, 163]	Week 4 [N=155, 161]	Week 8 [n=155, 159]
Bramitob	6.70	7.10	5.47
TOBI	6.93	7.63	5.37

Change From Baseline to End of Weeks 4 and 8 in Pseudomonas Aeruginosa Log10 Bacterial Load in Sputum

If a participant had more than one Pseudomonas aeruginosa (PA) morphotype at a given visit, and therefore more than one bacterial load value, then the bacterial load value corresponding to the highest tobramycin minimal inhibitory concentration (MIC) value regardless of the PA morphotype was used. If the tobramycin MIC value was the same for different PA morphotypes, then the bacterial load value corresponding to morphotype 1 (mucoid colony) was used. If morphotype 1 was not available, bacterial load value corresponding to morphotype 2 (dry colony) was used. (NCT00885365)
Timeframe: Day -10 to -1 (baseline), Week 4, Week 8

Intervention	colony forming units/gram (Mean)
	Week 4 [n=152, 156]	Week 8 [n=147, 147]
Bramitob	-2.14	-0.72
TOBI	-2.07	-0.87

Count of Participants With Treatment-Emergent Adverse Events (TEAEs)

"Treatment-Emergent Adverse Events defined as adverse events occurring after the first intake of study treatment (or the same day).~The investigator assessed relation to study treatment as a binary question: Reasonable possibility of relatedness or no reasonable possibility of relatedness. The expression reasonable possibility of relatedness is meant to convey in general that there are facts (evidence) or arguments meant to suggest a causal relationship.~A serious AE results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or an important medical event.~The investigator rates the severity of the AE based on a three point scale: mild, moderate or severe. A severe event prevents any usual routine activity of the participant and causes severe discomfort." (NCT00885365)
Timeframe: Day 0 to Week 8

Intervention	percentage of participants (Number)
	TEAE	Related TEAE	Serious TEAE	Severe TEAE	TEAE leading to withdrawal
Bramitob	31.4	6.4	3.8	1.9	0.6
TOBI	28.0	6.0	1.2	1.2	3.0

Microbiological Outcome Summary by Visit

"Microbiological outcomes are derived considering all P. aeruginosa (PA) morphotypes together.~Week 4 and Week 8 microbiological outcomes:~Eradication = elimination of PA~Persistence = persistence of PA detected at previous visit~Superinfection = appearance of a pathogen (other than PA) not detected at previous visit~Re-infection (week 8 only) = re-appearance of PA detected at Screening and eradicated at Week 4~Superinfection supersedes eradication. Persistence for P. aeruginosa supersedes superinfection.~Re-infection for P. aeruginosa supersedes superinfection." (NCT00885365)
Timeframe: Day -10 to -1 (screening), Weeks 4 and 8

Intervention	percentage of participants (Number)
	Screening: Presence of P aeruginosa	Week 4: Eradication	Week 4: Persistence	Week 4: Superinfection	Week 8: Eradication	Week 8: Persistence	Week 8: Superinfection	Week 8: Re-infection
Bramitob	100	9.2	82.9	7.9	2.7	78.9	9.5	8.8
TOBI	100	7.1	85.3	7.7	3.4	83.0	9.5	4.1

Minimal Inhibitory Concentration Inhibiting Growth of 50% (MIC50) of Pseudomonas Aeruginosa

"MIC50 is the concentration of tobramycin required to inhibit 50% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:~Morphotype 1: mucoid~Morphotype 2: dry~Morphotype 3: variant~Overall MIC50 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used." (NCT00885365)
Timeframe: Week 4, Week 8

Intervention	micrograms/milliliters (Number)
	Week 4 [n=126, 134]	Week 8 [n=129, 128]
Bramitob	1	1
TOBI	0.5	1

Minimal Inhibitory Concentration Inhibiting Growth of 90% (MIC90) of Pseudomonas Aeruginosa

"MIC90 is the concentration of tobramycin required to inhibit 90% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:~Morphotype 1: mucoid~Morphotype 2: dry~Morphotype 3: variant~Overall MIC90 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used." (NCT00885365)
Timeframe: Week 4, Week 8

Intervention	micrograms/milliliters (Number)
	Week 4 [n=126, 134]	Week 8 [n=129, 128]
Bramitob	32	32
TOBI	32	32

Participants With a Hearing Threshold >20 Decibel in at Least One Ear

The potential ototoxic effects (hearing loss) of tobramycin were investigated by performing audiometric tests. Participants with a loss of auditory acuity greater than the 20 decibels auditory threshold are reported. (NCT00885365)
Timeframe: Day -10 to -1 (screening), Weeks 4 and 8

Intervention	percentage of participants (Number)
	Screening	Week 4	Week 8
Bramitob	0	1.9	1.3
TOBI	0	1.2	1.2

Absolute Change From Baseline to End of Dosing (Day 29) and End of Off-cycle Period (Day 57) in Sputum Pseudomonas Aeruginosa Density (log10 Colony Forming Units(CFU) Per Gram Sputum)

"P. aeruginosa sputum density refers to overall density, defined as the sum of biotypes (mucoid, dry and small colony variant).~If sub-isolates exist for CFU biotype mucoid or dry, then the sum of sub-isolates is analyzed." (NCT00918957)
Timeframe: Baseline, Day 29, Day 57

Intervention	Log10 CFU (colony forming unit) (Mean)
	Number of participants analyzed (29, 28): Baseline	Number of participants analyzed (14, 27): Day 29	Number of participants analyzed (19, 24): Day 57
Placebo	7.3	0.0	-0.2
TIP (Tobramycin Inhalation Powder)	7.5	-2.4	-0.9

Acute Change in Airways Reactivity (FEV1 Percent Predicted) From Pre-dose to 30 Minutes After Completion of First Dose of Study Drug

"Relative change = 100 * (30-m-post-dose - pre-dose)/pre-dose assessed by the number and percentage of patients with a decrease of ≥20 % in FEV1 % predicted from pre dose to 30 minutes post dose.~Day 1 is the scheduled visit of first study drug administration." (NCT00918957)
Timeframe: Day 1, Day 29

Intervention	Percentage of participants (Number)
	Day 1	Day 29
Placebo	0.0	8.0
TIP (Tobramycin Inhalation Powder)	4.8	0.0

Change From Baseline of Forced Expiratory Flow Rate Over 25 and 75 Percent. (FEF25-75%) Predicted to End of Dosing (Day 29) and End of Off-cycle Period (Day 57)

"FEF25-75: Forced expiratory flow rate over 25% to 75% of vital capacity~For FEF25-75 percentage predicted the relative change is analyzed. If screening FEV1 percentage predicted is missing, it will be imputed by the baseline value." (NCT00918957)
Timeframe: Baseline, Day 29, Day 57

Intervention	percentage change (Least Squares Mean)
	Number of participants analyzed (31, 28): Baseline	Number of participants analyzed (25, 27): Day 29	Number of participants analyzed (28, 23): Day 57
Placebo	35.9	7.8	17.7
TIP (Tobramycin Inhalation Powder)	36.2	21.00	23.9

Change From Baseline of Forced Vital Capacity (FVC) Percent Predicted to End of Dosing (Day 29) and to the End of Off-cycle Period (Day 57)

"Results of statistical analysis were calculated from an ANOVA model. Baseline is defined as the latest measurement prior to the first dosing of study medication.~Response (percentage change) = treatment + Screening FEV1 percentage predicted (<50 and >=50) + age (<13 and >=13) + error" (NCT00918957)
Timeframe: Baseline, Day 29, Day 57

Intervention	percentage change (Mean)
	Number of participants analyzed (31, 28): Baseline	Number of participants analyzed (25, 27): Day 29	Number of participants analyzed (28, 23): Day 57
Placebo	76.9	1.6	3.1
TIP (Tobramycin Inhalation Powder)	73.3	7.2	5.2

Change From Baseline to End of Dosing (Day 29) and End of Off-cycle Period (Day 57) of Pseudomonas Aeruginosa Minimum Inhibitory Concentration (MIC)

Maximum MIC values from all biotypes were used. Absolute values and changes in tobramycin MIC for P. aeruginosa from baseline are summarized by biotype. Overall, a high variability of MIC was observed within each treatment group. For the maximum of all biotypes, large differences in mean changes from baseline at Day 29 were observed between the TIP group and the placebo group. (NCT00918957)
Timeframe: Baseline, Day 29, Day 57

Intervention	μg/mL (Mean)
	Number of participants analyzed (28, 29):Baseline	Number of participants analyzed (13, 27): Day 29	Number of participants analyzed (19, 24): Day 57
Placebo	2.7	10.0	1.4
TIP (Tobramycin Inhalation Powder)	0.8	0.1	0.5

Percentage of Participants With Adverse Events (AEs)

"Adverse Events (AEs) (on and off treatment) regardless of study relationship by primary system organ and treatment group.~Primary system organ classes are sorted in descending order of frequency in the TIP treatment group.~A patient with more than one AE within a primary system organ class is counted only once for that class." (NCT00918957)
Timeframe: First administration of study drug, study completion

Intervention	Percentage of participants (Number)
	Respiratory, thoracic & mediastinal disorders	Ear and labyrinth disorders	Infections and infestations	Gastrointestinal disorders	Metabolism and nutrition disorders	Nervous system disorders	Renal and urinary disorders	Skin and subcutaneous tissue disorder	Blood and lymphatic system disorder	Injury, poisoning and procedural complications	Investigation
Placebo	3.1	6.3	25.0	3.1	3.1	0.0	0.0	0.0	3.1	3.1	3.1
TIP (Tobramycin Inhalation Powder)	13.3	10.0	10.0	3.3	3.3	3.3	3.3	3.3	0.0	0.0	0.0

Percentage of Participants With Serious Adverse Events (SAEs)

"Serious Adverse Events (on and off treatment) by preferred term and treatment group.~Preferred terms are sorted in descending order of frequency in the TIP treatment group.~A patient with multiple occurrences of the same preferred term is counted only once in the preferred term." (NCT00918957)
Timeframe: Time of consent, 4 weeks after study completion

Intervention	percentage of participants (Number)
	Lower limb fracture	Pneumonia
Placebo	3.1	3.1
TIP (Tobramycin Inhalation Powder)	0.0	0.0

Post-hoc: Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29) Without Outlier

Relative change in percentage predicted FEV1 without outlier (outliers with respect to FEV1 values and PK data), in the Intent-to-treat (ITT), modified ITT (mITT) and Observed cases in the ITT populations were calculated from an adjusted analysis ANOVA model. (NCT00918957)
Timeframe: Baseline, Day 29

Intervention	change in percentage (Least Squares Mean)
	Participants analyzed: ITT Population (30, 28)	Parts. analyzed: Modified ITT Pop (24, 27)	Parts. analyzed: Observed Cases, ITT Pop (26, 27)
Placebo	3.1	3.5	3.4
TIP (Tobramycin Inhalation Powder)	10.4	12.4	13.1

Pre-planned Sensitivity Analysis: Absolute Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent (%) Predicted to End of Dosing (Day 29)

"Absolute change in percentage predicted FEV1 in the Intent-to-treat (ITT), modified ITT (mITT) and Observed cases in the ITT populations were calculated from an adjusted analysis ANOVA model.~In the adjusted analysis model: response = treatment + screening FEV1 % predicted (<50 and >=50) + age (<13 and >=13) + error.~Significance for the FEV1 % predicted is reached for p-values <= 0.05. There were 3 patients who had no screening nor baseline values (due to inadequate spirometry) and so were excluded from all change from baseline analyses." (NCT00918957)
Timeframe: Baseline, Day 29

Intervention	change in percentage (Least Squares Mean)
	Participants analyzed: ITT Population (31, 28)	Parts. analyzed: Modified ITT Pop (25, 27)	Parts. analyzed: Observed Cases, ITT Pop (27, 27)
Placebo	0.5	0.6	0.5
TIP (Tobramycin Inhalation Powder)	4.9	5.7	6.1

Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing (Day 29)

"Relative change in percentage predicted FEV1 in the Intent-to-treat (ITT), modified ITT (mITT) and Observed cases in the ITT populations were calculated from an adjusted analysis ANOVA model.~ITT Patients with missing or unacceptable Day 29 spirometry measurements had their primary endpoint data imputed with zero.~BSL = Baseline, defined as the latest measurement prior to the first dosing of study medication~- Relative change = 100 * (value - baseline) / baseline There were 3 patients who had no screening nor baseline values (due to inadequate spirometry) and so were excluded from all change from baseline analyses." (NCT00918957)
Timeframe: Baseline, Day 29

Intervention	change in percentage (Least Squares Mean)
	Participants analyzed: ITT Population (31, 28)	Parts. analyzed: Modified ITT Pop (27, 27)	Parts analyzed: Observed Cases in ITT Pop (25, 27)
Placebo	2.3	2.5	2.4
TIP (Tobramycin Inhalation Powder)	8.2	9.7	10.3

Shift From Baseline in Laboratory Parameters to Above Upper/Lower Limit of Normal

"Hematology values shift from baseline to above upper/below lower limit of normal at any time post-baseline.~Biochemistry values shift from baseline to above upper/below lower limit of normal at any time post-baseline." (NCT00918957)
Timeframe: Baseline, Study completion

Intervention	percentage of participants at risk (Number)
	Hematology (Hem): Absolute Basophilis- low - low	Hem: Absolute Basophilis - high	Hem: Absolute Eosinophils - low	Hem: Absolute Eosinophils - high	Hem: Absolute Lymphocytes - low	Hem: Absolute Lymphocytes - high	Hem: Absolute Monocytes - low	Hem: Absolute Monocytes - high	Hem: Absolute Neutrophils (Seg. + Bands) - low	Hem: Absolute Neutrophils (Seg. + Bands) - high	Hem: Basophils - low	Hem: Basophils - high	Hem: Eosinophils - low	Hem: Eosinophils - high	Hem: Lymphocytes -low	Hem: Lymphocytes - high	Hem: Monocytes - low	Hem: Monocytes - high	Hem: Neutrophils (Seg. + Bands) - low	Hem: Neutrophils (Seg. + Bands) - high	Hem: Platelet count (direct) - low	Hem: Platelet count (direct) - high	Hem: RBC- low	Hem: RBC- high	Hem: WBC (total)- low	Hem: WBC (total) - high	Hem: Hematocrit - low	Hem: Hematocrit - high	Hem: Hemoglobin - low	Hem: Hemoglobin - high	Biochemistry (Bio): Album - low	Bio: Album - high	Bio: Alkaline phosphatase, serum - low	Bio: Alkaline phosphatase, serum - high	Bio: Bilirubin (direct/conjugated) -low	Bio: Bilirubin (direct/conjugated) -high	Bio: Bilirubin (total) - low	Bio: Bilirubin (total) - high	Bio: Blood Urea Nitrogen (BUN) - low	Bio: Blood Urea Nitrogen (BUN) - high	Bio: Calcium -low	Bio: Calcium -high	Bio: Chloride - low	Bio: Chloride - high	Bio: Creatinine - low	Bio: Creatinine - high	Bio: Gamma Glutamyltransferase - low	Bio: Gamma Glutamyltransferase - high	Bio: Glucose - low	Bio: Glucose - high	Bio: Phosphate (Inorganic Phosphorus) - low	Bio: Phosphate (Inorganic Phosphorus) - high	Bio: Potassioum - low	Bio: Potassioum - high	Bio: SGOT (AST) - low	Bio: SGOT (AST) - high	Bio: SGPT (ALT) - low	Bio: SGPT (ALT) - high	Bio: Serum bicarbonate - low	Bio: Serum bicarbonate - high	Bio: Sodium - low	Bio: Sodium - high	Bio: Total Protein (Serum) - low	Bio: Total Protein (Serum) - high	Bio: Uric Acid - low	Bio: Uric Acid - high
Placebo	0.0	10.0	0.0	7.4	3.7	9.5	0.0	19.2	10.3	25.0	0.0	40.0	0.0	14.8	14.3	7.7	0.0	24.0	11.1	6.9	0.0	13.3	0.0	9.1	3.7	26.1	0.0	14.8	0.0	3.3	0.0	10.0	0.0	4.3	0.0	7.1	0.0	3.3	13.8	3.2	12.9	6.7	6.5	0.0	50.0	0.0	3.2	3.8	20.0	6.7	0.0	13.8	3.2	0.0	3.2	12.0	0.0	13.0	23.8	0.0	6.5	0.0	3.2	29.2	3.2	19.2
TIP (Tobramycin Inhalation Powder)	0.0	8.3	0.0	14.3	4.2	11.1	0.0	9.5	9.5	11.1	0.0	60.0	0.0	28.6	4.3	14.3	8.3	27.8	13.6	4.3	4.5	7.7	0.0	16.7	9.5	5.3	0.0	14.3	3.8	4.2	0.0	20.0	0.0	14.3	0.0	7.7	0.0	3.4	0.0	3.4	0.0	6.9	0.0	10.3	0.0	0.0	0.0	4.2	12.0	11.1	0.0	19.2	0.0	7.1	0.0	12.5	0.0	9.5	47.6	0.0	0.0	10.3	0.0	4.2	3.6	10.7

Tobramycin Serum Concentration

"Descriptive statistics of serum and sputum concentrations per scheduled sampling time.~Detectable concentration values at pre-dose on Day 1 were excluded from the analysis." (NCT00918957)
Timeframe: Pre-dose, 0 - 1 hour post-dose, 1 -2 hours post-dose, 2 - 6 hours post-dose

Intervention	μg/mL (Mean)
	Day1: 0 -1 hour (hr) post dose (28, 0)	Day 1: 1 -2 hours (hr) post dose (28, 0)	Day 1: 2 -6 hours (hr) post dose (29, 0)	Day 29: Pre-dose (27, 0)	Day 29: 0 -1 hr post dose (28, 0)	Day 29: 1 -2 hrs post dose (29, 0)	Day 29: 2 -6 hrs post dose (27, 0)
TIP (Tobramycin Inhalation Powder)	0.83	0.93	0.73	0.41	1.48	1.37	1.14

Absolute Change in Forced Expiratory Volume at One Second (FEV1) % Predicted Between Study Arms With Acute Pulmonary Exacerbation (APE) Treatment

absolute change in forced expiratory volume at one second (FEV1) % predicted, or percent predicted FEV1, between study arms with acute pulmonary exacerbation (APE) treatment (NCT02918409)
Timeframe: up to 14 days, from beginning to end of APE treatment

Intervention	ppFEV1 (Mean)
Standard Colistin Arm	6.5
Modified Colistin Arm	4.4
Standard Tobramycin Arm	4.5

Differences in Occurrences of Neurotoxicity and Ototoxicity Related Side Effects Between Study Arms as Reported by Treating Physician(s)

absolute occurrences of adverse event rates are being compared between treatment groups using logistic regression, adjusting for age, co-administration of medications such as vancomycin and trimethoprim-sulfamethoxazole, baseline FEV1, admits in the previous year, and diagnosis of CF related diabetes (CFRD) as covariates. (NCT02918409)
Timeframe: up to 14 days, from beginning to end of APE treatment

Intervention	Participants (Count of Participants)
Standard Colistin Arm	2
Modified Colistin Arm	1
Standard Tobramycin Arm	1

Longitudinal Differences in Exacerbation Rates Between Tobramycin and Colistin Use as Seen in Readmission Rate

time to next admission for exacerbation measured in days when comparing of different antibiotic therapies (NCT02918409)
Timeframe: from the beginning of APE treatment to 12 months after APE treatment

Intervention	days (Mean)
Standard Colistin Arm	154
Modified Colistin Arm	283
Standard Tobramycin Arm	241

Rate of Occurrence of the Development of Acute Kidney Injury (AKI) During APE Treatment

(NCT02918409)
Timeframe: up to 14 days, from beginning to end of APE treatment

Intervention	Participants (Count of Participants)
Standard Colistin Arm	1
Modified Colistin Arm	0
Standard Tobramycin Arm	5

Actual Change From Baseline in CF Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28

The CFQ-R is a validated patient-reported outcome tool measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from baseline, assessed with the CFQ-R RSS (range of scores [units]: 0-100; higher scores indicate fewer symptoms). (NCT00757237)
Timeframe: Baseline and end of treatment Course 1 (Day 28)

Intervention	Units on a scale (Least Squares Mean)
AZLI (75 mg TID)	8.20
TIS (300 mg BID)	2.59

Mean Actual Change From Baseline in CFQ-R RSS Score Across 3 Treatment Courses

The CFQ-R is a validated patient-reported outcome tool measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The endpoint was the average actual change in respiratory symptoms (e.g., coughing, congestion, wheezing) from baseline, assessed with the CFQ-R RSS (range of scores [units]: 0-100; higher scores indicate fewer symptoms) at the end of each treatment course (Weeks 4, 12, and 20). (NCT00757237)
Timeframe: Baseline and end of treatment Courses 1 (Week 4), 2 (Week 12), and 3 (Week 20)

Intervention	units on a scale (Least Squares Mean)
AZLI (75 mg TID)	6.30
TIS (300 mg BID)	2.17

Mean Actual Change From Baseline in FEV1 Percent Predicted Across 3 Treatment Courses in Subjects Who Received Inhaled Tobramycin for >= 84 Days in the 12 Months Prior to Randomization

"Spirometry was performed according to ATS guidelines at each visit. FEV1 percent predicted is a normalized value of FEV1 calculated using the Knudson equation and based upon participant age, gender, and height.~Treatment effect on the average adjusted means for the actual change in FEV1 percent predicted at Visits 4, 6, and 8 (Weeks 4, 12, and 20) was tested by MMRM analysis using the population of participants with prior inhaled tobramycin use of >=84 days in the previous 12 months." (NCT00757237)
Timeframe: Baseline and end of treatment Courses 1 (Week 4), 2 (Week 12), and 3 (Week 20)

Intervention	actual change in FEV1 percent predicted (Least Squares Mean)
AZLI (75 mg TID)	3.26
TIS (300 mg BID)	-0.21

Mean Actual Change From Baseline in FEV1 Percent Predicted Across 3 Treatment Courses

"Spirometry was performed according to ATS guidelines at each visit. FEV1 percent predicted is a normalized value of FEV1 calculated using the Knudson equation and based upon participant age, gender, and height.~Treatment effect on the average adjusted means for the actual change in FEV1 percent predicted at Visits 4, 6, and 8 (Weeks 4, 12, and 20) was tested by mixed-effect model repeated measures (MMRM) analysis using the ITT population analysis set." (NCT00757237)
Timeframe: Baseline, and end of treatment Courses 1 (Week 4), 2 (Week 12), and 3 (Week 20)

Intervention	actual change in FEV1 percent predicted (Least Squares Mean)
AZLI (75 mg TID)	2.05
TIS (300 mg BID)	-0.66

Number of Respiratory Events Requiring IV and/or Inhaled Antipseudomonal Antibiotics (Other Than Randomized Treatment)

Inhaled and/or IV antipseudomonal antibiotic use for respiratory event was determined through event adjudication by a sponsor-independent, blinded review committee. Use of IV and/or inhaled antipseudomonal antibiotics was compiled from data recorded on the concomitant medications eCRF and compared to reported AEs to determine use for a respiratory event. The time to IV and/or inhaled antipseudomonal antibiotic use was measured in days from baseline (Visit 2) to the date of first antipseudomonal antibiotic use or the date of study completion (last visit)/or early withdrawal if censored. (NCT00757237)
Timeframe: Day 0 through Day 168 (end of study)

Intervention	events (Number)
AZLI (75 mg TID)	84
TIS (300 mg BID)	121

Relative Change From Baseline in FEV1 Percent Predicted at Day 28 in Subjects Who Received Inhaled Tobramycin for >= 84 Days in the 12 Months Prior to Randomization

Spirometry was performed according to ATS guidelines. FEV1 percent predicted is a normalized value of FEV1 calculated using the Knudson equation and based upon participant age, gender, and height. Treatment effect on the relative change from baseline in FEV1 percent predicted at Day 28 (Visit 4) was tested using an ANCOVA model-based method, using the population of participants with prior inhaled tobramycin use of >= 84 days in the previous 12 months. (NCT00757237)
Timeframe: Baseline and end of treatment Course 1 (Day 28)

Intervention	percent change in FEV1 percent predicted (Least Squares Mean)
AZLI (75 mg TID)	10.04
TIS (300 mg BID)	0.54

Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28

Spirometry was performed according to American Thoracic Society (ATS) guidelines at each visit. FEV1 percent predicted is a normalized value of FEV1 calculated using the Knudson equation and based upon participant age, gender, and height. Treatment effect on the relative change from baseline in FEV1 percent predicted at Day 28 (Visit 4) was tested using an analysis of covariance (ANCOVA) model-based method. (NCT00757237)
Timeframe: Baseline and end of treatment Course 1 (Day 28)

Intervention	percent change in FEV1 percent predicted (Least Squares Mean)
AZLI (75 mg TID)	8.35
TIS (300 mg BID)	0.55

Time to First Respiratory Hospitalization

"This endpoint was determined through the adjudication of events by a sponsor-independent, blinded review committee. Committee members reviewed all hospitalizations and determined which were related to respiratory events.~Details of all hospitalizations, including the dates of admission and discharge, were recorded on the serious adverse event (SAE) eCRF.~Time to first respiratory hospitalization was the number of days from baseline (Visit 2) to the date of first respiratory hospitalization or the date of study completion (last visit) /or early withdrawal if censored." (NCT00757237)
Timeframe: Day 0 to Day 168 (end of study)

Intervention	days (Median)
AZLI (75 mg TID)	NA
TIS (300 mg BID)	NA

Time to Need for Inhaled and/or IV Antipseudomonal Antibiotics for Respiratory Event (Other Than Randomized Treatment)

"Antipseudomonal antibiotic use for respiratory event was determined through event adjudication by a sponsor-independent, blinded review committee.~Use of IV and/or inhaled antibiotics for a respiratory event was compiled from data recorded on the concomitant medications eCRF and compared to reported AEs to determine use for a respiratory event. The time to antibiotic use for a respiratory event was measured in days from baseline (Day 0) to the date of first antibiotic use for a respiratory event or the date of study completion (last visit)/or early withdrawal if censored." (NCT00757237)
Timeframe: Day 0 to Day 168 (end of study)

Intervention	days (Median)
AZLI (75 mg TID)	NA
TIS (300 mg BID)	117

Time to Need for Intravenous (IV) Antipseudomonal Antibiotics for Respiratory Events

"IV antipseudomonal antibiotic use for a respiratory event was determined through the adjudication of events by a sponsor-independent, blinded review committee.~Use was compiled from data recorded on the concomitant medications electronic case report form (eCRF) and compared to reported adverse events (AEs) to determine use for a respiratory event. The time to IV antipseudomonal antibiotic use was measured in days from baseline (Visit 2) to the date of first IV antipseudomonal antibiotic use or the date of study completion (last visit)/or early withdrawal if censored." (NCT00757237)
Timeframe: Day 0 to Day 168 (end of study)

Intervention	days (Median)
AZLI (75 mg TID)	NA
TIS (300 mg BID)	151

Total Number of Respiratory Hospitalizations

Respiratory hospitalizations were determined through the adjudication of events by a sponsor-independent, blinded review committee. Committee members reviewed hospitalizations and determined which were related to respiratory events. (NCT00757237)
Timeframe: Day 0 to Day 168 (end of study)

Intervention	hospitalizations (Number)
AZLI (75 mg TID)	40
TIS (300 mg BID)	58

Treatment Satisfaction Questionnaire for Medication (TSQM) - Global Satisfaction Results at Week 20

This 14 item questionnaire consists of 3 subscales that gauge participant perceptions of a medication's effectiveness, side effects, and convenience. The measure also contains a global satisfaction scale to evaluate overall participant satisfaction. The global satisfaction score is the endpoint reported here. The range of scores is 0 to 100, with higher scores indicating greater satisfaction. (NCT00757237)
Timeframe: At Week 20

Intervention	units on a scale (Least Squares Mean)
AZLI (75 mg TID)	75.85
TIS (300 mg BID)	61.73

Mean Elevated Intraocular Pressure (IOP) During Treatment

Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days. (NCT00834171)
Timeframe: 55 days

Intervention	Millimeters of mercury (mmHg) (Mean)
Loteprednol Etabonate Ophthalmic Suspension 0.5%	24.8
Loteprednol Etabonate (0.5%) and Tobramycin (0.3%)	23.9

Time to Recurrence of Pseudomonas (P.) Aeruginosa (Any Genotype) in Sputum or Deep Throat Cough Swab

Microbiological samples were obtained from sputum or by deep throat cough swab technique. Time to recurrence was defined as the time between the visit at 1 month after the end of treatment (when eradication was confirmed) and the time of the first positive culture with any genotype of P. aeruginosa. Time zero was Day 56 (Month 2) for the 28-day treatment group and Month 3 for the 56-day treatment group. Kaplan-Meier estimates were used. (NCT00391976)
Timeframe: From 1 month after the end of treatment (Day 56 for the 28-day treatment group and Month 3 for the 56-day treatment group) until the end of the study (Month 27)

Intervention	Months (Median)
Tobramycin 300 mg for 28 Days	26.12
Tobramycin 300 mg for 56 Days	25.82

Time to Recurrence of Pseudomonas (P.) Aeruginosa (New or Same Genotype) in Sputum or Deep Throat Cough Swab Based on Confirmatory Assessment by the Central Laboratory

Time to recurrence was defined as the time between the visit at 1 month after the end of treatment (when eradication was confirmed) and the time of the first positive culture with any genotype of P. aeruginosa. Time zero was Day 56 (Month 2) for the 28-day treatment group and Month 3 for the 56-day treatment group. (NCT00391976)
Timeframe: From 1 month after the end of treatment until the end of the study (Month 27)

Intervention	Months (Median)
Tobramycin 300 mg for 28 Days	9.84
Tobramycin 300 mg for 56 Days	16.62

Number of Participants Hospitalized for Pulmonary Exacerbations

Core study defined as from Baseline through to one month after the end of treatment (Day 56 for the 28-day treatment group and Month 3 for the 56-day treatment group). Follow-up phase began at the end of the core study through to the end of the study (Month 27). (NCT00391976)
Timeframe: From Baseline to end of study (27 months)

Intervention	Participants (Number)
	Core Study	Follow-up
Tobramycin 300 mg for 28 Days	0	5
Tobramycin 300 mg for 56 Days	2	2

Percentage of Patients With Pseudomonas (P.) Aeruginosa Eradicated From Deep Throat Cough Swab or Sputum

One month after the end of treatment was Day 56 (Month 2) for the 28-day treatment group and Month 3 for the 56-day treatment group. (NCT00391976)
Timeframe: From 1 month after the end of treatment until the end of the study (Month 27)

Intervention	Percentage of participants (Number)
	At 1 month after the end of treatment	At final visit
Tobramycin 300 mg for 28 Days	100	68
Tobramycin 300 mg for 56 Days	100	71

Tobramycin Tear Concentration Area Under the Curve (AUC)

Trapezoidal AUC was calculated from 2 to 18 minutes. (NCT00695435)
Timeframe: 2 to 18 minutes post administration

Intervention	min*ug/mL (Mean)
Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension	6124
TOBREX® Ophthalmic Solution	2119
TOBRADEX® Ophthalmic Suspension	2484

Tobramycin Tear Concentration Cmax (Maximum Concentration)

Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period. (NCT00695435)
Timeframe: 2, 4, 6, 12, and 18 minutes

Intervention	µg/mL (Mean)
Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension	853
TOBREX® Ophthalmic Solution	527
TOBRADEX® Ophthalmic Suspension	542

Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)

Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second) (NCT01315678)
Timeframe: Baseline to168 days

Intervention	Percent (%) change (Mean)
Arikayce™	0.47
TOBI®	1.67

Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum

Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum (NCT01315678)
Timeframe: Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168

Intervention	Log 10 CFU (Mean)
	Baseline	14 days	28 days	57 days	84 days	113 days	140 days	168 days
Arikayce™	6.872	-1.124	-1.208	-0.210	-0.945	-0.613	-1.440	-0.725
TOBI®	6.510	-1.663	-1.453	-0.098	-1.182	-0.135	-1.315	-0.136

Number of Participants Experiencing a Pulmonary Exacerbation

Number of participants experiencing a pulmonary exacerbation measured by number with event and number censored (NCT01315678)
Timeframe: 168 days

Intervention	participants (Number)
	Number with Event	Number Censored
Arikayce™	73	75
TOBI®	63	83

Number of Participants to First All Cause Hospitalization

Number of participants to first all cause hospitalization measured by number with event and number censored (NCT01315678)
Timeframe: 168 days

Intervention	participants (Number)
	Number with Event	Number Censored
Arikayce™	24	124
TOBI®	29	117

Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation

Number of participants to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored (NCT01315678)
Timeframe: 168 days

Intervention	Participants (Count of Participants)
	Number with Event	Number Censored
Arikayce™	55	93
TOBI®	48	98

Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)

Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1 (NCT01315678)
Timeframe: Baseline, Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168.

Intervention	percentage (%) change (Mean)
	Day 14	Day 28	Day 57	Day 84	Day 113	Day 140	Day 168
Arikayce™	2.59	0.79	-3.49	0.44	-0.90	0.43	-0.12
TOBI®	6.64	3.32	0.70	3.59	0.42	1.37	1.58

Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R

Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized. (NCT01315678)
Timeframe: Day 14, Day 28, Day 57, Day 84, Day 113, Day 140 and Day 168

Intervention	Percent (%) change (Least Squares Mean)
	Day 14	Day 28	Day 57	Day 84	Day 113	Day 140	Day 168
Arikayce™	13.65	15.54	8.00	13.20	3.58	13.84	12.06
TOBI®	8.81	11.03	7.97	8.55	5.03	6.10	8.07

Concentration of Antibiotics in Cementless Knees Post op

1. Determine the intra-articular concentration of vancomycin and tobramycin after administration of vancomycin and tobramycin powder in primary cementless total knee arthroplasty. (NCT04297631)
Timeframe: 1 hour, 4 hours, and 24 hours

Intervention	micrograms per milliliter (Median)
	1 hour Vancomycin Intraarticular concentration	4 hour Vancomycin Intraarticular concentration	24 hour Vancomycin Intraarticular concentration	1 hour tobramycin Intraarticular concentration	4 hour tobramycin Intraarticular concentration	24 hour tobramycin Intraarticular concentration
Intraarticular Concentrations of Tobramycin and Vancomycin	1702.5	582.5	56.1	1943	345	8.7

Serum Concentrations of Vancomycin and Tobramycin at 1, 4, and 24 Hours.

2. Determine the serum concentrations of these antibiotics postoperatively (NCT04297631)
Timeframe: 1 hour, 4 hours, and 24 hours

Intervention	micrograms per milliliter (Median)
	1 hour vancomycin serum concentration	4 hour vancomycin serum concentration	24 hour vancomycin serum concentration	1 hour tobramycin serum concentration	4 tobramycin	24 hour tobramycin
Vancomycin and Tobramycin Serum Concentration	2.3	4.6	3.1	6.3	8	.8

Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)

Microbiological success was declared if the pre-therapy pathogens were eradicated at the Exit Visit; conversely, microbiological failure was declared if pre-therapy pathogens persisted at the exit visit. The microbiological outcomes were calculated based on an algorithm that assessed whether pre-therapy pathogens were eradicated or persisted as demonstrated by comparative characterization of recovered bacteria. (NCT00576251)
Timeframe: Day 4 - Test Of Cure (TOC) compared to Day 0

Intervention	Percent of patients (Number)
Tobramycin 0.3%/Dexamethasone 0.05%	100.0
TOBRADEX Ophthalmic Suspension	94.4

The Use of the Approved US TOBI Podhaler Instructions for Use (IFU) to Communicates the Information Necessary to Achieve Safe and Effective Use of the Podhaler Device

Recording all use errors and close calls associated with inhalation of one dose of TOBI Podhaler (i.e., inhaling the contents of four placebo capsules via the Podhaler device) by subjects (CF patients, and caregivers, if applicable). The study population consisted of CF patients (and caregivers) naïve to the Podhaler device and untrained in the use of the device. Assessing the root cause of use errors and close calls for 6 defined critical errors (agreed with the FDA) and establishing those which can be attributed to a lack of clarity or presence of ambiguities in the IFU content, i.e., errors attributable to a failure to understand the IFU. (NCT02178540)
Timeframe: 1 Day

Intervention	Patients failing to understand IFU (Number)
	Failure to open blisters	Attempting to swallow the capsule	Placing capsule into the mouthpiece	Failure to pierce any of the 4 capsules (caps)*	Failure to inhale from all 4 capsules	Failure to inhale all powder from any of 4 caps†
Open Label	0	0	0	3	0	6

Number of Days of Hospitalization Due to Respiratory Serious Adverse Events

SAEs included adverse events that resulted in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. For calculation of days in hospitalization due to respiratory events, the end date was defined as the discharge date (if provided and even if after the end of the extension study), and otherwise as the date of last visit. (NCT00982930)
Timeframe: From first administration of study drug to study completion (up to approximately 25 weeks)

Intervention	days (Median)
Tobramycin Inhalation Powder	13.0

Percentage of Death Cases

(NCT00982930)
Timeframe: From time of consent to 4 weeks after study completion (up to approximately 29 weeks)

Intervention	percentage of participants (Number)
Tobramycin Inhalation Powder	0

Percentage of Participants With Adverse Events (AEs)

Intervention	percentage of participants (Number)
Tobramycin Inhalation Powder	47.3

Percentage of Participants With Anti-Pseudomonal Antibiotic Use During The Treatment Period

(NCT00982930)
Timeframe: From first administration of study drug to study completion (up to approximately 25 weeks)

Intervention	percentage of participants (Number)
Tobramycin Inhalation Powder	9.1

Percentage of Participants With Serious Adverse Events (SAEs)

Intervention	percentage of participants (Number)
Tobramycin Inhalation Powder	5.5

Absolute Change From Baseline in Sputum Pseudomonas Aeruginosa Density [log10 Colony Forming Units (CFU) Per Gram Sputum] to End of Dosing at Each Cycle and Study Completion

P. aeruginosa sputum density referred to overall density, defined as the sum of biotypes (mucoid, dry and small colony variant). If sub-isolates existed for CFU biotype mucoid or dry, then the sum of sub-isolates was analyzed. Absolute change from baseline was defined as: Absolute change = Post Baseline - Baseline. Baseline was defined as last measurement prior to first dose of study drug in the core study CTBM100C2303. Termination referred to the last available pre dose post-baseline measurement. (NCT00982930)
Timeframe: Baseline, Day 29 of Cycle 2, 3, 4, Day 57 of Follow Up and Termination (Study Completion)

Intervention	log10 Colony Forming Units (CFU) (Mean)
	Cycle 2: Day 29	Cycle 3: Day 29	Cycle 4: Day 29	Follow Up: Day 57	Termination
Tobramycin Inhalation Powder	-3.7	-3.5	-3.9	-1.1	-2.9

Acute Relative Change in Airways Reactivity [Forced Expiratory Value in One Second (FEV1) Percent (%) Predicted] From Pre-dose to 30 Minutes After Completion of First Dose of Study Drug

Airway Reactivity was defined as ≥20% FEV1 relative decrease in percent predicted from pre dose to 30 minutes post dose. FEV1 was defined as the volume of air expired in 1 second. FEV1 % predicted was a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. Relative change in FEV1 % predicted = 100* (30 minutes post dose - pre dose) / pre dose assessed by number and percentage of participants with a decrease in ≥20% FEV1 percent predicted from pre dose to 30 minutes post dose. Baseline for was defined as the last measurement prior to first dose of study drug in the core study CTBM100C2303. (NCT00982930)
Timeframe: Pre-dose and 30 minutes Post-dose on Day 1 and Day 29 of every Cycle (2, 3, 4)

Intervention	percentage change (Mean)
	Cycle 2: Day 1	Cycle 2: Day 29	Cycle 3: Day 1	Cycle 3: Day 29	Cycle 4: Day 1	Cycle 4: Day 29
Tobramycin Inhalation Powder	0.0	-3.0	-1.4	-1.8	-3.0	-0.6

Change From Baseline in Forced Expiratory Flow Rate Over 25 Percent and 75 Percent (FEF25-75%) Predicted to End of Dosing at Each Cycle and Study Completion

Relative change from baseline in FEF25-75% predicted to end of dosing in each cycle and study completion were reported. Relative change from baseline was defined as: Relative change = 100* (Post baseline- baseline) / baseline. Baseline was defined as last measurement prior to first dose of study drug in the core study CTBM100C2303. Termination referred to the last available pre dose post-baseline measurement. (NCT00982930)
Timeframe: Baseline, Day 29 of Cycle 2, 3, 4, Day 57 of Follow Up and Termination (Study Completion)

Intervention	percentage change (Mean)
	Cycle 2: Day 29	Cycle 3: Day 29	Cycle 4; Day 29	Follow Up: Day 57	Termination
Tobramycin Inhalation Powder	35.2	44.7	40.5	35.9	34.7

Change From Baseline in Forced Vital Capacity (FVC) Percent (%) Predicted to End of Dosing at Each Cycle and Study Completion

Relative change from baseline in FVC % predicted to end of dosing in each cycle and study completion were reported. Relative change from baseline was defined as: Relative change = 100* (Post baseline- baseline) / baseline. Baseline was defined as last measurement prior to first dose of study drug in the core study CTBM100C2303. Termination referred to the last available pre dose post-baseline measurement. (NCT00982930)
Timeframe: Baseline, Day 29 of Cycle 2, 3, 4, Day 57 of Follow Up and Termination (Study Completion)

Intervention	percentage change (Mean)
	Cycle 2: Day 29	Cycle 3: Day 29	Cycle 4: Day 29	Follow Up: Day 57	Termination
Tobramycin Inhalation Powder	7.0	7.2	9.6	7.4	7.9

Change From Baseline in Pseudomonas Aeruginosa Minimum Inhibitory Concentration (MIC) to End of Dosing at Each Cycle and Study Completion

Change in tobramycin MIC values for P. aeruginosa were reported for specimens and were used to assess the change in pathogen susceptibility to tobramycin before (baseline) and after (post-baseline) the treatment. Maximum MIC values from all biotypes were used. Change from baseline was defined as: Change = Post-baseline - Baseline. Baseline was defined as last measurement prior to first dose of study drug in the core studyCTBM100C2303.Termination referred to the last available pre dose post-baseline measurement. (NCT00982930)
Timeframe: Baseline, Day 29 of Cycle 2, 3, 4, Day 57 of Follow Up and Termination (Study Completion)

Intervention	μg/mL (Mean)
	Cycle 2: Day 29	Cycle 3: Day 29	Cycle 4: Day 29	Follow Up: Day 57	Termination
Tobramycin Inhalation Powder	15.1	30.7	24.0	28.6	22.3

Number of Participants With Adverse Events (AEs) Associated With the Use of New Antipseudomonal Antibiotic

AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal product. SAEs included adverse events that resulted in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. (NCT00982930)
Timeframe: From first administration of study drug to study completion (up to approximately 25 weeks)

Intervention	Participants (Count of Participants)
	Mild, Yes	Mild, No	Moderate, Yes	Moderate, No	Severe, Yes	Severe, No
Tobramycin Inhalation Powder	1	13	3	9	0	0

Percentage of Participants With Adverse Events and Serious Adverse Events Leading to Permanent Study Discontinuation

Intervention	percentage of participants (Number)
	Discontinuation Due to Adverse Events	Discontinuation Due to Serious Adverse Events
Tobramycin Inhalation Powder	1.8	0

Percentage of Participants With Frequency Decrease From Baseline in the Post-baseline Audiology Tests

Auditory acuity of participants was measured using a standard dual-channel audiometer at frequencies from 250 to 8000 Hertz, and an audiogram (pure-tone air conduction) and tympanogram were performed by an audiologist. The categories reported includes >= 10dB decrease in 3 consecutive frequencies in either ear, >= 15dB decrease in 2 consecutive frequencies in either ear, and >= 20dB decrease in at least one frequency in either ear. (NCT00982930)
Timeframe: From first dose of study drug to study completion (up to approximately 25 weeks)

Intervention	percentage of participants (Number)
	Cycle 2: Day 1; ˃= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 2: Day 1: >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Cycle 2: Day 1; >= 20 dB Decrease in at Least One Frequency In Either Ear	Cycle 2: Day 29; ˃= 10 dB decrease in 3 Consecutive Frequencies in Either Ear	Cycle 2: Day 29; >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Cycle 2: Day 29; >= 20 dB Decrease in at Least One Frequency In Either Ear	Cycle 3: Day 29; ˃= 10 dB Decrease in 3 Consecutive Frequencies in Either Ear	Cycle 3: Day 29; >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Cycle 3: Day 29; >= 20 dB Decrease in at Least One Frequency In Either Ear	Cycle 4: Day 29; ˃= 10 dB decrease in 3 Consecutive Frequencies in Either Ear	Cycle 4: Day 29; >= 15 dB Decrease In 2 Consecutive Frequencies in Either Ear	Cycle 4: Day 29; >= 20 dB Decrease in at Least One Frequency In Either Ear	Follow Up: Day 57; ˃= 10 dB decrease in 3 Consecutive Frequencies in Either Ear	Follow Up: Day 57: >= 15 dB Decrease in 2 Consecutive Frequencies in Either Ear	Follow Up: Day 57; >= 20 dB Decrease in at Least One Frequency In Either Ear
Tobramycin Inhalation Powder	5.6	0.0	0.0	5.0	0.0	0.0	9.1	4.5	4.5	4.5	0.0	0.0	0.0	0.0	0.0

Relative Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Percent Predicted to End of Dosing at Each Cycle and Study Completion

FEV1 was defined as the volume of air expired in 1 second. FEV1 % predicted was a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. Relative change in FEV1 % predicted = 100* (30 minutes post dose - pre dose) / pre dose assessed by number and percentage of participants with a decrease in ≥20% FEV1 percent predicted from pre dose to 30 minutes post dose. Baseline for was defined as the last measurement prior to first dose of study drug in the core study CTBM100C2303. Termination referred to the last available pre dose post-baseline measurement. (NCT00982930)
Timeframe: Baseline, Day 29 of Cycle 2, 3, 4, Day 57 of Follow Up and Termination (Study Completion)

Intervention	percentage change (Mean)
	Cycle 2: Day 29	Cycle 3: Day 29	Cycle 4: Day 29	Follow Up: Day 57	Termination
Tobramycin Inhalation Powder	13.5	14.8	17.3	13.5	13.9

Shift From Baseline in Laboratory Parameters to Above Upper/Lower Limit of Normal

Shift from baseline in hematology and biochemistry values to above upper/below lower limit of normal at any time post-baseline were reported. Baseline for safety analyses was defined as the last measurement prior to first dose of study drug in the core study CTBM100C2303. Change to low referred to number of participants with normal or high values at baseline. Change to high referred to number of participants with normal or low values at baseline. (NCT00982930)
Timeframe: From baseline to study completion (up to approximately 25 weeks)

Intervention	percentage of participants at risk (Number)
	Hematology (Hem): Absolute Basophils - low	Hem: Absolute Basophils - high	Hem: Absolute Eosinophils - low	Hem: Absolute Eosinophils - high	Hem: Absolute Lymphocytes - low	Hem: Absolute Lymphocytes - high	Hem: Absolute Monocytes - low	Hem: Absolute Monocytes - high	Hem: Absolute Neutrophils (Seg. + Bands) - low	Hem: Absolute Neutrophils (Seg. + Bands) - high	Hem: Basophils - low	Hem: Basophils - high	Hem: Eosinophils - low	Hem: Eosinophils - high	Hem: Hematocrit - low	Hem: Hematocrit - high	Hem: Hemoglobin - low	Hem: Hemoglobin - high	Hem: Lymphocytes - low	Hem: Lymphocytes - high	Hem: Monocytes - low	Hem: Monocytes - high	Hem: Neutrophils (Seg. + Bands) - low	Hem: Neutrophils (Seg. + Bands) - high	Hem: Platelet count (direct) - low	Hem: Platelet count (direct) - high	Hem: RBC- low	Hem: RBC- high	Hem: WBC (total)- low	Hem: WBC (total)- high	Biochemistry (Bio): Albumin - low	Bio: Albumin - high	Bio: Alkaline phosphatase, serum - low	Bio: Alkaline phosphatase, serum - high	Bio: Bilirubin (direct/conjugated) -low	Bio: Bilirubin (direct/conjugated) -high	Bio: Bilirubin (total) - low	Bio: Bilirubin (total) - high	Bio: Blood Urea Nitrogen (BUN) - low	Bio: Blood Urea Nitrogen (BUN) - high	Bio: Calcium -low	Bio: Calcium - high	Bio: Chloride - low	Bio: Chloride - high	Bio: Creatinine - low	Bio: Creatinine - high	Bio: Gamma Glutamyltransferase - low	Bio: Gamma Glutamyltransferase - high	Bio: Glucose - low	Bio: Glucose - high	Bio: Phosphate (Inorganic Phosphorus) - low	Bio: Phosphate (Inorganic Phosphorus) - high	Bio: Potassium - low	Bio: Potassium - high	Bio: SGOT (AST) - low	Bio: SGOT (AST) - high	Bio: SGPT (ALT) - low	Bio: SGPT (ALT) - high	Bio: Serum bicarbonate - low	Bio: Serum bicarbonate - high	Bio: Sodium - low	Bio: Sodium - high	Bio: Total Protein (Serum) - low	Bio: Total Protein (Serum) - high	Bio: Uric Acid - low	Bio: Uric Acid - high
Tobramycin Inhalation Powder	0.0	16.0	0.0	33.3	10.6	32.4	0.0	20.9	28.3	35.7	0.0	70.4	0.0	37.8	0.0	29.5	5.8	6.0	12.8	39.5	14.9	42.5	37.8	10.4	2.0	24.0	0.0	27.8	20.5	31.7	0.0	32.4	0.0	22.0	0.0	11.8	0.0	7.4	16.7	10.9	12.7	11.1	9.1	1.8	36.4	1.9	1.9	10.4	24.0	15.1	1.8	47.1	3.8	7.4	3.7	30.4	0.0	39.0	45.9	0.0	10.9	5.5	1.8	27.9	1.8	16.0

Change in Cystic Fibrosis Questionnaire - Revised Respiratory Symptom Score (CFQ-R RSS)

Absolute change in the CFQ-R RSS from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. Age appropriate versions of Cystic Fibrosis Questionnaire - Revised ask a participant from 4 to 6 questions related to respiratory symptoms. The Respiratory Domain Scaled Score is calculated as follows: 100*[sum of {responses-1}] / [{number of responses}*3] only if [number of responses] ≥ [number of possible responses]/2; otherwise the score is set to missing. The scaled score ranges from 0 to 100 and higher scores indicate improvement of symptoms. (NCT02677701)
Timeframe: baseline (week 0) to week 6 (6 week period)

Intervention	score on a scale (Mean)
Azithromycin	1.0
Placebo	-0.5

Change in Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)

"Absolute change in CFRSD-CRISS from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. The Cystic Fibrosis Respiratory Symptoms Diary asks a participant to state the extent of 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest, and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present a great deal or extremely. A summed score (ranging from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where lower scores indicate improvement of symptoms." (NCT02677701)
Timeframe: baseline (week 0) to week 6 (6 week period)

Intervention	score on a scale (Mean)
Azithromycin	-2.3
Placebo	0.6

Change in Sputum Pseudomonas Aeruginosa Bacterial Density

Absolute change in log10 transformed quantitative Pseudomonas aeruginosa (Pa) bacterial density as measured by colony forming units (CFUs) per mL of sputum from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6. Culture results below the lower limit of detection of 1x10^2 were set to 1/2 of that LLD prior to log transformation. (NCT02677701)
Timeframe: baseline (week 0) to week 6 (6 week period)

Intervention	log10(CFUs/mL) (Mean)
Azithromycin	0.3
Placebo	-0.5

Relative Change in Lung Function

Relative change in FEV1 (L) from the beginning of the 4-week period with inhaled tobramycin at week 2 to the end of the 4-week period with inhaled tobramycin at week 6 (NCT02677701)
Timeframe: week 2 to week 6 (4 week period)

Intervention	percent change (Mean)
Azithromycin	0.44
Placebo	-0.91

Relative Change in Lung Function

Relative change in FEV1 volume (L) from enrollment at week 0 to the end of the 4-week period with inhaled tobramycin at week 6 (NCT02677701)
Timeframe: baseline (week 0) to week 6 (6 week period)

Intervention	percent change (Mean)
Azithromycin	1.69
Placebo	-1.95

Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty

We wanted to measure the effect of elution level of vancomycin and tobramycin together (NCT03928522)
Timeframe: 24 hours

Intervention	mg/mL (Median)
Pre-mixed Tobramycin	23.9
Hand Mixed Tobramycin	30.6
Hand Mixed Vancomycin	12.6
Hand-mixed Vancomycin and Tobramycin	16.2
Intr-articular Vancomycin	1315

The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3

Clinical cure was defined as a score 0 for bulbar conjunctival injection (evaluated using a 4 point ordinal scale) and a score 0 for conjunctival purulent discharge (evaluated using a 4 point ordinal scale). (NCT01155999)
Timeframe: Day 3

Intervention	participants (Number)
T1225	48
Tobramycin	29

Presence of Wound Infection

Infection will be defined as major and minor, with major indicated by return to the operating room for irrigation and debridement. Minor infection is represented by documentation of cellulitis or superficial infection at surgical site and administration of oral antibiotics (NCT03705962)
Timeframe: 6 weeks post op

Intervention	Participants (Count of Participants)
Antibiotic	0
Normal Saline	0

Time to a Protocol-defined Pulmonary Exacerbation

Time to a protocol-defined pulmonary exacerbation requiring oral, inhaled, or intravenous antibiotics, using a prespecified definition available in the study protocol. (NCT02054156)
Timeframe: Over the 18-month study period

Intervention	years (Median)
Azithromycin	1.350
Placebo	0.758

Time to Pseudomonas Aeruginosa (Pa) Recurrence

Time to Pseudomonas aeruginosa (Pa) recurrence after the first quarter of treatment (NCT02054156)
Timeframe: Over the 18-month study period

Intervention	years (Median)
Azithromycin	1.51
Placebo	1.46

Adverse Events (AEs) and Serious Adverse Events (SAEs)

The number and percentage of participants with at least one event over the 18-month study period. (NCT02054156)
Timeframe: Over the 18-month study period

Intervention	Participants (Count of Participants)
	Number of Participants with AE	Number of Participants with SAE
Azithromycin	102	25
Placebo	98	28

Rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Rate is defined as the number of events per participant follow-up month. (NCT02054156)
Timeframe: Over the 18-month study period

Intervention	events per participant-month (Number)
	Number of AEs per participant month	Number of SAEs per participant month
Azithromycin	0.92	0.06
Placebo	1.06	0.05

Average Actual Change From Baseline in FEV1 % Predicted Across All Courses of AZLI/Placebo Treatment (Weeks 4, 12 and 20)

FEV1 % predicted is defined as FEV1 of the patient divided by the average FEV1 in the population for any person of similar age, sex and body composition. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction. (NCT01641822)
Timeframe: Comparative Phase: Baseline and Weeks 4, 12 and 20

Intervention	percentage of FEV1 % predicted (Mean)
AZLI	1.37
Placebo	0.04

Average Change From Baseline in the CFQ-R Respiratory Symptom Scale (RSS) Score Across All Courses of AZLI/Placebo Treatment (Weeks 4, 12 and 20)

Respiratory symptoms (eg, coughing, congestion, wheezing) were assessed with the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS). The range of scores (units) was 0 to 100 with higher scores indicating fewer symptoms. The adjusted mean is from a mixed-effect model repeated measures (MMRM) analysis. The model includes terms for baseline value, previous exacerbations (1, 2, ≥ 3), treatment, visit (categorical), and treatment by visit interaction. (NCT01641822)
Timeframe: Comparative Phase: Baseline and Weeks 4, 12 and 20

Intervention	units on a scale (Mean)
AZLI	1.00
Placebo	-2.06

Percentage of Participants Who Used Non-study IV or Inhaled Antibiotics for PDEs

(NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)

Intervention	percentage of participants (Number)
AZLI	48.8
Placebo	55.3

Rate of Hospitalizations for a Respiratory Event

The rate of hospitalizations for a respiratory event per participant year was calculated using negative binomial regression analysis. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)

Intervention	hospitalizations per participant year (Number)
AZLI	1.043
Placebo	1.624

Rate of Protocol-defined Exacerbations (PDE) From Baseline Through Week 24

PDEs were characterized by a change or worsening from baseline of 1 or more documented signs or symptoms (decreased exercise tolerance, increased cough, increased sputum or chest congestion, decreased appetite, or other signs or symptoms) associated with the use of non-study IV or inhaled antibiotics and be verified by a blinded independent adjudication committee. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)

Intervention	PDEs per participant year (Number)
AZLI	1.309
Placebo	1.762

Time to First Protocol-defined Pulmonary Exacerbation

The time to first protocol-defined pulmonary exacerbation was calculated using the Kaplan-Meier method. (NCT01641822)
Timeframe: Baseline in the comparative phase to the end of study (average time on study during the Comparative Phase: 155.4 days)

Intervention	days (Median)
AZLI	175
Placebo	140.0

Change in P. Aeruginosa Sputum Density

Sputum samples were sent to a central laboratory at the start and end of 2 treatment periods. The absolute change in the number of colony forming units (CFU) of Pseudomonas aeruginosa in sputum = the value of end of on/off treatment period of the cycle minus the pre-dose value at the start of that cycle. A negative change from baseline indicates improvement. (NCT01844778)
Timeframe: days 1, 28 (cycle 1); 57, 84, 112 (cycle 2)

Intervention	log10 CFU/mL (Mean)
	Cycle 1, on-treatment change (n=11,22,9)	Cycle 1, off-treatment change (n=10,20,8)	Cycle 2, on-treatment (n=9,16,5)	Cycle 2, off-treatment (n=9,18,5)
COLI/TIP	-0.6	-0.6	-0.5	0.5
TIP/TIP	-1.7	-0.2	-1.6	0.0
TIS/TIP	-1.4	0.2	-0.9	0.0

Mean Total Administration Time

The mean total time for administration of TIP via T-326 inhaler versus the total time for administration of COLI or TIS was assessed from information entered by participants into an ediary during the last 7 days prior to the last dose of a cycle. The total time included the setup, preparation, administration and cleaning/disinfection time. (NCT01844778)
Timeframe: days 22 through 28 (cycle 1), days 78 through 84 (cycle 2)

Intervention	minutes (Mean)
	Cycle 1 (n=8,17,14)	Cycle 2 (n=10,16,11)
COLI/TIP	16.4	3.8
TIP/TIP	4.2	3.4
TIS/TIP	37.0	5.0

Minimum Inhibitory Concentration (MIC) - MIC50 and MIC90 Tobramycin Values

MIC50/90 is the lowest concentration required to inhibit 50%/90% of the isolates tested. The MIC50/90 of a range of antibiotics for P.aeruginosa was determined at the start and end of each treatment cycle, and at the end of the off-treatment period of the second cycle. (NCT01844778)
Timeframe: days 1, 28, 57, 84, 112

Intervention	ug/mL (Number)
	MIC50: Day 1, n=14,27,18; m=27,51,29	MIC50: Day 28, n=13,23,13; m=25,46,21	MIC50: Day 57, n=11,19,15; m=23,34,24	MIC50: Day 84, n=12,17,11; m=25,29,18	MIC50: Day 112, n=12,19,12; m=24,33,19	MIC90: Day 1, n=14,27,18; m=27,51,29	MIC90: Day 28, n=13,23,13; m=25,46,21	MIC90: Day 57, n=11,19,15; m=23,34,24	MIC90: Day 84, n=12,17,11; m=25,29,18	MIC90: Day 112, n=12,19,12; m=24,33,19
COLI/TIP	2	2	4	4	2	16	16	16	32	32
TIP/TIP	2	2	2	2	1	64	64	64	64	32
TIS/TIP	2	2	4	4	2	256	256	64	512	32

Number of Participants With Any Contaminated Delivery Device

Devices used to administer the drugs (the T-326 inhaler and nebulisers) were swabbed for contamination testing at the start and end of each treatment cycle (or discontinuation visit if the participant withdrew). No assessments were required from the T-326 inhaler when participants started the treatment period (days 1 and 57). Microbial contamination was measured according to device type and the frequency of organism growth (light/ moderate/ heavy). All nebulisers (neb) used by the participants were analyzed, including those for inhaling other medications, like mucolytics. (NCT01844778)
Timeframe: days (d) 1, 28, 57, 84

Intervention	Participants (Number)
	P. a biotype 2 - dry,d1,neb, moderate,(n=0,0,1)	A. baumannii,d1,neb,heavy,n=0,7,0	A. junii,d1,neb,moderate,n=0,7,0	A.lwoffi,d1,neb,light,n=0,7,0	H. parainfluenza,d1,neb,light,n=0,7,0	O. anthropic,d1,neb,heavy,n=0,7,0	P. fluorescens,d1,neb,light,n=0,7,0	P. putida,d1,neb,light,n=0,7,0	P. stutzeri,d1,neb,moderate,n=0,7,0	S.liquefaciens,d1,neb,light,n=0,7,0	S. multivorum,d1,neb,light,n=0,7,0	S. maltophilia,d1,neb,light,n=0,7,0	Acinetobacter species,d28,neb,light,n=0,6,0	C. indologenes,d28,neb,moderate,n=0,6,0	D. acidovorans,d 28,neb,light,n=0,6,0	P. fluorescens,d28,neb,light,n=0,6,0	S. paucimobilis,d28,neb,heavy,n=0,6,0	S. aureus,d28,neb,light,n=0,6,0	P. a biotype 2 - dry,d57,neb,light,n=1,0,0	S. aureus,d84,T-326,light,n=1,0,0
COLI/TIP	NA	1	1	2	1	1	1	1	1	1	1	1	1	1	1	2	1	1	NA	NA
TIP/TIP	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
TIS/TIP	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	1

Number of Participants With Post-inhalation Bronchospasm

Bronchospasm was defined as the relative decrease of 20% or more in forced expiratory volume in 1 second (FEV1) percent predicted from pre-dose to 15 to 45 minutes post-dose. (NCT01844778)
Timeframe: days 1, 28, 57, 84

Intervention	Participants (Number)
	Day 1, n=8,17,14	Day 28, n=6,19,14	Day 57, n=10,22,13	Day 84, n=8,14,10
COLI/TIP	1	1	0	0
TIP/TIP	0	0	1	0
TIS/TIP	0	0	0	0

Chalazion Size Difference Post-Treatment

Change of size of eyelid chalazion in millimeters from baseline to 4-6 weeks post-treatment (NCT01230593)
Timeframe: baseline and 4-6 weeks

Intervention	millimeters (Mean)
Hot Compress	1.20
Hot Compress + Tobramycin Drops and Ointment	1.69
Hot Compress + Tobramycin/Dexamethasone Drops and Ointment	1.54

Number of Participants With Complete Resolution

Defined as number of patients with chalazion size regression of 100% (NCT01230593)
Timeframe: 4-6 weeks

Intervention	participants (Number)
Hot Compress	13
Hot Compress + Tobramycin Drops and Ointment	12
Hot Compress + Tobramycin/Dexamethasone Drops and Ointment	11

Corneal Fluorescein Staining Score

Corneal Fluorescein Staining is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of corneal epitheliopathy. (NCT01456780)
Timeframe: Week 4 Time Point

Intervention	units on a scale (Mean)
Zylet	6.3
Lotemax	5.0
Bausch & Lomb Lubricant Drops	4.8

Ocular Surface Disease Index

OSDI is a 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms. (NCT01456780)
Timeframe: Week 4 Time Point

Intervention	units on a scale (Mean)
Zylet	56.6
Lotemax	46.4
Bausch & Lomb Lubricant Drops	48.4

Symptom Assessment iN Dry Eye (SANDE) Frequency Score

Questionnaire given to patients to assess the frequency of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the frequency of the patient's dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of frequency of dry eye symptoms and 100 being the maximum level of frequency of dry eye symptoms. (NCT01456780)
Timeframe: Week 4 Time Point

Intervention	units on a scale (Mean)
Zylet	65.9
Lotemax	51.7
Bausch & Lomb Lubricant Drops	50.5

Symptom Assessment iN Dry Eye (SANDE) Severity Score

Questionnaire given to patients to assess the severity of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the severity of the patient's dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE severity scale is 0-100, with minimum level of severity of dry eye symptoms and 100 being the maximum level of severity of dry eye symptoms. (NCT01456780)
Timeframe: Week 4 Time Point

Intervention	units on a scale (Mean)
Zylet	64.5
Lotemax	54.4
Bausch & Lomb Lubricant Drops	51.2

Clinical Response in Subjects Who Received Prior Antibiotics

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	1
ME Group - Meropenem Only	2
m-MITT Group - Meropenem Plus Aminoglycoside	1
m-MITT Group - Meropenem Only	2

Clinical Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	2
MEGroup - Meropenem Only	8
m-MITT Group - Meropenem Plus Aminoglycoside	2
m-MITT Group - Meropenem Only	8

Mortality

Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	1
ME Group - Meropenem Only	0
m-MITT Group - Meropenem Plus Aminoglycoside	2
m-MITT Group - Meropenem Only	2

Mortality

Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	2
ME Group - Meropenem Only	1
m-MITT Group - Meropenem Plus Aminoglycoside	3
m-MITT Group - Meropenem Only	3

Occurrence of Repeat Negative Cultures

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	3
ME Group - Meropenem Only	6
m-MITT Group - Meropenem Plus Aminoglycoside	3
m-MITT Group - Meropenem Only	7

Overall Microbiologic Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	2
ME Group - Meropenem Only	6
m-MITT Group - Meropenem Plus Aminoglycoside	2
m-MITT Group - Meropenem Only	7

Pretreatment Pathogen Response

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	3
ME Group - Meropenem Only	9
m-MITT Group - Meropenem Plus Aminoglycoside	3
m-MITT Group - Meropenem Only	11

Suppression of the Emergence of Resistance in Other Gram-negative Pathogens

Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation

Intervention	Participants (Count of Participants)
ME Group - Meropenem Plus Aminoglycoside	1
ME Group - Meropenem Only	1
m-MITT Group - Meropenem Plus Aminoglycoside	1
m-MITT Group - Meropenem Only	2

Number of Participants With Suppression and Emergence of Resistance

The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment

Intervention	participants (Number)
	suppression of emergence of resistance	emergence of resistance
I.V. Meropenem	5	1

Article	Year
Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial. The clinical respiratory journal, Volume: 17, Issue: 8	2023
Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 22, Issue: 5	2023
Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin Current drug safety, Volume: 19, Issue: 1	2024
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity. The Biochemical journal, 12-22, Volume: 479, Issue: 24	2022
Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. The Journal of antimicrobial chemotherapy, 10-11, Volume: 76, Issue: 11	2021
Tobramycin and vestibulotoxicity: retrospective analysis of four cases. European journal of hospital pharmacy : science and practice, Volume: 29, Issue: e1	2022
Rates of adverse and serious adverse events in children with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 6	2021
Binary Medical Nanofluids by Combination of Polymeric Eudragit Nanoparticles for Vehiculization of Tobramycin and Resveratrol: Antimicrobial, Hemotoxicity and Protein Corona Studies. Journal of pharmaceutical sciences, Volume: 110, Issue: 4	2021
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 2	2021
Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis. Pediatric pulmonology, Volume: 55, Issue: 12	2020
Efficacy and safety of TOBI Podhaler in The European respiratory journal, Volume: 57, Issue: 1	2021
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 2	2021
Ebselen attenuates tobramycin-induced ototoxicity in mice. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 2	2021
A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific reports, 02-04, Volume: 10, Issue: 1	2020
Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary pharmacology & therapeutics, Volume: 58	2019
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study. British journal of clinical pharmacology, Volume: 85, Issue: 9	2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial agents and chemotherapy, Volume: 63, Issue: 7	2019
Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use. Scientific reports, 02-20, Volume: 9, Issue: 1	2019
Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. Scientific reports, 03-23, Volume: 8, Issue: 1	2018
Antibacterial activity and safety of commercial veterinary cationic steroid antibiotics and neutral superoxidized water. PloS one, Volume: 13, Issue: 3	2018
Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Current medical research and opinion, Volume: 32, Issue: 11	2016
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 15, Issue: 5	2016
HEI-OC1 cells as a model for investigating drug cytotoxicity. Hearing research, Volume: 335	2016
A case of aminoglycosides induced retinal toxicity treated with megadoses of steroids and an intravitreal dexamethasone implant (Ozurdex(®)). Archivos de la Sociedad Espanola de Oftalmologia, Volume: 91, Issue: 6	2016
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatric pulmonology, Volume: 51, Issue: 4	2016
Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 3	2016
The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 15, Issue: 4	2016
d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 15, Issue: 4	2016
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 14, Issue: 4	2015
Predicting the long-term toxicity of five-antibiotic mixtures to Vibrio qinghaiensis sp. Q67. Pakistan journal of pharmaceutical sciences, Volume: 27, Issue: 5 Suppl	2014
Aminoglycoside-induced nephrotoxicity. Journal of pharmacy practice, Volume: 27, Issue: 6	2014
Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 13, Issue: 6	2014
Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 13, Issue: 4	2014
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. The British journal of ophthalmology, Volume: 98, Issue: 6	2014
Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatric pulmonology, Volume: 49, Issue: 11	2014
A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. Journal of aerosol medicine and pulmonary drug delivery, Volume: 27, Issue: 3	2014
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax, Volume: 68, Issue: 4	2013
Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proceedings of the National Academy of Sciences of the United States of America, Jul-03, Volume: 109, Issue: 27	2012
Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Paediatric drugs, Apr-01, Volume: 14, Issue: 2	2012
A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current medical research and opinion, Volume: 28, Issue: 3	2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, Volume: 7, Issue: 12	2011
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of pediatrics & adolescent medicine, Volume: 165, Issue: 9	2011
Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits. International journal of pediatric otorhinolaryngology, Volume: 75, Issue: 7	2011
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Current medical research and opinion, Volume: 27, Issue: 1	2011
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 10, Issue: 1	2011
Efficacy and safety of netilmycin/dexamethasone preservative-free and tobramycin/dexamethasone-preserved fixed combination in patients after cataract surgery. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, Volume: 26, Issue: 6	2010
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Current opinion in pulmonary medicine, Volume: 16, Issue: 6	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, Jul-19, Volume: 23, Issue: 7	2010
Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. The Pediatric infectious disease journal, Volume: 29, Issue: 3	2010
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 8, Issue: 5	2009
Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicologic pathology, Volume: 37, Issue: 3	2009
Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC infectious diseases, Mar-09, Volume: 9	2009
Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections. Current clinical pharmacology, Volume: 4, Issue: 1	2009
Protective effect of edaravone against tobramycin-induced ototoxicity. Acta oto-laryngologica, Volume: 129, Issue: 1	2009
Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients. Acta oto-laryngologica, Volume: 129, Issue: 1	2009
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Current medical research and opinion, Volume: 24, Issue: 1	2008
Tobramycin-induced hepatotoxicity. The Annals of pharmacotherapy, Volume: 41, Issue: 12	2007
Experimental study of a new vascular graft prebonded with antibiotic: healing, toxicity, and antibiotic retention. Annals of vascular surgery, Volume: 21, Issue: 5	2007
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 7, Issue: 2	2008
Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Investigative ophthalmology & visual science, Volume: 48, Issue: 8	2007
Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Clinical orthopaedics and related research, Volume: 462	2007
Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatric drugs, Volume: 9 Suppl 1	2007
Interaction of neomycin, tobramycin and amikacin with melanin in vitro in relation to aminoglycosides-induced ototoxicity. Die Pharmazie, Volume: 62, Issue: 3	2007
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatric pulmonology, Volume: 42, Issue: 4	2007
Efficacy and safety of meropenem plus tobramycin followed by meropenem plus vancomycin for treating peritonitis in patients on continuous ambulatory peritoneal dialysis. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, Volume: 22	2006
Safeness of Simplex-tobramycin bone cement in patients with renal dysfunction undergoing total hip replacement. Journal of orthopaedic surgery (Hong Kong), Volume: 14, Issue: 1	2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, Volume: 1, Issue: 4	2004
Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. Eye (London, England), Volume: 21, Issue: 1	2007
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, Volume: 24, Issue: 7	2005
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest, Volume: 127, Issue: 4	2005
Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clinic proceedings, Volume: 79, Issue: 9	2004
Effect of dietary n-3 and n-6 fatty acids on tobramycin induced nephrotoxicity. Indian journal of experimental biology, Volume: 42, Issue: 7	2004
Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Critical care medicine, Volume: 32, Issue: 8	2004
Protective effect of corticosteroid against the cytotoxicity of aminoglycoside otic drops on isolated cochlear outer hair cells. The Laryngoscope, Volume: 114, Issue: 4	2004
Novispirin G10-induced lung toxicity in a Klebsiella pneumoniae infection model. Antimicrobial agents and chemotherapy, Volume: 47, Issue: 12	2003
Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function. Pediatric pharmacology (New York, N.Y.), Volume: 2, Issue: 2	1982
Determination of ototoxicity of common otic drops using isolated cochlear outer hair cells. The Laryngoscope, Volume: 111, Issue: 12	2001
Aminoglycoside ototoxicity: a human temporal bone study. The Laryngoscope, Volume: 111, Issue: 10	2001
Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatric pulmonology, Volume: 32, Issue: 4	2001
Recovery from vestibular ototoxicity. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, Volume: 22, Issue: 5	2001
Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrobial agents and chemotherapy, Volume: 45, Issue: 9	2001
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy, Volume: 21, Issue: 4	2001
Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs. Journal of pineal research, Volume: 28, Issue: 1	2000
Tolerability and safety of 0.1% diclofenac plus 0.3% tobramycin fixed-dose ophthalmic solution: a randomized, comparative, controlled study in healthy volunteers. Methods and findings in experimental and clinical pharmacology, Volume: 21, Issue: 3	1999
Comparison of tobramycin nephrotoxicity in young adult and aged female rats. Pharmacology & toxicology, Volume: 84, Issue: 4	1999
Risk factors for toxicity in elderly patients given aminoglycosides once daily. Journal of general internal medicine, Volume: 13, Issue: 11	1998
The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. The Journal of antimicrobial chemotherapy, Volume: 42, Issue: 1	1998
Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Hearing research, Volume: 115, Issue: 1-2	1998
Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest, Nov-05, Volume: 112, Issue: 5	1997
Calcium hydroxide ameliorates tobramycin toxicity in cultured chick tibiae. Bone, Volume: 21, Issue: 5	1997
Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clinical pharmacology and therapeutics, Volume: 62, Issue: 1	1997
Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. The Pediatric infectious disease journal, Volume: 16, Issue: 6	1997
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrobial agents and chemotherapy, Volume: 40, Issue: 11	1996
Day-night treatment difference of tobramycin serum and intrarenal drug distribution and nephrotoxicity in rats: effects of fasting. Chronobiology international, Volume: 13, Issue: 2	1996
Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax, Volume: 51, Issue: 4	1996
Ototoxicity of tobramycin in young adult and old rats. Toxicology and applied pharmacology, Volume: 136, Issue: 1	1996
Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure--toxicity relationships). Carbohydrate research, Oct-16, Volume: 276, Issue: 1	1995
Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. The Journal of clinical investigation, Volume: 91, Issue: 1	1993
Temporal changes of pharmacokinetics, nephrotoxicity, and subcellular distribution of tobramycin in rats. Antimicrobial agents and chemotherapy, Volume: 38, Issue: 1	1994
Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrobial agents and chemotherapy, Volume: 38, Issue: 4	1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Topical corticosteroids for dry eye. The Cochrane database of systematic reviews, 10-21, Volume: 10	2022
Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance. Critical care (London, England), 05-30, Volume: 22, Issue: 1	2018
Colistin and tobramycin resistance during long- term use of selective decontamination strategies in the intensive care unit: a post hoc analysis. Critical care (London, England), Mar-25, Volume: 19	2015
Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatric pulmonology, Volume: 49, Issue: 11	2014
Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. Journal of medical economics, Volume: 14, Issue: 6	2011
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric pulmonology, Volume: 43, Issue: 9	2008
Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert opinion on pharmacotherapy, Volume: 8, Issue: 4	2007
Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance. Intensive care medicine, Volume: 32, Issue: 10	2006
The long-term use of inhaled tobramycin in patients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 1, Issue: Suppl 2	2002
Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. The Journal of antimicrobial chemotherapy, Volume: 28, Issue: 4	1991
[Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)]. La Nouvelle presse medicale, Nov-29, Volume: 7, Issue: 42	1978
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. The Journal of antimicrobial chemotherapy, 09-05, Volume: 78, Issue: 9	2023
Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. Clinical therapeutics, Volume: 45, Issue: 5	2023
New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Therapeutic drug monitoring, 04-01, Volume: 45, Issue: 2	2023
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. The Journal of antimicrobial chemotherapy, 09-30, Volume: 77, Issue: 10	2022
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. Antimicrobial agents and chemotherapy, 04-19, Volume: 66, Issue: 4	2022
Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. The Journal of antimicrobial chemotherapy, 10-11, Volume: 76, Issue: 11	2021
Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. The Journal of antimicrobial chemotherapy, 08-12, Volume: 76, Issue: 9	2021
Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population. Pediatric pulmonology, Volume: 55, Issue: 10	2020
An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa. BMC pulmonary medicine, Jun-12, Volume: 20, Issue: 1	2020
Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis? Therapeutic drug monitoring, Volume: 42, Issue: 4	2020
Extrapolation of Drug Clearance in Children ≤ 2 Years of Age from Empirical Models Using Data from Children (> 2 Years) and Adults. Drugs in R&D, Volume: 20, Issue: 1	2020
Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. Clinical chemistry and laboratory medicine, 01-28, Volume: 58, Issue: 2	2020
Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. British journal of clinical pharmacology, Volume: 86, Issue: 1	2020
Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. The Journal of antimicrobial chemotherapy, 01-01, Volume: 75, Issue: 1	2020
Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. The Journal of antimicrobial chemotherapy, 08-01, Volume: 74, Issue: 8	2019
Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharmaceutical research, May-30, Volume: 36, Issue: 8	2019
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study. British journal of clinical pharmacology, Volume: 85, Issue: 9	2019
Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. Anesthesiology, Volume: 131, Issue: 2	2019
Optimizing Estimated Glomerular Filtration Rate to Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients with Cystic Fibrosis. Clinical pharmacokinetics, Volume: 58, Issue: 10	2019
Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. International journal of pharmaceutics, Oct-05, Volume: 549, Issue: 1-2	2018
Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Chest, Volume: 154, Issue: 5	2018
Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Antimicrobial agents and chemotherapy, Volume: 62, Issue: 6	2018
Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. The Journal of antimicrobial chemotherapy, Dec-01, Volume: 72, Issue: 12	2017
A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Burns : journal of the International Society for Burn Injuries, Volume: 43, Issue: 8	2017
Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Journal of pharmaceutical sciences, Volume: 106, Issue: 11	2017
Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. PloS one, Volume: 12, Issue: 4	2017
Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 109	2016
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. The Journal of antimicrobial chemotherapy, Volume: 72, Issue: 1	2017
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrobial agents and chemotherapy, Volume: 60, Issue: 6	2016
Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PloS one, Volume: 11, Issue: 3	2016
Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. Journal of aerosol medicine and pulmonary drug delivery, Volume: 29, Issue: 3	2016
Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 3	2016
Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis. Journal of chemotherapy (Florence, Italy), Volume: 28, Issue: 4	2016
Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Clinical nephrology, Volume: 84, Issue: 4	2015
The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 15, Issue: 4	2016
Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Internal medicine journal, Volume: 45, Issue: 3	2015
Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 13, Issue: 6	2014
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharmaceutical research, Volume: 31, Issue: 10	2014
Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. Journal of pharmacokinetics and pharmacodynamics, Volume: 41, Issue: 1	2014
Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis. Journal of chemotherapy (Florence, Italy), Volume: 26, Issue: 2	2014
Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 10	2013
A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. Journal of aerosol medicine and pulmonary drug delivery, Volume: 27, Issue: 3	2014
Mechanical properties and elution characteristics of polymethylmethacrylate bone cement impregnated with antibiotics for various surface area and volume constructs. The Iowa orthopaedic journal, Volume: 32	2012
Pharmacokinetics of tobramycin following intravenous, intramuscular, and intra-articular administration in healthy horses. Journal of veterinary pharmacology and therapeutics, Volume: 36, Issue: 6	2013
Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. The Journal of antimicrobial chemotherapy, Volume: 68, Issue: 6	2013
Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clinical pharmacokinetics, Volume: 52, Issue: 4	2013
Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 12, Issue: 4	2013
Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Pulmonary pharmacology & therapeutics, Volume: 26, Issue: 2	2013
Pharmacokinetic analysis of topical tobramycin in equine tears by automated immunoassay. BMC veterinary research, Aug-21, Volume: 8	2012
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transplant infectious disease : an official journal of the Transplantation Society, Volume: 13, Issue: 6	2011
Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrobial agents and chemotherapy, Volume: 55, Issue: 9	2011
Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Pharmacotherapy, Volume: 30, Issue: 7	2010
Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients. Anaesthesia and intensive care, Volume: 37, Issue: 6	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, Aug-13, Volume: 52, Issue: 15	2009
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Journal of critical care, Volume: 25, Issue: 1	2010
Clinical pharmacokinetics of aminoglycosides in the neonate: a review. European journal of clinical pharmacology, Volume: 65, Issue: 4	2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, Volume: 36, Issue: 7	2008
Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns : journal of the International Society for Burn Injuries, Volume: 34, Issue: 6	2008
Pharmacokinetics of tobramycin in ducks and sex-related differences. Veterinary journal (London, England : 1997), Volume: 179, Issue: 3	2009
Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. Acta anaesthesiologica Scandinavica, Volume: 52, Issue: 2	2008
Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. British journal of clinical pharmacology, Volume: 65, Issue: 4	2008
Pharmacokinetic studies on tobramycin in horses. Journal of veterinary pharmacology and therapeutics, Volume: 30, Issue: 4	2007
Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 68, Issue: 2	2008
Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatric drugs, Volume: 9 Suppl 1	2007
Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. The Journal of antimicrobial chemotherapy, Volume: 59, Issue: 6	2007
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatric pulmonology, Volume: 42, Issue: 4	2007
Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 6, Issue: 5	2007
Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. Journal of paediatrics and child health, Volume: 42, Issue: 10	2006
Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. The Annals of pharmacotherapy, Volume: 40, Issue: 1	2006
Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagnostic microbiology and infectious disease, Volume: 52, Issue: 2	2005
Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis. Antimicrobial agents and chemotherapy, Volume: 5, Issue: 6	1974
Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial agents and chemotherapy, Volume: 49, Issue: 1	2005
Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrobial agents and chemotherapy, Volume: 48, Issue: 11	2004
A Bayesian approach to tracking patients having changing pharmacokinetic parameters. Journal of pharmacokinetics and pharmacodynamics, Volume: 31, Issue: 1	2004
Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. British journal of clinical pharmacology, Volume: 58, Issue: 1	2004
Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Pharmacotherapy, Volume: 24, Issue: 5	2004
Volume and surface area study of tobramycin-polymethylmethacrylate beads. Clinical orthopaedics and related research, Issue: 420	2004
The pharmacokinetics of Simplex-tobramycin bone cement. The Journal of bone and joint surgery. British volume, Volume: 85, Issue: 5	2003
Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, Volume: 54, Issue: 5-6	2003
Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. The Journal of antimicrobial chemotherapy, Volume: 52, Issue: 2	2003
The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics. Journal of chemotherapy (Florence, Italy), Volume: 14, Issue: 6	2002
Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase Pharmacokinetic Systems. Therapeutic drug monitoring, Volume: 24, Issue: 6	2002
Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrobial agents and chemotherapy, Volume: 46, Issue: 12	2002
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest, Volume: 122, Issue: 1	2002
Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 - 1G --> A). Pediatric pulmonology, Volume: 33, Issue: 4	2002
Pharmacokinetic model for tobramycin in acinetobacter meningitis. The Annals of pharmacotherapy, Volume: 36, Issue: 1	2002
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clinical therapeutics, Volume: 23, Issue: 8	2001
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment. Journal of clinical pharmacology, Volume: 41, Issue: 9	2001
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy, Volume: 21, Issue: 4	2001
Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. The Journal of trauma, Volume: 49, Issue: 5	2000
Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. International journal of antimicrobial agents, Volume: 15, Issue: 3	2000
Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. Journal of the American Society of Nephrology : JASN, Volume: 11, Issue: 7	2000
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrobial agents and chemotherapy, Volume: 44, Issue: 4	2000
Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. Therapeutic drug monitoring, Volume: 21, Issue: 2	1999
Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. British journal of pharmacology, Volume: 126, Issue: 5	1999
[Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis]. Pathologie-biologie, Volume: 46, Issue: 6	1998
Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Archives of disease in childhood, Volume: 78, Issue: 6	1998
The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. The Journal of antimicrobial chemotherapy, Volume: 42, Issue: 1	1998
Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model. The Journal of antimicrobial chemotherapy, Volume: 42, Issue: 1	1998
Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery, Volume: 124, Issue: 1	1998
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
PVA/anionic collagen membranes as drug carriers of ciprofloxacin hydrochloride with sustained antibacterial activity and potential use in the treatment of ulcerative keratitis. Journal of biomaterials applications, Volume: 35, Issue: 3	2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. The Journal of antimicrobial chemotherapy, 10-01, Volume: 73, Issue: 10	2018
Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, Volume: 34, Issue: 3	2018
Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Journal of pharmaceutical sciences, Volume: 106, Issue: 11	2017
Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. PloS one, Volume: 12, Issue: 4	2017
Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 109	2016
Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Drug development and industrial pharmacy, Volume: 42, Issue: 9	2016
The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 14, Issue: 6	2015
Tobramycin exposure from active calcium sulfate bone graft substitute. BMC pharmacology & toxicology, Mar-04, Volume: 15	2014
Mechanical properties and elution characteristics of polymethylmethacrylate bone cement impregnated with antibiotics for various surface area and volume constructs. The Iowa orthopaedic journal, Volume: 32	2012
Pharmacokinetics of tobramycin following intravenous, intramuscular, and intra-articular administration in healthy horses. Journal of veterinary pharmacology and therapeutics, Volume: 36, Issue: 6	2013
Development and characterization of anionic liposaccharides for enhanced oral drug delivery. International journal of pharmaceutics, Jul-01, Volume: 430, Issue: 1-2	2012
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, Volume: 46, Issue: 1	2011
Fasting increases tobramycin oral absorption in mice. Antimicrobial agents and chemotherapy, Volume: 54, Issue: 4	2010
Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. Acta anaesthesiologica Scandinavica, Volume: 52, Issue: 2	2008
Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Volume: 33, Issue: 1	2008
Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 68, Issue: 2	2008
Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatric drugs, Volume: 9 Suppl 1	2007
PTC124 targets genetic disorders caused by nonsense mutations. Nature, May-03, Volume: 447, Issue: 7140	2007
[Aqueous humor penetration of topically applied ofloxacin, ciprofloxacin and tobramycin]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology, Volume: 39, Issue: 12	2003
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest, Volume: 122, Issue: 1	2002
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. International journal of pharmaceutics, May-15, Volume: 238, Issue: 1-2	2002
Comparative review of topical ophthalmic antibacterial preparations. Drugs, Volume: 61, Issue: 2	2001
Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life sciences, Sep-08, Volume: 67, Issue: 16	2000
Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrobial agents and chemotherapy, Volume: 41, Issue: 9	1997
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. The Pediatric infectious disease journal, Volume: 16, Issue: 1	1997
Serum and milk concentrations of apramycin in lactating cows, ewes and goats. Journal of veterinary pharmacology and therapeutics, Volume: 18, Issue: 5	1995
Enhancement of the ocular bioavailability of topical tobramycin with use of a collagen shield. Journal of cataract and refractive surgery, Volume: 19, Issue: 2	1993
Ocular pharmacokinetics of tobramycin. A comparative radioimmunoassay and microbiological assay. International ophthalmology, Volume: 17, Issue: 4	1993
Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. Journal of clinical pharmacology, Volume: 34, Issue: 3	1994
Antimicrobial therapy and the neonate. Obstetrics and gynecology, Volume: 58, Issue: 5 Suppl	1981
Studies on systemic absorption of tobramycin in polyethylene glycol ointment applied to wounds of burn patients. Burns, including thermal injury, Volume: 12, Issue: 3	1986
Comparative bioavailability and efficacy of fortified topical tobramycin. Investigative ophthalmology & visual science, Volume: 28, Issue: 5	1987
Pharmacokinetics of tobramycin in cats. American journal of veterinary research, Volume: 49, Issue: 5	1988
The solubility of antibiotic and corticosteroid combinations. American journal of ophthalmology, Aug-15, Volume: 114, Issue: 2	1992
Distribution and elimination kinetics of intravenously and intramusculary administered tobramycin in man. International journal of clinical pharmacology and biopharmacy, Volume: 14, Issue: 4	1976
Bacteriological, clinical, and pharmacological investigations with tobramycin in patients with serious urinary tract infection. The Journal of infectious diseases, Volume: 134 Suppl	1976
Pharmacokinetics of tobramycin in the newborn. Infection, Volume: 7, Issue: 4	1979
Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. Mayo Clinic proceedings, Volume: 52, Issue: 11	1977
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Nebuliser systems for drug delivery in cystic fibrosis. The Cochrane database of systematic reviews, 11-09, Volume: 11	2023
Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria. Clinical therapeutics, Volume: 45, Issue: 5	2023
Liquid crystalline lipid nanoparticles improve the antibacterial activity of tobramycin and vancomycin against intracellular Pseudomonas aeruginosa and Staphylococcus aureus. International journal of pharmaceutics, May-25, Volume: 639	2023
Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable? Therapeutic drug monitoring, 10-01, Volume: 45, Issue: 5	2023
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. Contact lens & anterior eye : the journal of the British Contact Lens Association, Volume: 46, Issue: 3	2023
Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations. Therapeutic drug monitoring, 04-01, Volume: 45, Issue: 2	2023
Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles. Pharmacotherapy, Volume: 43, Issue: 1	2023
Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods. The Journal of antimicrobial chemotherapy, 11-28, Volume: 77, Issue: 12	2022
New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Therapeutic drug monitoring, 04-01, Volume: 45, Issue: 2	2023
Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals. Journal of chemotherapy (Florence, Italy), Volume: 34, Issue: 5	2022
Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations. British journal of clinical pharmacology, Volume: 88, Issue: 5	2022
Combined Treatment of 6-Gingerol Analog and Tobramycin for Inhibiting Pseudomonas aeruginosa Infections. Microbiology spectrum, 10-31, Volume: 9, Issue: 2	2021
Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. The Journal of antimicrobial chemotherapy, 08-12, Volume: 76, Issue: 9	2021
Evaluating the Impact of Education on Pharmacist Tobramycin Dose Recommendations for Cystic Fibrosis and a Review of Perceptions on Pharmacist-Led Charting. Journal of pharmacy practice, Volume: 35, Issue: 6	2022
Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis. Pediatric pulmonology, Volume: 56, Issue: 12	2021
Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval. Therapeutic drug monitoring, 08-01, Volume: 43, Issue: 4	2021
Pivotal Role of Translation in Anti-Infective Development. Clinical pharmacology and therapeutics, Volume: 109, Issue: 4	2021
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 2	2021
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 20, Issue: 2	2021
Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population. Pediatric pulmonology, Volume: 55, Issue: 10	2020
External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. Paediatric drugs, Volume: 22, Issue: 4	2020
Nanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing. The Analyst, Jun-07, Volume: 145, Issue: 11	2020
Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis? Therapeutic drug monitoring, Volume: 42, Issue: 4	2020
Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. The Journal of antimicrobial chemotherapy, 01-01, Volume: 75, Issue: 1	2020
Effects of Intraoperative Intrawound Antibiotic Administration on Spinal Fusion: A Comparison of Vancomycin and Tobramycin in a Rat Model. The Journal of bone and joint surgery. American volume, Oct-02, Volume: 101, Issue: 19	2019
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 19, Issue: 2	2020
Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. The Journal of antimicrobial chemotherapy, 08-01, Volume: 74, Issue: 8	2019
Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharmaceutical research, May-30, Volume: 36, Issue: 8	2019
Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. Anesthesiology, Volume: 131, Issue: 2	2019
Adsorptive removal of apramycin antibiotic from aqueous solutions using Tween 80-and Triton X-100 modified clinoptilolite: experimental and fixed-bed modeling investigations. International journal of environmental health research, Volume: 30, Issue: 5	2020
Temperature-responsive PNDJ hydrogels provide high and sustained antimicrobial concentrations in surgical sites. Drug delivery and translational research, Volume: 9, Issue: 4	2019
PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. Anaesthesia, critical care & pain medicine, Volume: 38, Issue: 5	2019
Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? The Journal of antimicrobial chemotherapy, 01-01, Volume: 74, Issue: 1	2019
Altering polymerization temperature of antibiotic-laden cement can increase porosity and subsequent antibiotic elution. International orthopaedics, Volume: 42, Issue: 11	2018
Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice? Clinical pharmacokinetics, Volume: 58, Issue: 3	2019
Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Chest, Volume: 154, Issue: 5	2018
Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Antimicrobial agents and chemotherapy, Volume: 62, Issue: 6	2018
Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption. International journal of antimicrobial agents, Volume: 51, Issue: 3	2018
Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis. Clinical pharmacokinetics, Volume: 57, Issue: 8	2018
Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? The Journal of antimicrobial chemotherapy, Dec-01, Volume: 72, Issue: 12	2017
A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Burns : journal of the International Society for Burn Injuries, Volume: 43, Issue: 8	2017
Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Journal of pharmaceutical sciences, Volume: 106, Issue: 11	2017
Acute Kidney Injury After First-Stage Joint Revision for Infection: Risk Factors and the Impact of Antibiotic Dosing. The Journal of arthroplasty, Volume: 32, Issue: 10	2017
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane database of systematic reviews, 03-27, Volume: 3	2017
The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 16, Issue: 3	2017
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. The Journal of antimicrobial chemotherapy, Volume: 72, Issue: 1	2017
High throughput LSPR and SERS analysis of aminoglycoside antibiotics. The Analyst, Aug-15, Volume: 141, Issue: 17	2016
Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis. Pharmacotherapy, Volume: 36, Issue: 6	2016
A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. PloS one, Volume: 11, Issue: 4	2016
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrobial agents and chemotherapy, Volume: 60, Issue: 6	2016
Surgical Site Infections following Spine Surgery for Non-idiopathic Scoliosis. Journal of pediatric orthopedics, Volume: 37, Issue: 8	2017
Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Drug development and industrial pharmacy, Volume: 42, Issue: 9	2016
Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis. Journal of chemotherapy (Florence, Italy), Volume: 28, Issue: 4	2016
Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study. Nephron, Volume: 131, Issue: 3	2015
Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. Clinical nephrology, Volume: 84, Issue: 4	2015
The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 15, Issue: 4	2016
Dynamic Proteome Response of Pseudomonas aeruginosa to Tobramycin Antibiotic Treatment. Molecular & cellular proteomics : MCP, Volume: 14, Issue: 8	2015
Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance. Analytical chemistry, May-19, Volume: 87, Issue: 10	2015
Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. The Journal of antimicrobial chemotherapy, Volume: 70, Issue: 7	2015
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrobial agents and chemotherapy, Volume: 59, Issue: 4	2015
Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Internal medicine journal, Volume: 45, Issue: 3	2015
Development of spectrofluorimetric method for determination of certain aminoglycoside drugs in dosage forms and human plasma through condensation with ninhydrin and phenyl acetaldehyde. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, Feb-05, Volume: 136 Pt C	2015
Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clinical pharmacokinetics, Volume: 54, Issue: 4	2015
Validated spectrofluorimetric method for determination of selected aminoglycosides. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, Jan-25, Volume: 135	2015
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharmaceutical research, Volume: 31, Issue: 10	2014
A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respiratory care, Volume: 59, Issue: 9	2014
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. The British journal of ophthalmology, Volume: 98, Issue: 6	2014
Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. Journal of pharmacokinetics and pharmacodynamics, Volume: 41, Issue: 1	2014
Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis. Journal of chemotherapy (Florence, Italy), Volume: 26, Issue: 2	2014
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric pulmonology, Volume: 48, Issue: 11	2013
Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 10	2013
Nebuliser systems for drug delivery in cystic fibrosis. The Cochrane database of systematic reviews, Apr-30, Issue: 4	2013
Spectrofluorimetric determination of tobramycin in human serum and pharmaceutical preparations by derivatization with fluorescamine. Luminescence : the journal of biological and chemical luminescence, Volume: 29, Issue: 1	2014
Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clinical pharmacokinetics, Volume: 52, Issue: 4	2013
Articulating spacers for the treatment of infected total knee arthroplasty: effect of antibiotic combinations and concentrations. Orthopedics, Volume: 36, Issue: 1	2013
Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 12, Issue: 4	2013
Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. Journal of aerosol medicine and pulmonary drug delivery, Volume: 26, Issue: 2	2013
The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Volume: 31, Issue: 10	2012
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane database of systematic reviews, Feb-15, Issue: 2	2012
[Outpatient use of topical antimicrobials in Spain associated with other drugs (2005-2007)]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Volume: 24, Issue: 4	2011
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transplant infectious disease : an official journal of the Transplantation Society, Volume: 13, Issue: 6	2011
[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. Zhonghua yi xue za zhi, May-31, Volume: 91, Issue: 20	2011
Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrobial agents and chemotherapy, Volume: 55, Issue: 9	2011
Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, Apr-01, Volume: 68, Issue: 7	2011
Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. British journal of clinical pharmacology, Volume: 71, Issue: 1	2011
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis. Current medical research and opinion, Volume: 27, Issue: 1	2011
Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS immunology and medical microbiology, Volume: 61, Issue: 2	2011
Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Archives of orthopaedic and trauma surgery, Volume: 131, Issue: 5	2011
Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume: 10, Issue: 1	2011
Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Pharmacotherapy, Volume: 30, Issue: 7	2010
[Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]. Journal francais d'ophtalmologie, Volume: 33, Issue: 4	2010
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane database of systematic reviews, Jan-20, Issue: 1	2010
Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy, Volume: 30, Issue: 1	2010
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection, Volume: 37, Issue: 5	2009
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, Volume: 53, Issue: 9	2009
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. Journal of critical care, Volume: 25, Issue: 1	2010
Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicologic pathology, Volume: 37, Issue: 3	2009
A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatric pulmonology, Volume: 44, Issue: 4	2009
Clinical pharmacokinetics of aminoglycosides in the neonate: a review. European journal of clinical pharmacology, Volume: 65, Issue: 4	2009
Suboptimal aminoglycoside dosing in critically ill patients. Therapeutic drug monitoring, Volume: 30, Issue: 6	2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. The Journal of antimicrobial chemotherapy, 09-05, Volume: 78, Issue: 9	2023
Analyzing the Activity of Micafungin Combined with Tobramycin Against Pseudomonas Aeruginosa Biofilm. Clinical laboratory, Jun-01, Volume: 69, Issue: 6	2023
Effect of sodium hyaluronate eye drops combined with tobramycin, dexamethasone and pranoprofen eye drops in the treatment of dry eye after phacoemulsification. Indian journal of ophthalmology, Volume: 70, Issue: 12	2022
Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Journal of chemotherapy (Florence, Italy), Volume: 32, Issue: 4	2020
Effects of low-intensity and low-frequency ultrasound combined with tobramycin on biofilms of extended-spectrum beta-lactamases (ESBLs) Escherichia coli. FEMS microbiology letters, 02-01, Volume: 366, Issue: 3	2019
Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatric pulmonology, Volume: 52, Issue: 8	2017
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. The Journal of antimicrobial chemotherapy, Volume: 71, Issue: 8	2016
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. BioMed research international, Volume: 2014	2014
Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses, Oct-03, Volume: 6, Issue: 10	2014
Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 6	2013
In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy, Volume: 57, Issue: 6	2011
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. International journal of antimicrobial agents, Volume: 35, Issue: 6	2010
Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa. Chemotherapy, Volume: 55, Issue: 6	2009
In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses. American journal of veterinary research, Volume: 69, Issue: 1	2008
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. The Journal of antimicrobial chemotherapy, Volume: 59, Issue: 4	2007
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, Volume: 50, Issue: 6	2006
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respiratory medicine, Volume: 100, Issue: 9	2006
Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrobial agents and chemotherapy, Volume: 49, Issue: 1	2005
[In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa]. The Japanese journal of antibiotics, Volume: 53, Issue: 4	2000
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrobial agents and chemotherapy, Volume: 43, Issue: 2	1999
In vitro synergism of ceftriaxone combined with aminoglycosides against Pseudomonas aeruginosa. Diagnostic microbiology and infectious disease, Volume: 19, Issue: 1	1994
High-dose tobramycin combined with clindamycin or lincomycin in the treatment of septic peritonitis and intraabdominal sepsis. Acta chirurgica Scandinavica, Volume: 147, Issue: 5	1981
Tobramycin versus gentamicin, in combination with cephalotin and carbenecillin, in patients undergoing bone marrow transplantation. Tumori, Dec-31, Volume: 67, Issue: 6	1981
Cefamandole alone and combined with gentamicin or tobramycin in the treatment of acute pyelonephritis. Scandinavian journal of infectious diseases. Supplementum, Volume: suppl 25	1980
Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics. Antimicrobial agents and chemotherapy, Volume: 24, Issue: 4	1983
Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. European journal of respiratory diseases, Volume: 63, Issue: 2	1982
In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, Volume: 24, Issue: 2	1983
Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, Volume: 19, Issue: 2	1981
Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (4). Effects of tobramycin alone and in combination with latamoxef on the stability of rat kidney lysosomal membranes. Japanese journal of pharmacology, Volume: 43, Issue: 1	1987
Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer chemotherapy and pharmacology, Volume: 18, Issue: 2	1986
[Study of the activity of a new glycopeptide antibiotic eremomycin combined with tobramycin against Staphylococci in vitro]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], Volume: 33, Issue: 5	1988
Cefotaxime combined with selective decontamination in long term intensive care unit patients. Virtual absence of emergence of resistance. Drugs, Volume: 35 Suppl 2	1988
In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrobial agents and chemotherapy, Volume: 32, Issue: 3	1988
[Ciprofloxacin in combination with other antimicrobial substances]. Arzneimittel-Forschung, Volume: 38, Issue: 3	1988
In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrobial agents and chemotherapy, Volume: 31, Issue: 9	1987
[Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization]. Zhurnal mikrobiologii, epidemiologii i immunobiologii, Issue: 9	1986
Comparative study of serum bactericidal activity of cefotaxime alone or in combination with tobramycin. Antimicrobial agents and chemotherapy, Volume: 29, Issue: 2	1986
Evaluation of the combination effects of ampicillin or vancomycin combined with streptomycin, gentamicin, tobramycin or netilmicin against enterococci. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, Volume: 97, Issue: 1	1989
[Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus]. Pathologie-biologie, Volume: 37, Issue: 4	1989
Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci. Antimicrobial agents and chemotherapy, Volume: 11, Issue: 1	1977
Susceptibility of Pseudomonas aeruginosa to tobramycin or gentamicin alone and combined with carbenicillin. Antimicrobial agents and chemotherapy, Volume: 8, Issue: 3	1975
In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens. Microbiology and immunology, Volume: 23, Issue: 10	1979
[In vitro antibacterial activity of tobramycin used in combination with cephalothin or carbenicillin (author's transl)]. The Japanese journal of antibiotics, Volume: 31, Issue: 3	1978
In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains. Chemotherapy, Volume: 25, Issue: 5	1979
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

tobramycin

Description

Cross-References

Synonyms (184)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (3)

Drug Classes (1)

Pathways (1)

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (41)

Molecular Functions (24)

Ceullar Components (17)

Bioassays (1643)

Research

Studies (4,576)

Study Types

Clinical Trials (117)

Trial Overview

Trial Outcomes

Change in Patient Physical Exam as Measured by the Lund-Kennedy Endoscopic Exam Scores.

Change in Patient Symptoms as Measured by the Sino-Nasal Outcomes Test (SNOT-22) Survey

Subjects Who Developed Antibiotic Resistance Organisms

Number of Participants With Critical Use Errors and Close Calls Associated With the Simulated Inhalation of One Dose Using TOBI Podhaler

Adverse Events

Burning, Stinging, Blurred Vision

Global Evaluation of Local Tolerability

Intraocular Pressure (IOP)

Number of Participants With Endophthalmitis

Total Ocular Symptoms Score (TOSS)

Visual Acuity

Conjunctival Hyperemia

Number of Participants Without Signs of Anterior Ocular Chamber Inflammation

Ocular Pain/Discomfort: 4-point Scale

Antipseudomonal Antibiotic Usage During the Study

Hospitalization Due to Respiratory Events During the Study

Change From Baseline in Pseudomonas Aeruginosa Sputum Density

Change From Baseline in Tobramycin Minimum Inhibitory Concentration

Number of Participants With Treatment-emergent Adverse Events

Patient Satisfaction Assessed Using the Treatment Satisfaction Questionnaire for Medication

Percentage of Participants With a Decrease From Baseline in Auditory Acuity

Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%FEV1)

Serum Tobramycin Concentrations

Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization

Number of Participants With a Pulmonary Exacerbation Requiring Oral, Inhaled, or Oral Antibiotics

Proportion of Participants With a Pa Positive Culture

Number of Days of Hospitalization Due to Respiratory Serious Adverse Events (SAEs)

Number of Participants Who Used New Antipseudomonal Antibiotic During Treatment Period

Number of Participants With Adverse Events (AEs)

Number of Participants With Serious Adverse Events (SAEs)

Percentage of Participants With Hospitalization Due to Respiratory Serious Adverse Events (SAEs)

Change From Baseline in Pseudomonas Aeruginosa Sputum Density to Each Post-baseline Visit

Change From Baseline in Tobramycin Minimum Inhibitory Concentration (MIC) Values for Pseudomonas Aeruginosa to Each Post-baseline Visit

Percentage of Participants With a Decrease of ≥20% in Forced Expiratory Value in One Second (FEV1) Percent (%) Predicted From Pre-dose to 30-minute Post-dose

Percentage of Participants With Frequency Decrease From Baseline in the Post-baseline Audiology Tests

Relative Change From Baseline of Forced Expiratory Flow Rate Over 25 and 75 Percent (FEF25-75%) Predicted to Each Post-baseline Visit

Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to Each Post-baseline Visit

Relative Change From Baseline of Forced Vital Capacity (FVC) Percent Predicted to Each Post-baseline Visit

Safety Evaluations: Number and Frequency of Adverse Events Among Participants

Signs and Symptoms Composite Score - Change From Baseline to Day 15 - ITT Population

Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population

Signs and Symptoms Composite Score - Change From Baseline to Day 8 - ITT Population

Signs and Symptoms Composite Score - Change From Baseline to Day 8 - PP Population

Signs and Symptoms Composite Score Change From Baseline to Day 3 - ITT Population

Signs and Symptoms Composite Score Change From Baseline to Day 3 - PP Population

Change From Baseline in the Total Blepharoconjunctivitis Grade.

Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 2

Change From Baseline in Total Blepharoconjunctivitis Graded at Visit 3

Number of Participants Who Achieved Bacterial Eradication at Visit 3

Number of Participants Who Achieved Clinical Resolution at Visit 3

Assessment of Ocular Signs in the Study Eye - Visit 1

Assessment of Ocular Signs in the Study Eye - Visit 2

Assessment of Ocular Signs in the Study Eye - Visit 3

Investigators Global Assessment of the Clinical Condition

Treatment Emergent Adverse Events